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Abstract 
Introduction 
Melanoma is most common in populations with European ancestry. The highest incidence 
rates are reported from Australia and New Zealand with more than 50/100,000 new cases and 
6/100 000 deaths per year compared to around 20/100,000 new cases and 3/100 000 deaths 
in Western Europe. Established host risk factors are the total body naevus number, fair skin 
and a family history of melanoma. In the last decade several new genetic loci identified 
through genome-wide association analyses (GWAS) were shown to influence pigmentation 
traits and melanoma risk. Recently an intronic SNP in PPARGC1B has been shown to modify 
tanning ability and melanoma survival. The aims of this thesis were to conduct phenotypic and 
genetic comparisons of early and late stage melanoma patients, and to compare melanoma 
patients from Brisbane, Australia and Tübingen, Germany. This included associations of 
PPARGC1B and PPARGC1A coding polymorphisms with pigmentation traits, melanoma risk 
and progression in both these populations. 
Methods 
Two cohorts of melanoma patients and controls from Tübingen (n=614) and Brisbane (n=893) 
have been collected and analysed to investigate phenotypes and genotypes associated with 
melanoma risk and progression. Data and material included questionnaires, clinical assess-
ments, melanoma specific parameters and germline DNA. Genotyping was performed by 
Sanger Sequencing, TaqMan SNP assays and with a high throughput Illumina CoreExome Chip 
assay. Phenotype and genotype associations were analysed using cross tabulation and logistic 
regression models. Survival probabilities were assessed genome-wide and for single variables 
using Kaplan Meier estimates, and comparisons were done with the log rank test. 
Results 
Patients with high naevus counts had no favourable outcome in the analysed cohort from Tü-
bingen, however being a carrier of a MC1R r allele was associated with an improved survival 
probability (p=0.049). Two SNPs, the intronic variants rs7551288 in DHCR24, and rs12146110 
in USH2A, were found in a genome-wide association analyses to be associated with overall 
survival and furthermore with progression in stage IV (p<0.001). Melanoma patients from Bris-
bane had favourable prognostic tumour characteristics and a higher rate of familial and mul-
tiple melanomas compared to patients from Tübingen. Furthermore, the influence of the 
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PPARGC1 transcription factors (PGC-1) on pigmentation was investigated. The exon SNP 
rs3736265 (T612M) in PPARGC1A was found for the first time to reduce naevus count. The  
intronic SNPs rs251468 and rs32579 in PPARGC1B were both confirmed to increase tanning 
ability and decrease naevus count, the SNP rs32579 additionally to improve survival in a meta-
analysis. 
Conclusion 
Genetic variants have been identified that influence pigmentation traits, melanoma risk and 
progression. New loci of potential relevance for naevus count, melanoma risk and progression 
have reached statistical significance. UV radiation has an overriding influence on the impact 
of genetic predisposition, especially in countries with high UV exposure and is leading to an 
increase of preventable, initially less aggressive melanomas.  
UV protection, early recognition and early treatment remain the most important strategies to 
overcome the rise of preventable melanomas and to reduce melanoma deaths. 
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German Abstract 
Einleitung 
Das Melanom ist am häufigsten in Bevölkerungen mit europäischer Abstammung. Australien 
und Neuseeland haben die höchsten Inzidenzraten mit mehr als 50/100 000 Neuerkrankungen 
und 6/100 000 Todesfällen pro Jahr, verglichen mit ungefähr 20/100 000 Neuerkrankungen 
und 3/100 000 Todesfällen in Westeuropa. Etablierte Risikofaktoren sind die Gesamtzahl der 
melanozytären Nävi, helle Haut und eine positive Familienanamnese für Melanom.  Im letzten 
Jahrzehnt wurden einige neue genetische Marker durch genomweite Assoziationsstudien ent-
deckt, für die ein Einfluss auf die Pigmentierung und das Melanom Risiko gezeigt wurden. 
Kürzlich konnte gezeigt werden, dass ein intronischer SNP in PPARGC1B das Bräunungsverhal-
ten und das Melanom Überleben modifiziert. Die Ziele dieser Thesis waren, phänotypische 
und genetische Vergleiche zwischen Melanomen im frühen und im späten Stadium durchzu-
führen und Melanom Patienten von Brisbane, Australien und Tübingen, Deutschland zu ver-
gleichen. Dies beinhaltete Assoziationen von PPARGC1B und PPARGC1A codierenden Poly-
morphismen mit Pigmentierung, Melanom Risiko und Progression in beiden Populationen. 
Methoden 
Zwei Kohorten aus Melanom Patienten und Kontrollen von Tübingen (n=614) und Brisbane 
(n=893) wurden erfasst und ausgewertet, um Phänotypen und Genotypen zu untersuchen, die 
mit Melanom Risiko und Progression assoziiert sind. Daten und Material beinhalteten Frage-
bögen, klinische Untersuchungen, Melanom spezifische Parameter und Keimbahn DNA. Ge-
notypisierungen erfolgten mit Sanger Sequenzierung, TaqMan SNP Assays und mit dem Hoch-
durchsatz Illumina CoreExome Chip Assay.  Phänotyp- und Genotyp-Assoziationen wurden 
mittels Kreuztabellen und logistischen Regressionsmodellen analysiert. Überlebenswahr-
scheinlichkeiten wurden genomweit und für einzelne Variablen unter Verwendung von Ka-
plan-Meier-Schätzungen berechnet, und Vergleiche wurden mit dem Log-Rank-Test durchge-
führt. 
Ergebnisse 
Patienten mit hoher Zahl melanozytärer Nävi hatten in der untersuchten Tübinger Kohorte 
keine günstigere Prognose, jedoch war das Vorhandensein eines MC1R r - Allels mit einer ver-
besserten Überlebenswahrscheinlichkeit assoziiert (p = 0,049). Zwei SNPs, die intronischen 
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Varianten rs7551288 in DHCR24 und rs12146110 in USH2A, wurden in einer genomweiten 
Assoziationsanalyse gefunden, die sowohl mit dem Gesamtüberleben als auch mit der Pro-
gression im Stadium IV assoziiert waren (p <0,001). Melanom Patienten aus Brisbane hatten 
günstige prognostische Tumor Merkmale und eine höhere Rate an familiären und multiplen 
Melanomen im Vergleich zu Patienten aus Tübingen. Weiterhin wurde der Einfluss der 
PPARGC1 Transkriptionsfaktoren (PGC-1) auf die Pigmentierung untersucht. Der Exon SNP 
rs3736265 (T612M) in PPARGC1A wurde erstmals mit einer reduzierten Nävuszahl in Verbin-
dung gebracht. Die Assoziationen der beiden intronischen SNPs rs251468 und rs32579 in 
PPARGC1B mit erhöhtem Bräunungsvermögen und reduzierter Anzahl an Nävi wurde bestä-
tigt, der SNP rs32579 war zusätzlich mit einem verbesserten Überleben in einer Metaanalyse 
assoziiert. 
Schlussfolgerung 
Es wurden genetische Varianten identifiziert, die die Pigmentierung, das Melanom Risiko und 
die Progression beeinflussen. Neue Loci von potentieller Relevanz für Nävuszahl, Melanom 
Risiko und Progression haben statistische Signifikanz erreicht. Vor allem in Ländern mit hoher 
UV-Exposition hat die UV-Strahlung einen dominierenden Einfluss auf die genetische Prädis-
position und führt zu einer Zunahme von vermeidbaren, zunächst weniger aggressiven Mela-
nomen. 
UV-Schutz, Früherkennung und frühzeitige Behandlung bleiben die wichtigsten Strategien, um 
den Anstieg von vermeidbaren Melanomen zu überwinden und Melanom-Todesfälle zu redu-
zieren. 
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1. Introduction 
The work of this thesis is focussing on melanoma patients from two countries with different 
daily UV exposure intensities, Germany and Australia. The main research interests included 
the phenotypic and genotypic differences of early and late stage melanoma patients, the dif-
ferent characteristics of melanoma patients from Australia and Germany and the effect of 
genetic germline variants. 
This thesis document commences with in a general introduction chapter and a method chap-
ter giving an overview of how patient data and material was collected and processed in the 
laboratory and which information technologies were used for this work.  
The general introduction will give an overview on the disease melanoma, including the differ-
ent melanoma subtypes, historical aspects, the incidence, risk and prognostic factors of the 
disease. Biological aspects of the melanocytes, which are the cells of origin of naevi and mel-
anoma will be described as well. The introduction will furthermore cover the process of nae-
vogenesis, the development of naevi on the skin to understand the background of the pheno-
type characteristic “total body naevus count” and the meaning of naevi as potential precursor 
of melanoma. The next topic will be melanoma susceptibility genes, those genes which are 
thought to influence the breakout and the course of the disease. The last chapter of the intro-
duction is focussing on the transcription factors PGC-1α and PGC-1β (peroxisome proliferator-
activated receptor gamma coactivators alpha and beta) and its biologic interactions. This will 
establish the potential meaning of genetic variants within the coding regions for these pro-
teins in relation to the pigment system and melanoma outcome. 
The following four chapters are covering the four different research areas: 1) the pilot study, 
which was initiated in 2013 in Tübingen, 2) the comparison of early stage and late stage mel-
anoma patients from a large cohort study conducted in Tübingen combining phenotypes and 
genotypes with disease specific survival data, 3) the comparison of melanoma patients from 
Australia and from Germany with a focus on phenotype and genotype characteristics as well 
as melanoma specific data and 4) the association analyses of genetic variants coding for PGC-
1 family members. Each of these four chapters are structured in a short introduction and 
methods chapter, with specific aspects not covered by the general introduction and method 
chapter followed by a result, discussion and conclusion chapter.  
The thesis finishes with a summary of findings and a final conclusion chapter. 
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1.1. Melanoma 
Melanoma is a high mortality risk cancer originating from pigment producing cells, the mela-
nocytes. Given the predominant localisation on the outer skin this type of cancer is exception-
ally vulnerable to the main carcinogen UV radiation but also suitable for early detection.1 Mel-
anomas either develop from single melanoma cells or evolve from existing naevi, original be-
nign conglomerations of melanocytes in the skin. Tumour thickness is the main prognostic 
factor, which is raising the risk of tumour spread and the hazard of distant organ metastases 
even years after primary excision. Affecting adults of all races and also at a younger age com-
pared to other solid tumours, melanoma is among those cancers with the most substantial 
impact on years of life lost.2 The incidence rates are still rising globally and are the highest 
among fair skinned populations in environments with intense UV radiation.3  
Despite the high mortality risk of metastatic melanoma, it is important to note that today most 
melanomas are cured by excision after early detection. The individual prognosis of a patient 
however drops dramatically if the primary tumour has reached a tumour thickness of 2mm or 
greater, and if other adverse factors like an increased mitoses rate or ulceration of the primary 
are present. Metastases are rarely found at primary diagnoses but develop frequently in high 
risk patients after a latency of commonly 1-3 years, yet can also occur more than 10 years 
after primary excision in single cases. Patients with solitary metastases can still be cured with 
surgery, some patients with disseminated metastases do experience long term remissions 
with the recently developed systemic treatments, but in general survival chances diminish if 
the disease has spread more widely. 
1.1.1. Subtypes 
According to the distribution of melanocytes throughout the body, melanoma develops pre-
dominantly in the skin but can also primarily arise in nail beds, mucosa and in the uveal tract 
of the eye. In respect to these locations melanomas are categorized in cutaneous melanoma, 
mucosal melanoma and uveal melanoma. The most common cutaneous melanomas have 
been classified as different melanoma subtypes in regard to their clinical and histopathological 
appearance: Lentigo maligna melanoma, superficial spreading melanoma, nodular melanoma 
and acral lentiginous melanoma.4 The clinical presentation of the different subtypes is shown 
in Figure 1. Lentigo maligna melanoma is linked to the amount of cumulative sun exposure, 
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superficial spreading melanoma to intermittent sun exposure, while the subtypes nodular 
melanoma and acral lentiginous melanoma are thought to develop independently of UV as 
carcinogen.1 
 
 
Figure 1: Clinically images of the diverse subtypes, underpinning the variety of clinical melanoma 
presentations. 1A Lentigo Maligna Melanoma, 1B Superficial spreading melanoma, 1C Nodular mela-
noma (with ulceration), 1D Acral lentiginous melanoma. (Photographs: Department of Dermatology, 
Tübingen, Germany) 
1.1.2. Historical Background 
The first report on melanoma retrieved in PubMed was from the year 1905. It was a case on 
a melanoma of the choroid written by DeSchweinitz and Shumway.5 In this report the authors 
stated that the pathologist Virchow was the first who described malignant tumour growth on 
pre-existing pigmented naevi on the skin. The pathologists at that time called those tumours 
sarcomas. Other common terms were naevocarcinoma, melanosarcoma and melanocarci-
noma.6,7 Interestingly to note is that initially the term melanoma was used synonymously for 
the terms “moles” or “pigmented naevus”.8 Only with using the term “malignant melanoma” 
the malignant counterpart was correctly described, whereas today it is more and more com-
mon to use solely the term melanoma. The pathologists in the early 20th century proposed 
that the pigmented hairy mole was a sensory organ of the mammal, as they described the 
nerve fibres in the lesion and compared it with tactile organs of reptiles.9 The pigmentation of 
melanoma metastases was considered to be extruded chromatin from the nuclei.6 The first 
case reports are predominantly covering the topic uveal melanoma or metastatic findings.10-
12 In the 1940s, the first clinical cohort studies were published with a detailed description of 
35, 117 and 862 melanoma cases respectively and calculated overall survival probabilities be-
low 20%.13-15 The authors considered mechanical trauma or irritation to be the main cause of 
disease at that time and pointed out the necessity of deep and wide surgical excision. The 
A 
 
B 
 
C 
 
D 
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association of sunlight and melanoma was described in the 1950s.16,17 In the 1970s families 
with multiple and atypical moles were reported and their increased risk for developing mela-
noma as well as contributing hereditary factors were discussed.18,19 These reports marked the 
beginning of an ongoing exploration of the genetic and environmental risk factors for naevus 
and melanoma development. 
1.1.3. Incidence 
The incidence and mortality rates for melanoma are steadily increasing over the last decades 
and are projected to further increase in most regions of the world.20 In Germany 6-8 melano-
mas per 100 000 inhabitants were registered in the eighties of the last century, while 18 cases 
per 100 000 were reported in 2011.21 22 Australia and New Zealand have the highest incidence 
rates of melanoma in the world with a lifetime risk of 3.6% compared to 1.9% in the white US 
population and up to 1.6% in European countries.23 In Australia the age-standardised mortality 
rate in 2007 was 5.8 per 100,000 for men and 2.5 per 100,000 for women in Australia and 
even higher in New Zealand with 6.4 and 3.4 per 100,000, respectively.24 Recently it was 
shown that the incidence of thin melanomas was declining in Queensland for the first time, 
the incidence of melanomas >1mm tumour thickness however was still remaining stable. The 
decline of thin melanomas was linked to the successful prevention program “Slip Slap Slop”, 
which was introduced in Queensland 30 years ago. The stable incidence of thick melanomas 
was thought to be explained by melanomas with a different biology, e.g. fast growing mela-
nomas or not sun-induced melanomas.25 This for the first time reported decline in diagnosed 
melanoma cases was criticised by the argument that the incidence rates were diluted with a 
high number of immigrants from “low risk” countries, e.g. from Asia, who were not susceptible 
for melanoma as were the inhabitants with European ancestry.26 However, even under the 
assumption that all population increases were due to immigrants from “low risk” countries, 
the decline in incidence rates was confirmed.27,28 Thus, for the first time, a decline in incidence 
rates was observed which is most probably linked to an effective primary prevention via UV 
protection. 
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1.1.4. Risk Factors 
Environmental, phenotypic and genetic risk factors for the development of primary melanoma 
have been explored in the past. Genetically determined host risk factors for the development 
of melanoma are fair skin, low tanning capacity and a family history of melanoma. There is 
evolving knowledge of genes that influence melanoma development and prognosis. The only 
known environmental risk factor to date is sun exposure. Sun exposure and genetic predispo-
sition both influence the total number of acquired melanocytic naevi, which is the strongest 
known risk factor for primary melanoma.29 
The typical phenotype of a melanoma patient is fair skinned with blue eyes and blond or red 
hair or with multiple naevi. The first studies investigating the association with pigment traits 
and constitutional factors with melanoma risk were published in the 1980’s. One of the first 
case-control study reported naevus count as the strongest risk factor. Further traits were ina-
bility to tan, susceptibility to sunburn and hair colour, whereas skin and eye colour had no 
independent effect.30 Having red or blond hair was also reported as risk factor as well as nae-
vus count in another study.31 The strong relation between increasing numbers of benign naevi 
and melanoma risk was repeatedly reported.32-34 With the combined assessment of 16 case-
control studies, based on more than 3000 cases, the lower impact traits like hair colour, eye 
colour, freckling, skin colour were also confirmed as independent risk factors besides naevus 
count.35 In subsequent studies the presence of atypical naevi were included in the analyses 
and were added as independent risk factors.29 The largest study so far included 12,387 indi-
viduals from 15 case cohort studies into a pooled dataset to calculate a risk prediction model 
based on seven different risk factors. The strongest individual risk factor based on this dataset 
was the total naevus body count, followed by the existence of large naevi (5mm) on the body, 
hair colour, family history of melanoma, freckling, hair colour, and the history of sunburns.36 
Apart from this well-established phenotype risk factors, which are mainly based on pigment 
traits, research has been done in the last years to find additional factors, such as obesity. Obe-
sity is a long established risk factor for several types of cancer, e.g. breast, endometrium, colon 
and kidney.37 A meta-analyses published in 2013 found an increased melanoma risk for obese 
male but not for obese female individuals.38 No association was found in a large prospective 
cohort study from Denmark.39 However, detailed data to adjust for UV exposure were not 
available and the authors stated that further studies are needed to address this question. 
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UV Exposure is the main carcinogen for melanoma and for skin cancer in general. The sun’s 
impact on the development of melanoma is revealed by clear geographical differences, with 
rising incidence rates for Caucasians living closer to the equator.23 Furthermore, sun seeking 
behaviour, especially in early childhood, as well as occupational sun exposure is a frequently 
reported melanoma risk factor in epidemiological studies.40-42 The dramatically increased mel-
anoma risk of patients with xeroderma pigmentosum, a hereditary syndrome with a deficiency 
in nucleotide excision repair and UV hypersensitivity, strongly supports the role of UV associ-
ated DNA damage in melanoma development as well.43 Despite those findings, the role of UV 
exposure was still a controversial topic in recent years. In contrast to keratinocyte cancers 
(KCs), which occur predominantly on chronically sun-exposed body areas, only the lentigo ma-
ligna subtype is clearly associated with chronical sun damage, whereas some melanomas de-
velop in intermittent or not sun exposed areas.44 The absence of UV signature mutations in 
BRAF and other melanoma related genes, as well as the absence of p53, a driver mutation in 
KCs with UV signature mutations45 seemed to lower the role of UV in melanoma. Moreover 
an UV independent pathway, based on oxidative damage, was described recently in a mouse 
model with and without pheomelanin production.46 However, the presence of multiple UV 
signature mutations in melanoma was finally revealed with new sequencing approaches, in-
cluding the discovery of a new set of driver mutations in melanoma, highlighting the role of 
UV light in melanoma pathogenesis.47-49 Beside possible alternative pathways to melanoma, 
UV exposure remains the most important acquired melanoma risk factor. 
1.1.5. Prognosis, Staging and Prognostic Factors 
The term prognosis derived from the Greek word πρóγνωσις which means forecast. It is de-
scribing the attempt to declare what will occur within a specific area of interest in future. In 
melanoma these outcomes of interest are the prediction of progression, in particular the 
event of new metastases, as well as the prediction of survival for an individual patient. These 
predictions are generally made based on experiences with other melanoma patients in the 
past. This information can be obtained by personal observations, by adapting observations 
made by others or obtained from the literature, ideally based on systematic scientific analyses 
of a large group of patients. The analyses of differences in melanoma patients and their out-
comes permit the establishment of prognostic factors. 
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The currently used melanoma staging system was updated in 2009 and uses the factors tu-
mour thickness, mitoses in the primary tumour, number of lymph node metastases, site of 
distant metastases and the blood marker LDH. Tumour thickness and the presence of ulcera-
tion or mitoses in the primary tumour are defining the T Stage, the N Stage is summarizing the 
number and size of lymph node metastases and the presence of satellite or in-transit metas-
tases and the M Stage is defined by the presence and site of distant metastases and the LDH 
blood level.50 In January 2017 the 8th Edition staging system was presented.51 Relevant revi-
sions included the definition of the primary tumour with a 0.8mm threshold for T1 and the 
remove of the mitotic rate as staging criteria. The updated TNM definitions are summarized 
in Table 1. The melanoma stage is based on the TNM definitions. The new staging system will 
be implemented in 2018. The pathological staging of the lymph nodes is requiring a sentinel 
lymph node biopsy which is generally performed at primary diagnoses. The recommended 
threshold for this procedure in Germany is currently a tumour thickness of 1mm.52 
The 20 year survival rates for patients with a clinical stage IB, comprising tumours with a thick-
ness below 2mm and the absence of lymph node involvement are above 70%. The survival 
curves in stage IV based on the different sites of metastases are shown in Figure 2. 
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Table 1: TNM disease classification used by the latest AJCC staging system from 2017. Figure 
from Gershenwald et al. 201751 
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Table 2: Updated melanoma staging system published by the American Joint Committee on 
Cancer in 2017. Adapted from Gershenwald et al. 201751 
Clinical 
stage 
group* 
Clinical Staging Pathologi-
cal stage  
group** 
Pathologic Staging 
 T N M  T N M 
0 Tis N0 M0 0 Tis N0 M0 
IA T1a N0 M0 IA T1a N0 M0 
IB T1b N0 M0 IB T1b N0 M0 
T2a N0 M0 T2a N0 M0 
IIA T2b N0 M0 IIA T2b N0 M0 
T3a N0 M0 T3a N0 M0 
IIB T3b N0 M0 IIB T3b N0 M0 
T4a N0 M0 T4a N0 M0 
IIC T4b N0 M0 IIC T4b N0 M0 
III Any T ≥N1 M0 IIIA T1a/b–T2a N1a or N2a M0 
 IIIB T0 N1b, N1c M0 
T1a/b–T2a N1b/c or 
N2b 
M0 
T2b/T3a N1a–N2b M0 
IIIC T0 N2b, N2c, 
N3b or N3c 
M0 
T1a–T3a N2c or 
N3a/b/c 
M0 
T3b/T4a ≥N1 M0 
T4b N1a–N2c M0 
IIID T4b N3a/b/c M0 
IV Any T, Tis Any N M1 IV Any T, Tis Any N M1 
*Clinical staging includes the microstaging of the primary melanoma and evaluation for metastases 
**Pathological staging includes the microstaging of the primary melanoma and pathological information about 
the regional lymph nodes after sentinel lymph node biopsy. 
 
 
 
Figure 2: Survival rates based on the different T categories from time of diagnoses (Fig 2A) 
and survival rates calculated from time of Stage IV disease comparing different site of distant 
metastases (Fig 2B). Image from Balch et al. 200950 
A 
 
B 
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Apart from the factors which the American Joint Committee on Cancer used to build the cur-
rently used staging system, several other prognostic factors were assessed and discussed in 
the literature, some having a clear prognostic impact and some of them with inconsistent re-
sults. Those investigated factors include tumour specific factors, phenotype factors, blood 
based biomarkers and hereditary genetic factors. 
Regression is a regularly observed phenomenon in primary melanomas and is thought to be 
an immunologic event in which malignant cells are diminishing and are being replaced by fi-
brosis. These regression zones can already be observed visually, notably with the use of der-
moscopy, and more accurately diagnosed in the histologic specimen. A systematic review and 
meta-analysis including more than 8 000 patients found a significantly decreased risk of death 
for patients with histologic regression in their primary melanoma.53 
The majority of melanoma patients develop a single melanoma, while a subset will have fur-
ther melanomas in their lifetime. Those patients having multiple melanomas were investi-
gated in regard to their outcome and several studies found a better survival rate for those 
patients compared to patients with a single melanoma.54-56 This favourable association was 
confirmed in a large multicentre melanoma cohort study for a subset of patients, those with 
thick melanomas above 4mm.57  
Antigen expression on primary melanomas is widely studied and some expression patterns 
were found to be associated with prognosis, albeit none of those markers have transferred 
into clinical routine so far.58 
The phenotypic characteristic total body naevus number is the most important risk factor for 
melanoma. A favourable outcome for patients with high total body naevus count was reported 
by Ribero et al. in 2015 based on a cohort of more than 2 000 patients. The results remained 
statistically significant even after adjustment for known prognostic and other factors, such as 
age, tumour thickness, sex, site of primary, presence of ulceration, the mitotic rate and the 
country of the patients.59 However, there are concerns about the validity of this association 
due to the used statistical model, assuming a constant linear association of tumour thickness 
and prognosis, and due to the suspected over-diagnosis of indolent screen-detected melano-
mas, notably in this group of high risk patients.60 
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Several studies found a better outcome for woman with melanoma across all stages.61-63 The 
favourable prognosis was discussed to be associated with thinner melanomas in women due 
to a better participation in screening programs but remained statistically significant after ad-
justment for other prognostic factors. A pooled analysis of three large studies showed an en-
hanced survival of women with metastatic melanoma which supports the biologic influence 
rather than a behavioural difference of females on disease outcome.64 
Obesity was assessed as risk factor for melanoma in many studies and is thought to be asso-
ciated with an aggressive course of disease as well, as reviewed by Clement et al. based on 
molecular mechanisms and animal models.65 One study showed an increased rate of thick 
melanomas in obese patients.66 Clear evidence of a prognostic survival impact of obesity is 
still lacking. 
Elevated levels of the serum biomarker LDH are associated with impaired survival. This bi-
omarker is used by the current staging classification. Other biomarkers with a prognostic im-
pact have been studied as well, such as MIA, CRP and S100b. Serum S100b protein is routinely 
used as a diagnostic biomarker.58 
Germline variants in the genome are increasingly investigated given the modern and fast 
evolving sequencing techniques. Variants were found to contribute to melanoma susceptibil-
ity as discussed later in this introduction chapter, as well as having a prognostic impact on 
disease outcome.67 
Somatic gene alterations in the primary melanoma and in metastases have been discovered 
in an increasing number with clinical significance and some of them with evidence of prognos-
tic impact. The first candidate that resulted in a novel effective treatment strategy was the 
BRAF mutation which was published in 2002.68 A prognostic impact was not found for patients 
with BRAF positive melanomas.69-71 The Cancer Genome Atlas (TCGA), a project conducted by 
the National Cancer Institute and the National Human Genome Research Institute of the 
United States, has published a genomic classification of cutaneous melanoma in 2015. The 
extensive analyses of primary melanomas and melanoma metastases from 333 patients re-
sulted in 4 distinct subtypes, the BRAF, RAS, NF1 and triple WT subtype. An improved survival 
was found for melanomas with an overexpression of immune related genes compared to 
those who were classified as “keratin” subclass.72 
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There are several aspects connected with the search for prognostic factors. Understanding of 
those specific characteristics that are associated with poor prognoses not only allows for the 
potential prediction of an individual course of the disease but can also serve as a foundation 
for clinical interventions. These potential interventions could be the implementation of 
adapted surveillance strategies to enhance secondary prevention as well as the discovery of 
new therapeutic targets. 
1.2. Melanocytes 
Malignant melanomas and melanocytic naevi have their cell of origin in common. This is the 
melanocyte, a pigment producing, dendritic cell derived from the neural crest during embry-
onal development with a subsequent migration into skin, eye and other tissues.73 The main 
localisation of melanocytes is the lower epidermis and the precursor cells, the melanoblasts 
are located in the hair follicles.74 However, melanocytes are rare in the skin compared to other 
cell populations with 1,500 melanocytes per square millimetre epidermis.75 One important 
function of melanocytes is the production of melanin, the so called melanogenesis.76 The mel-
anin is packed in melanosomes which are membrane-bound organelles. The dendrites of the 
melanocytes enable the distribution of the pigment packed melanosomes towards the sur-
rounding keratinocytes, where they built a layer over the nuclei of keratinocytes to protect 
the DNA from UVR damage.77,78 The neighbourhood and organisation between keratinocytes 
and the corresponding melanocyte is called “the epidermal melanin unit” and includes an es-
timated sum of 40 keratinocytes per melanocyte.79 The production of melanin is initiated by 
DNA damage of the keratinocytes typically caused by UV light.80 As a result keratinocytes se-
crete α-melanocyte-stimulating hormone (αMSH)81 which binds to the melanocortin-1 recep-
tor (MC1R) on the surface of melanocytes and activates the tanning response through MITF. 
The initiation of this pathway requires the induction of the transcription factor p53.82 The en-
zymatic cascade to produce melanin pigments involves tyrosinase, tyrosinase-related protein-
1 (TYRP1), and tyrosinase-related protein 2/dopachrome tautomerase (DCT).83 The high pen-
etrance for TYR wildtypes correlating with darker pigmentation was demonstrated in cultured 
melanocytes.84 There are two types of melanin, the orange-yellow pigment pheomelanin and 
the brown-black eumelanin which has better UV protection properties. Both were detected in 
hair and epidermis in the same relative proportions with lower concentrations of eumelanin 
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in individuals with skin type I.85 The lighter pigment pheomelanin is more frequent among 
individuals with MC1R germline variants.86 Those individuals have at higher risk for mela-
noma.87 Apart from the impaired UV protection properties of pheomelanin with a higher prob-
ability of UV induced mutations, pheomelanin also induces reactive oxygen species (ROS). ROS 
in turn contributes to mutations such as BRAFV600E which are relevant for both melanoma and 
naevus development (naevogenesis).88 
1.3. Naevogenesis 
Melanocytic naevi (from now on referred as naevi) are common benign conglomerates of mel-
anocytes and result from oncogenic mutations.89 They develop in utero as congenital naevi or 
as acquired naevi in the first decades of life. Some naevi remain completely stable over the 
lifetime, while others change in size and pattern or involute completely, resulting in lower 
naevus numbers in elder individuals.90 Naevi can occur throughout the body wherever mela-
nocytes are found as well. This includes the most common location of sun exposed skin, such 
as trunk, extremities and face, but naevi can also arise in sun protected areas like the scalp, 
soles and the genitals. Naevi locations outside the skin involve nailbeds, iris, conjunctivae, 
mucosae and menginges.91,92 Common acquired naevi of the skin can be characterised accord-
ing to typical clinical and histological features. Junctional naevi are flat lesions and have nests 
of clustered melanocytes at the dermoepidermal zone. Compound naevi are usually light 
brown papules with additional nests in the dermis containing melanocytes with smaller cell 
nuclei and with lower pigment production. Dermal naevi are skin-coloured nodules having 
only dermal nests of non-pigmented melanocytes.93 Nesting is one histopathological feature 
of naevi. Maturation, the decrease in size and pigment density in the lower areas is the other 
typical feature and is used as separation criteria towards melanoma.94 Special entities of com-
mon naevi are Halo naevus (Sutton’s naevus), with a depigmented surrounding, Blue naevus, 
with dermal nests of spindled melanocytes and a characteristic blue-grey colour, Naevus 
spilus, typically a large light brown macula including sprinkled dots and Spitz naevus, a com-
mon melanoma simulator in children with atypical cells.93  
Different from common naevi are “dysplastic” (histopathological description) or “atypical” 
(clinical description) naevi. This entity was first described in melanoma families as irregular 
coloured and shaped lesions of larger size (frequently 5-10mm) than common naevi as part of 
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the so-called B-K mole syndrome.18 Several epidemiological studies evaluated the presence of 
dysplastic naevi as an independent melanoma risk factor.29 However, the individual risk for 
one dysplastic naevi to develop into a melanoma is low and prophylactic excisions are not 
reasonable.95,96 Melanoma arise in most cases from single, isolated melanocytes and only in 
about one third from nested melanocytes of common or dysplastic naevi.97 Models of a linear 
progression from melanocytes through dysplastic towards malignant lesions as well as the 
location and type of precursor cell are still under debate.98,99 
1.3.1. Development Models and Cell of Origin 
For a long time, initiating naevus cells were thought to be located in the epidermis, based on 
Unnas concept “Abtropfung” (drip down) from 1893. He postulated a downwards movement 
of naevus cells from the epidermis towards the dermis.100 This concept was questioned in the 
last decades and the concept “Hochsteigerung” (rise up) was opposed, arguing the cells move 
upwards instead.101 Both directions of naevus cell migration have been demonstrated in fol-
low up images using dermoscopy which supported either of the two concepts.102 Again based 
on dermoscopic follow up images, different naevogenesis pathways were introduced. A con-
stitutional pathway, with persisting dermal proliferations and an acquired pathway with epi-
dermal proliferations that grow and disappear later in life were postulated.103 Evidence for 
both location of origin models, the epidermal as well as dermal precursor models are on hand 
as reviewed by Grichnik et al, a view replacing the one-direction models of the past.98 
The initiation of naevus development is requiring oncogenic mutations, in most cases one that 
activates the MAPK pathway.104 It has been demonstrated that most naevi show clonal-
ity105,106, assuming that one melanocyte initially gains a mutation, consequently enters a pro-
liferating state and forms the lesion. In the absence of additional mutations, the lesions remain 
benign and enter senescence. The concept of oncogene induced senescence was established 
on the observation that the induction of an oncogenic HRAS mutation resulted paradoxically 
in a growth arrest in vitro.107 Most naevi seem to remain in a senescence state due to a 
BRAFV600E mutation.108 Somatic alteration which for example lead to an activation of the Wnt 
signalling pathway109, TERT promoter mutations or alterations of CDKN2A99 can overcome this 
senescence and turn the faith towards a malignant lesion.  
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The kind of precursor cell of melanocytic naevi is still not defined. Beside mature or immature 
melanocytes of the skin, other cells like multipotent stem cells110 or Schwann cells111 have 
been proposed to serve as cells of origin as well. Some clinical observations support the im-
mature progenitor cell model in contrast to the concept that already differentiated melano-
cytes develop initiating mutations. Immature mutated cells would remain silent until activa-
tion. This behaviour explains the association of childhood sun exposure and the delayed de-
velopment of naevi and melanoma, as well as the occurrence of eruptive naevi under certain 
medications or other modulating circumstances such as pregnancy, as reviewed by Ross et 
al.112 
1.3.2. Naevus Susceptibility Genes 
Several germline variants have been identified in the last years which were demonstrated to 
be associated with naevus count and characteristics. One of the first reports of a genetic back-
ground of dysplastic naevi and melanoma was published in 1983 and postulated an autosomal 
dominant trait with a localisation of the respective gene on chromosome 1.113 A few years 
later this suspected single responsible gene was located on the chromosome band 1p36.114 
Heterogeneity of the genetic basis however was suggested based on results of a subsequent 
study from Australia115, and the immense complexity of genetic causes has been confirmed in 
the following years. The inherited background of naevus count and characteristics was proven 
in multiple twin studies, all demonstrating a higher correlation between monozygous com-
pared to dizygous twins.116-121 Specific genetic loci with an influence on naevi were retrieved 
by candidate approaches as well as genome-wide analyses with an ongoing increase of de-
tected markers. A case-control analysis from Queensland found three variants, MTAP 
rs10757257, PLA2G6 rs132985 and IRF4 rs12203592 which had a significant association with 
naevus number.122 A meta-analysis of genetic studies exploring the association of loci with 
naevi and melanoma confirmed two of those loci, MTAP and PLA2G6.123 Not only coding var-
iants but also variants outside the coding region of a gene were identified, such as the marker 
D9S942 which is adjacent to the CDKN2A gene.124 A genome-wide search for naevus count 
found two loci at chromosomes 9p21 and 5q31-32 in subjects from the UK Adult twin regis-
try.118 The NID1 locus was identified in a GWAS from the USA conducted in a large cohort of 
individuals with European ancestry.125 A candidate approach was used to identify PAX3 as a 
candidate nevus gene.126 Variants in IRF4 were found to be associated with melanoma risk 
Dr. med. Annette Pflugfelder  Phenotypes and Genotypes of Melanoma Patients 
 
26 
 
and with naevus number. One allele, the rs12203592*T, was associated with flat naevi on the 
trunk in young adults and with melanoma.127 The most recent meta-analysis of 11 naevus 
GWAS including more than 50 000 phenotyped individuals from Australis, Netherlands, United 
Kingdom and the United States confirmed known loci such as MTAP, with the strongest asso-
ciation, followed by PLA2G6 and IRF4, 9q31.2, CYP1B1, PPARGC1B, and others and found ad-
ditional SNPS with strong associations in DOCK8, KITLG, HDAC4 and other genes. Most of these 
genes with the exception of KITLG were also associated with melanoma risk. (Duffy et al., in 
submission) 
1.3.3. Somatic Mutations and Naevus Subtypes 
Mutations in protein coding genes of the MAPK pathway are in most cases the underlying 
cause of naevogenesis.104 The mutations seem to occur mutual exclusive, indicating a func-
tional redundancy with no additional advantage of secondary mutations in this pathway, as 
reviewed by Damsky et al.128 The activating BRAF mutation is the most common mutation in 
naevi and was found with about 80%129,130 in a higher frequency than in primary melanomas.68 
Yazdi et al. found the BRAF mutation most frequently in papillomatous naevi (78%) but not in 
Spitz and in blue naevi.130 Spitz naevi were found to have frequently a HRAS activation through 
copy number gains.131 HRAS mutations in Spitz naevi were additionally found in several studies 
in a frequency between 11% and 26%.132 NRAS mutations are less frequent than BRAF muta-
tions in acquired naevi. However, all acquired naevi without a BRAF mutation seem to harbor 
a NRAS mutation.133 NRAS mutations are in contrast common in congenital naevi.134 Muta-
tions in GNAQ, again resulting in an activation of the MAPK pathway were found in 83% of 
investigated blue naevi.135 The use of BRAF inhibitors in the treatment of metastatic mela-
noma enabled the study of naevus behaviour in vivo. A report described the appearance of 
new lesions, nevi increase and nevi involution in one patient under BRAF inhibitor treatment. 
The involuted lesions were predominantly elevated papillomatous nevi with a globular der-
moscopic pattern.136 The speculation that these nevi must have been BRAF positive was di-
rectly demonstrated in a similar case using microbiopsy sampling and genotyping tech-
niques.137 
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Life Cycle of Naevi 
Naevi are considered to be benign but neoplastic lesions. While some naevi are stable 
throughout the life, others undergo a currently accepted model of a naevus life cycle. This 
cycle starts with an initiating mutation. An activation step is required to enter the promotion 
state which involves the proliferation of the lesion. The naevus growth stops in the senescence 
state, which is different in melanoma lesions. The last step is the involution of the naevus, 
which results in an incomplete or complete regression.112 
1.4. Melanoma Susceptibility Genes 
Several genes were discovered in the last years that influence melanoma susceptibility and 
prognosis. These genes are generally classified as high-, moderate- and low risk alleles. Vari-
ants in low risk genes are common in the population but their penetrance is low in contrast to 
high risk genes which are rare but have a high penetrance of development of cutaneous mel-
anoma.67,138 
1.4.1. High Penetrance Genes 
The cell cycle regulators CDKN2A and CDK4 are considered as high-penetrance melanoma sus-
ceptibility alleles. Both are discovered among melanoma families.139 CDKN2A is located on 
chromosome 9p21 and can be translated via alternative splicing into 2 different proteins, 
p16/Ink4a and p14/Arf. Inactivating mutations of the CDKN2A gene are found in 20-40% of all 
familial melanoma cases and constitute the most frequent cause for melanoma susceptibil-
ity.140 CDK4 is located on chromosome 12q13 and represents a target of p16/Ink4a. All three 
proteins are part of the retinoblastoma (Rb) pathway and important players in tumour sup-
pression.141 
In the last years several new high risk genes were discovered, such as new loss-of-function 
variants in the protection of telomeres 1 gene (POT1), which were identified in familial mela-
noma patients.142,143 Other mutations were found in the genes BAP1, TERT, ACD and 
TERF2IP.144 An overview on the prevalence of high-risk melanoma susceptibility genes identi-
fied in melanoma-prone families so far is given in Figure 3. 
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Figure 3: Prevalence of high-risk genes which were identified in melanoma families. Figure 
from Potrony et al. 138 
1.4.2. Moderate Penetrance genes 
MC1R (melanocortin-1 receptor) is a key regulator of skin pigmentation and a moderate pen-
etrance melanoma risk gene.145 The gene encodes for a 7-transmembrane G-protein coupled 
receptor on the surface of melanocytes and is activated by α-melanocyte-stimulating hor-
mone (MSH), which is secreted by keratinocytes as a response to UV exposure. The receptor 
protein is highly polymorphic. A large number of single nucleotide exchanges were described 
which lead to amino acid substitutions within the coding region and alter receptor function.146 
A decrease of MC1R function is shifting the balance from the black, photo protective pigment 
eumelanin towards the reddish pheomelanin, resulting in the red hair and fair skin pheno-
type.147 The different MC1R variants were classified in big R types with a strong influence on 
pigmentation traits and small r types, those with a weak influence.148 Carriers of MC1R vari-
ants have a significant higher risk of melanoma development and were also shown to increase 
penetrance of CDKN2A mutations.149,150 Activation of MC1R induces the expression of MITF 
(microphthalmia transcription factor), a regulator of melanocyte proliferation and survival.151 
A novel MITF variant allele leading to an aminoacid change E318K was found in familial and 
sporadic melanoma and was associated with multiple primary melanomas. This allele in-
creased melanoma risk by approximately 5-fold compared to the general population.152,153 
The encoded protein is deficient in SUMOylation and allows melanocytic cells to more effi-
ciently overcome BRAF induced senescence, potentially favouring melanoma progression.154 
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1.4.3. Low Penetrance genes 
As fair skin and decreased tanning ability is a risk factor for developing melanoma, not only 
MC1R but also other genes involved in pigmentation pathways were found to influence mel-
anoma risk. The association of several candidate genes, like ASIP (Agouti signalling protein, 
nonagouti homolog (mouse) gene), TYR (tyrosinase), TYRP1 (tyrosinase-related protein 1), 
OCA2 (oculocutaneous albinism type II), SLC24A4 (solute carrier family 24, member 4), 
SLC45A2 (solute carrier family 45, member 2) and IRF4 (interferon regulatory factor 4) have 
been discovered in the recent years.155 Conflicting risk associations of the IRF4 
rs12203592*C/T alleles have been reported, with either increased melanoma risk attributed 
to the T allele127,156, or to the C allele122,157, while the latter association was found to be age 
dependant.122 A potential prediction of melanoma subtypes based on divergent pathways was 
reported later, showing an association of melanoma with solar elastosis and the T allele and 
of melanoma with naevus residues and the C allele.158,159 Further evidence of the significance 
of IRF4 in melanoma is the association of the T allele with increased tumour thickness160 and 
an impaired survival161. The influence of the C/C and T/T genotype on IRF4 protein levels and 
its response to UV radiation have been recently demonstrated in melanoblasts, highlighting 
the role of IRF4 in melanoma development.162 
1.4.4. Genome Wide Association Studies 
Genome-wide association studies (GWAS) allow the exploration of multiple genetic markers 
across the genome to search for uneven distributions of the markers frequencies in regard to 
a specific trait or disease among the study population. This method however does not allow a 
prediction of a causal relationship between the genetic variant and the trait or the impact of 
its influence. The first GWAS in melanoma were performed in 2008. A study from Iceland 
found variants near ASIP, in the genes TYR and TYRP1 to be associated with melanoma risk.163 
Brown and MacGregor et al. and detected variants on the 20q11.22 locus associated with mel-
anoma.164 One year later a GWAS from the GenoMEl consortium was published including 1650 
cases and 4336 controls. Loci within the genes MC1R, TYR, MTAP, CDKN2A were identified.165 
In 2011 Amos et al detected two loci in 2011 on chromosome 15 (locus 15q13.1, HERC2/OCA2 
region) and on chromosome 16 (locus 16q24.3, MC1R region) associated with melanoma 
risk.166 Another study from the GenoMeL consortium replicated previous findings and 
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reported three novel loci (ATM, MX2 and CASP8) which seemed to be independent to naevus 
or pigmentation associations.167 A meta-analyses of genetic association studies including ge-
nome-wide association studies found four loci with genome wide significance (16q24.3 
(MC1R), 20q11.22 (MYH7B/PIGU/ASIP), 11q14.3 (TYR), and 5p13.2 (SLC45A2).168 An Australian 
GWAS confirmed previous loci and detected two novel loci at chromosome 1, 1q21.3 in prox-
imity of the genes ARNT and SETDB1 and at 1q42.12 in the DNA repair gene PARP1.169 The 
GWAS performed by Nan et al. identified NID1 as susceptibility locus.125 A pathway based ap-
proach was used by Schoof et al. to focus on regions with previously known association to 
immunosuppression pathways as potential melanoma susceptibility loci. However, initial sig-
nificant associations were not replicated in a second phase.170 Investigating 156 melanoma 
cases from high-risk pedigrees three SNPs with genome-wide significance were detected on 
chromosome 10.171 The latest GWAS with the largest study population to date was published 
by Ransohoff et al. using the 23andMe research cohort with self-reported melanoma cases 
and controls of European ancestry and a smaller stage 2 cohort for replication. The study con-
firmed 20 previously known loci and found a novel SNP (rs187843643) downstream of BASP1 
at chromosome 5.172 The clinical significance of this region is supported by a prior report of 
the prognostic impact of BASP1 methylation in human melanoma samples.173 
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1.5. PGC-1 Family Coactivators 
The first member of the PGC-1 family (Peroxisome proliferator-activated receptor gamma co-
activator encoded by the PPARGC1A gene) was identified in 1998 by Puigserver et al. They 
found a strong expression of PCG-1α upon cold exposure in mice. Expression of PCG-1α was 
associated with an increased function of PPARγ and an increased amount of mitochondrial 
DNA.174 Two other members of the PGC-1 family, PCG-1ß (PPARGC1B) and a more distant rel-
ative, PGC-1 related coactivator (PRC) were found through their similar amino acid sequence. 
PCG-1ß was first cloned in 2002 revealing a conserved amino acid motif between PCG-1α and 
PCG-1ß.175 This motif serves as a binding site for nuclear receptors to enhance transcriptional 
activity. PCG-1α and PCG-1ß both work as co-regulatory proteins together with estrogen-re-
lated receptors (ERRs) to regulate the expression of metabolic and mitochondrial genes and 
to maintain energy homeostasis.176 High levels of PGC-1 are found in energy demanding tis-
sues like brown adipose tissue, heart, brain and kidney which have also high numbers of mi-
tochondria. PGC-1 coactivators directly influence mitochondrial biogenesis through up-regu-
lation and coactivation of nuclear respiratory factor 1 (NRF1).177 Other roles of PGC-1 are the 
control of hepatic gluconeogenesis 178 and Glut4 expression in muscle cells.179 
 
 
 
 
Figure 4: PGC-1 family members: PGC-1alpha, PGC-1beta and PRC share important primary 
sequence characteristics. Image from Finck et al. 2006 180 
1.5.1. Role in Melanocytes 
Recently Shoag et al. described for the first time a role in the skin for two members of the 
PGC-1 family.181 They could show that both, PCG-1α and PCG-1ß, are involved in melanogen-
esis and are induced by secretion of a-MSH as a response of UV radiation. In turn PCG-1α and 
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PCG-1ß lead to the induction of MITF and other melanogenic genes. Furthermore, there is 
evidence for an association between a PGC-1ß variant (rs32579, located in intron 4) and in-
creased tanning ability.182 A recent analysis done by David Duffy et al. found evidence for a 
decreased naevus count and decreased melanoma risk for the minor allele at rs251464, lo-
cated in intron 1 (Duffy et al., in submission). 
1.5.2. Role in Cell Survival 
The survival of cells is regulated in a complex way with opposing pathways promoting either 
death or life. Cell death can occur through different routes e.g. via apoptosis, the well sorted 
deconstruction of a cell, or via necrosis which is a more chaotic process involving acute rupture 
of cell organelles. One important strategy of cancer cells is to resist cell death.183 Dysregulation 
of mitochondrial cell death pathways can result in either neurodegenerative and autoimmune 
diseases or malignant transformation, suggesting an important role of PGC-1 as a master 
regulator of mitochondria in these diseases.184,185 The mitochondrial death pathway can be 
activated by mitochondrial Ca2+ accumulation and overexpression of PCG-1α has been shown 
to reduce mitochondrial Ca2+ uptake and thus enhance survival in a cervical cancer cell line.186 
PGC-1 family members are physiologically expressed in tissues with a high energy need. Stress 
conditions like fasting, cold exposure and exercise increase the expression of PGC-1 and 
subsequently lead to an elevated mitochondria density.180 Overexpression of PGC-1 was 
demonstrated to support the cells coping with oxidative stress, e.g. through increased 
detoxification of mitochondrial and cytosolic reactive oxygen species (ROS).187 Cancer cells are 
dependent on an increased cell metabolism. A study published by Vasquez et al. could show 
that overexpression of PGC-1α in melanoma cells resulted in increased survival under 
oxidative stress conditions based on enhanced ROS detoxification capacities. PGC-1α negative 
melanoma cells were more sensitive to ROS-inducing drugs.188 Furthermore, activation of the 
PGC-1α – MITF axis may support the increased energy demand in melanoma cells as reviewed 
by Ze’ev Ronai.189  
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1.6. Hypothesis and Aims 
Hypotheses 
Melanoma risk is based on genotype, phenotype and environmental factors. Each of these 
factors also influence naevus development, which is the most important melanoma risk factor. 
Understanding the genetic determinants of naevus pattern might foster the understanding of 
melanoma development. 
Melanoma risk is higher for individuals with high total body nevus count, but these patients 
are more likely to have low risk melanomas and an improved prognosis. The typical patient at 
high risk of melanoma is not the typical patient at high risk of progression and death. 
UV exposure is the only predominant environmental risk factor.190 Comparing melanoma pa-
tients from two countries with different daily UV exposure might reveal the impact of this 
factor on melanoma risk and prognosis. 
Variants of the genes PPARGC1B and PPARGC1A might influence pigment traits and melanoma 
risk and prognoses. 
Research Questions 
Chapter 3: 
• Is the dominant dermoscopic naevus pattern different between early and late stage 
melanoma patients? 
• Is the dominant dermoscopic naevus pattern of an individual patient genetically deter-
mined? 
Chapter 4: 
• Are there differences between early and late stage melanoma patients? 
• Do melanoma patients with multiple melanocytic naevi have a more favourable prog-
nosis as compared to melanoma patients with few naevi? 
Chapter 5: 
• Are there differences between German and Australian melanoma patients? 
Chapter 6: 
• Is there an influence of PPARGC1B and PPARGC1A germline coding variants on naevus 
count, skin reaction, melanoma risk and melanoma progression? 
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Aims 
Aim 1 
To initiate a Melanoma cohort study in Tübingen with phenotypic, genotypic and dermoscopic 
data in order to test initial hypotheses / generate further hypothesis 
• Chapter 3: Case Reports of a Pilot Study from Tübingen 
Aim 2 
To establish a German dataset similar to the dataset of the Brisbane Naevus Morphology Study 
in order to perform comparative analyses with two independent cohorts 
• Chapter 4: Comparisons of early stage and late stage melanoma patients from Tübingen 
• Chapter 5: Comparisons of German and Australian melanoma patients 
Aim 3 
To generate a library of SNP data derived from germline DNA of two independent cohorts, the 
Australian and the German cohort of melanoma patients and controls. 
• Chapter 4: Genome-wide association with survival 
• Chapter 6: PGC-1 Associations 
Outlook:  First genome wide association study (GWAS) on melanoma risk as future pro-
ject with the use of the generated SNP library and healthy controls from the 
KORA dataset 
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2. Methods 
2.1. Ethical Clearance 
The work of this PhD thesis was based on data, images and biomaterial from melanoma pa-
tients and controls of two different countries, which were sampled during different time pe-
riods by the candidate and by colleagues. A total of 4 different ethical approvals were obtained 
to gather and to work with the data and material of the individuals. 
A positive ethic vote was obtained in 2013 by the candidate for the pilot study with the title 
“Genetics and naevus pattern in melanoma patients“. After submission of the protocol de-
scription, the planned assessments and a copy of the patient information and consent sheet, 
the positive ethic vote was assigned by the ethic committee of the Eberhard Karls University 
on the 8th July 2013 with the ethic number 326/2013BO2. 
The Brisbane Naevus Morphology Study was initiated in 2009 by Prof. H. Peter Soyer to inves-
tigate melanoma patients and controls from Brisbane with phenotype and genetic data. The 
study was approved from the Metro South human ethics committee with the reference num-
ber HREC-09-QPAH-162. The UQ human ethics number was 2009001590.  
The second cohort from Tübingen was drawn from a study with the title “Hereditary defects 
and cutaneous malignant melanoma“, which was approved by the ethic committee of the 
Eberhard Karls University on the 12th December 2007, the ethics number was 376/2007B01. 
The study was designed to examine genetic and environmental risk factors for the develop-
ment of melanoma. One analysis with collaborators at the Copenhagen University Hospital in 
Denmark was performed with the data in the past and published in 2011.191 Future analyses 
of genetic associations were approved by the ethics committee in 2007.  
In 2014 the candidate applied for an ethic approval to use data and material from the study 
‘Hereditary defects and cutaneous malignant melanoma’, in order to perform comparative 
analyses with the data from the Brisbane Naevus Morphology Study. An institutional human 
research ethics approval was obtained from the University of Queensland (Approval Number 
2014001223). 
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2.2. Study Populations 
The present work and the analyses of this PhD thesis are based on three study populations. 
The first study was the pilot study, which was initiated and conducted by the candidate in 
Tübingen and consisted of 16 melanoma patients. The patients were recruited in July and Au-
gust 2013. The second study was the Brisbane Naevus Morphology Study, initiated by Prof. H. 
Peter Soyer. This study has been commenced in 2009 and still has an ongoing recruitment. 
The candidate was involved in patient recruitment in 2014. The third study was the study with 
the title ‘Hereditary defects and cutaneous malignant melanoma’ from Tübingen and was ini-
tiated by Dr. Thomas Eigentler and Prof. Claus Garbe in 2007. The candidate was involved in 
patient recruitment as a resident in the department of Dermatology. The last study participant 
was included in 2011. 
Recruitment and patient selection for the analyses as the basis of this PhD thesis will be de-
scribed for each of the three studies in the following. 
2.2.1. Pilot Study Tübingen 
The patients were recruited at the University Hospital Tübingen in the Department of Derma-
tology. They were asked during their regular visit in the melanoma outpatient clinic if they 
would be interested to take part in a clinical study. The patients gave written informed consent 
before any study specific procedures were performed. A total of 16 melanoma patients were 
recruited in July and August 2013. 
None of the patients had withdrawn their consent and all patients were included in the anal-
yses. 
2.2.2. Australian Cohort Study 
The patients and controls were recruited at the Dermatology Department and the Melanoma 
Unit of the Princess Alexandra Hospital in Brisbane, Australia as well as in community private 
dermatology clinics. Participants who had no personal history of melanoma were recruited by 
public advertisement and by contacting participants from a previous study, the Brisbane Twin 
Naevus Study.127 All participants had given written informed consent prior to study entry. 
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For the purpose of the analyses for this PhD thesis all consecutively recruited individuals with 
the first entry at the 19th Oct 2009 until a defined cut-off date (12th Oct 2015) were considered. 
The definition of this cut-off date was based on the last patient whose germline DNA was 
submitted for CoreExome genotyping by 13th Dec 2016, which was the time point of dataset 
closure. One patient (Patient ID 1374MB) was excluded, as no data at all were obtained after 
enrolment. Participants with missing genetic data were excluded as well. Those were 12 par-
ticipants (Patient IDs: 141JB, 384KN, 550BB, 704JG, 709SJ, 747LH, 761PO, 957TJ, 1009MF, 
1016RC, 1028PM and 1049PC) who did not give saliva at study entry and two participants 
(Patient IDs: 745SS, 903JA) whose samples did fail for genotyping on the Illumina CoreExome 
Chip. 
A total of 893 participants of the study were thereby considered for the Australian cohort, 
including 454 melanoma patients and 439 controls. 
2.2.3. German Cohort Study 
The patients and controls were recruited at the Department of Dermatology of the University 
Hospital Tübingen. Melanoma patients were asked to participate at the study during their fol-
low up visits in the melanoma outpatient clinic, participants without a history of melanoma 
were recruited during other dermatologic consultations, mainly at the general dermatologic 
outpatient clinic, or from clinic staff. All participants had given written informed consent prior 
to study entry. The first participant was included in 2007, the last one in 2011. A first report 
using the data was published in 2012.191 
For the purpose of the analyses for this PhD thesis all participants with available frozen blood 
samples were considered. These were 558 samples from melanoma patients and 204 samples 
from controls, which were shipped to Australia. Two EDTA blood tubes were stored for one 
participant without a history of melanoma, reducing the number of control cases to 203 cases. 
All melanoma samples and 58 control samples were genotyped with the Illumina CoreExome 
Chip. Two cases of the melanoma group showed a mismatch of their recorded sex and the 
gender based on the genotype result (M316 and M372). One was recorded as female and 
showed a male genotype, one was recorded as male and showed a female genotype. Both 
cases were melanoma patients. Most likely those two blood samples were swapped by 
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accident. Both cases were excluded from the analyses for safety reasons. All participants with 
available genetic data were included. 
A total of 614 participants of the study were considered for the German cohort, including 556 
melanoma patients and 58 controls.  
2.3. Study Measures 
The study specific procedures consisted in all three studies of i. the performance of physical 
assessments, ii. the completion of questionnaires by the physicians and by the participants 
and iii. the sampling of blood or saliva of the participants to obtain germline DNA. 
Naevus images and overview images were taken from the participants of the pilot study Tü-
bingen and of the Australian cohort study, but not of the German cohort study. 
Measurements of the skin reflectance as a marker for the skin colour were only done for par-
ticipants of the Australian cohort study. 
2.3.1. Pilot Study Tübingen 
The detailed description of the study measures is given in chapter 3.2.3. The procedures were 
similar to those of the Australian participants as explained in the next paragraph. 
2.3.2. Australian Cohort Study 
The study participants of Brisbane were investigated by research assistants in the study centre 
of the Princess Alexandra Hospital. Prior to the study examinations they were asked to fill out 
a questionnaire which covered information of their ethnical background, hair- and eye colour, 
response to sun exposure, sun behaviour, personal and family history of melanoma and med-
ication. Skin reflectance measurements were done at the inner and outer forearm to quantify 
constitutive and facultative skin pigmentation. The total naevus count of naevi from 5mm was 
recorded and each naevus was classified as flat or raised. Additionally, a total body photog-
raphy as well as dermoscopic imaging of each individual naevus was performed using a digital 
computer dermoscope (FotoFinder Dermoscope, Bad Birnbach, Germany). Each participant 
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donated 2ml saliva using an Oragene-DNA self-collection kit (DNA Genotec, Ottawa, ON, Can-
ada) in order to obtain germline DNA. 
Melanoma specific data, such as localisation of the primary, histology and specific details of 
the histopathological report like ulceration, naevus association and signs of regression as well 
as subsequent metastases during the follow up were retrospectively recorded by research 
assistants. The first reports with data from study participants of the Australian cohort study 
were published in 2014 and 2016.152,192 
2.3.3. German Cohort Study 
The study participants of Tübingen were investigated by physicians of the melanoma outpa-
tient clinic during their regular appointment. The patients were asked to complete a question-
naire which covered information on the ethnical background, pigmentation traits, like hair and 
eye colour, response to sun exposure, personal sun behaviour, personal and family history of 
melanoma or other cancers and medication. Participants were also asked to estimate the total 
number of their moles. Part of the study was a full body examination by a dermatologist. In 
order to quantify the presence of melanocytic naevi, the total number of naevi was grouped 
into 6 categories, which were 0-10, 11-30, 31-50, 51-100, 101-150 and above 150 naevi. All 
naevi with a diameter from 3mm were included. The number of dysplastic naevi was addition-
ally recorded within the categories 0, 1-5, 6-10, 11-20 and above 20 dysplastic naevi. Further-
more, the Fitzpatrick skin type, signs of sun damage and the presence of actinic keratoses 
were documented. Blood was drawn to extract the germline DNA of each participant. 
Data from all melanoma patients from Tübingen are generally included into the Central Ger-
man Melanoma Registry after written informed consent. Therefore, detailed melanoma spe-
cific data were additionally available for the patients of the German cohort study. These in-
cluded data related to the primary melanoma, such as the date of excision, localisation, his-
tology and initial stage of disease. Furthermore, date and localisation of subsequent metasta-
ses, subsequent clinical stages, date and cause of death were recorded. These data were 
based on prospectively obtained follow up reports provided by the responsible physicians and 
entered by research assistants of the Central German Melanoma Registry.  
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2.4. Genotyping 
Germline DNA from all selected study participants were processed for genetic analyses. These 
were 16 and 556 melanoma patients and 58 control cases from Tübingen (N=630) as well as 
454 melanoma patients and 439 control cases from Brisbane (N=893). The first set of 16 pa-
tients from Tübingen and the individuals from Brisbane gave saliva samples with an Oragene-
DNA self-collection kit (DNA Genotec, Ottawa, ON, Canada) for DNA extraction. The second 
set of samples from Tübingen consisted of frozen EDTA blood samples.  
2.4.1. DNA Extraction 
2.4.1.1. Saliva Samples 
The germline DNA extraction of the saliva samples from Brisbane and the first 16 samples from 
Germany were done using the prepITTM L2P kit from DNA Genotek®. The saliva samples from 
Germany were extracted at the Institute for Molecular Bioscience in Brisbane. The saliva sam-
ples from Brisbane were collected between 2009 and 2015. The extractions were done at the 
Institute for Molecular Bioscience in Brisbane and from 2014 at the Dermatology Research 
Centre (DRC), Translational Research Institute (TRI) in Brisbane. 
The DNA purification was done according to the manufacturer's protocol as follows. Each sam-
ple was mixed by inversion and was incubated in a water bath at 50°C for one hour to release 
the DNA and to inactivate nucleases in the probe. For one extraction step, 500ul of the sample 
were transferred to a 1.5ml microcentrifuge tube and 20ul of PT-L2P was added to precipitate 
impurities and inhibitors. After incubation on ice for 10 minutes the sample was centrifuged 
for 5 min at 13,000rpm. The supernatant was transferred to a microcentrifuge tube and 600ul 
ethanol was added to precipitate the DNA. The sample was left for 10min at room tempera-
ture and then centrifuged for 2min at 13,000rpm. The supernatant was removed with a pi-
pette tip and discarded. After a washing step with ethanol the DNA pellet was dissolved with 
100ul of TE solution. The DNA was incubated for an hour at room temperature followed by 
vortexing. The rehydrated DNA was stored in TE solution at 4°C. 
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The DNA quality and concentration were measured using a Spectrophotometer (NanoDrop™). 
For each sample the volume, the concentration (mg/ul), the absorbance at A260, the 
A260/A280 ratio and the total yield (uq) was recorded in an excel sheet. 
2.4.1.2. Blood Samples 
The germline DNA extraction of the blood samples from Germany were done using the column 
based QIAamp DNA Blood Midi Kit. The blood samples were collected during the years 2007 
and 2011 and were stored in EDTA tubes at -80°C in Germany. In 2014 they were shipped on 
dry ice to Australia and stored again at -80°C. The extractions were done between December 
2014 and March 2015 at the DRC, TRI in Brisbane. 
The extractions were performed with each sample following the instructions of the Qiagen 
protocol as follows. Two ml of the thawed blood sample were mixed with 200ul Protease in a 
15ml centrifuge tube. As a next step 2.4ml Buffer AL was added and after inverting 15 times 
and shaking for 1min the probe was placed in a 70°C water bath for 10min. After adding 2ml 
ethanol, half of the sample was transferred into a QIAamp Midi column and centrifuged at  
3 000 rpm for 3min. The filtrate was discarded and the rest of the sample was transferred, 
centrifuged and the filtrate discarded. Subsequently two washing steps by adding Buffer AW1 
and Buffer AW2, 2ml each, and centrifugation at 5 000rpm for 1min and 15min respectively 
were performed. The column was then transferred into a clean 15 ml centrifuge tube. An 
amount of 300ul Buffer AE was placed on the column membrane and the DNA was solved 
during a 5min incubation followed by a centrifugation at 5000rpm for 2min. This last step was 
repeated in order to increase the DNA yield. 
The DNA quality and concentration were measured using a Spectrophotometer (NanoDrop™). 
For each sample the volume, the concentration (mg/ul), the absorbance at A260, the 
A260/A280 ratio and the total yield (uq) was recorded in an excel sheet. 
2.4.2. Sanger Sequencing 
Sanger Sequencing was performed with 175 germline DNA samples of the Brisbane cohort and 
with 16 samples of the German pilot study samples. Two different loci were sequenced. The 
first one was the melanocortin 1 receptor (MC1R) coding sequence at chromosome 16. The 
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second locus was on chromosome 5 within the gene PPARGC1B, coding for the protein Perox-
isome proliferator-activated receptor gamma coactivator 1-beta. 
The steps are described below in detail. At a glance they included the amplification of the 
germline DNA template via Polymerase chain reaction (PCR) with the use of oligonucleotide 
primers. A nested PCR with suitable primers was already established for the MC1R locus.149 
Customized primers were designed for the PGC-1b locus and a single PCR was performed. The 
subsequent steps for both loci were the separation on a gel via Electrophoresis, gel extraction, 
quantification and quality check with a spectrophotometer and the performance of the se-
quencing reaction. The samples were then submitted to the Australian Equine Genetics Re-
search Centre (AEGRC, Brisbane, Australia) for sequencing. The retrieved data was analysed 
using the Sequencher® software (Company: Gene Codes Corporation). 
2.4.2.1. PCR 
MC1R 
A nested PCR was performed to amplify the long MC1R locus. Two sets of primer pairs were 
used. 
 
The oligonucleotide sequence of the primers for the first step, the outer PCR were: 
N-outer (5’ -AGATGGAAGGAGGCAGGCAT-3’) 
C-outer (5’ -CCGCGCTTCAACACTTTCAGAGATCA-3’) 
 
The oligonucleotide sequence of the primers for the second step, the inner PCR were: 
N-inner (5’-CCCCTGGCAGCACCATGAACT-3’) 
C-inner (5’ -TGCCCAGGGTCACACAGGAAC-3’) 
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A 25ul system was used with an amount of 50-100ng germline DNA, dNTPs, primers, DMSO, 
MgCl2, Promega buffer and Taq enzyme in defined amounts as listed below. 
 
1. 10X Promega buffer 2.5ul 
2. DMSO   2.5ul 
3. dNTPs    2.0 
4. N primer   1.0 
5. C primer  1.0 
6. MgCl2   0.75 
7. Taq   0.25 
8. DNA    50-100ng 
9. H2O   bring total up to 25ul 
 
The components No 1 – No 7 of the system were multiplied with the number of the processed 
samples +1 to set up a master mix. Taq polymerase was added as the last component and the 
master mix was kept on ice. It was instantly distributed on the prepared PCR tubes containing 
the germline DNA of each sample and the calculated amount of Millipore water (water puri-
fied with a Milli-Q® Water System). 
 
The probes were then transferred into a standard PCR thermal cycler. The cycling steps were 
programmed with the following specifications: 
 
First cycle (initialization step)      94°C for 3 min 
34 cycles (denaturation, annealing, extension), each:  94°C for 1 min 
         55°C for 1 min 
72°C for 2 min 
Last step (final elongation)      72°C for 7 min 
 
The resulting PCR product of the outer PCR was used as a template for the inner PCR. The 
master mix with the inner primers was set up as above with 1ul of the DNA template. The PCR 
program was repeated as described above. 
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PGC-1b 
A single PCR was performed to amplify a selected region of PGC-1b at exon 5. Primers were 
designed using Primer3, an online tool, available at http://biotools.umassmed.edu/bio-
apps/primer3_www.cgi. 
The reference sequence of the PGC-1b region of interest was given in the 5´ 3´direction and 
a forward and backward primer were calculated according to the predefined standard settings  
 
The oligonucleotide sequences of the primers were: 
Forward primer:  5’-TGAGACACATGGGAGGAGTG-3’ 
Reverse primer:  5’-AGGTAAGGATCGCAGCTTCAC-3’ 
 
The master mix components were set up using the following ingredients per sample. 
 
1. 10X Promega buffer 5ul 
2. DMSO   2.5ul 
3. dNTPs    1.0 
4. N primer   1.0 
5. C primer  1.0 
6. MgCl2   0.5 
7. Taq   0.5 
8. DNA    50-100ng 
9. H2O   bring total up to 50ul 
 
The PCR program was performed in an analogous fashion to the above described PCR of MC1R. 
2.4.2.2. Gel Electrophoresis 
A 1% agarose gel was prepared to run a gel electrophoresis with the PCR products. Sybr® Safe 
was used to visualise the DNA. The PCR products were mixed with loading dye on the cham-
bers of the gel, which was placed on the gel tray within Tris Acetat EDTA Buffer. The Electro-
phoresis was run at 100V. Images of the bands were documented on a Gel Doc Imaging 
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system. Gels with clear bands around 1000bp for the MC1R PCR and around 700bp for the 
PGC-1 PCR were transferred to an ultraviolet light station and the bands were excised with a 
scalpel and stored in an Eppendorf tube. 
2.4.2.3. DNA Gel Extraction and Quantification 
The single stranded DNA products of the PCR reaction were extracted from the gel using a Gel 
Extraction Kit from QIAGEN. The extractions were performed according to the manufacturer´s 
protocol as described below. The excised DNA fragments from the agarose gel were added 
with 3 volumes Buffer QG per volume gel and incubated at 50°C for 10min and the sample 
was mixed every two minutes until the gel slice has completely dissolved. Isopropanol was 
added. The sample was transferred to the spin column and centrifuged for one minute. In the 
next steps 500ul Buffer QG and 750ul Buffer PE were added consecutively, each time centri-
fuged and the flow-through was discarded. Finally, the DNA was eluted by adding 50ul Buffer 
EB to the centre of the membrane, followed by a centrifugation for one minute. 
The purified DNA was measured using a Spectrophotometer (Nanodrop®). After calibrating 
the system with Millipore water, an amount of 0.7ul sample was pipetted onto the pedestal. 
With closing the arm, a sample column was formed. Measurements were performed at the 
wavelengths of 260nm and 280nm. The concentration (mg/ul), the absorbance at A260, the 
A260/A280 ratio were displayed by the spectrophotometer and recorded. 
2.4.2.4. Sequencing Reaction und Submission for Sequencing 
For the sequencing reaction a master mix was set up using the following components in a 
system of 20ul per sample. 
1. Big dye terminator v3.1   1ul 
2. Seq buffer (5XB)    3.5ul 
3. 3.2pmol Primer    1ul 
4. DNA      20ng 
5. sH20      bring total up to 20ul 
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For the MC1R sequencing reaction two separate reactions for N and C-inner were prepared to 
obtain a bi-directional sequencing.149 The PGC-1b sequencing was performed with one se-
quencing reaction per sample, using the forward primer of the PCR reaction. 
 
The PCR tubes were placed in an Eppendorf PCR machine with the following sequence reaction 
program: 
Step 1:     94°C, 3 min 
Step 2 was repeated 30 times: 94°C, 12 sec 
     50°C, 8 sec 
     60°C, 4 min 
Step 3     hold at 4°C 
The samples were submitted to the Australian Equine Genetics Research Centre (AEGRC, Bris-
bane, Australia) were the reading out of the sequences was performed. 
2.4.2.5. Analyses of Chromatograms 
The chromatograms with the analysed sequences were provided as “ab1” and “seq” files. The 
data was assessed with the program Sequencer 5.1 (Gene Codes Corporation). The reference 
sequences of the analysed DNA region of PPARGC1B was obtained from the online SNP data-
base (https://www.ncbi.nlm.nih.gov/snp) of the National Center for Biotechnology Infor-
mation. The reference of the analysed region within MC1R was already available in the work-
ing group and was provided for the analyses. 
In average a set of four chromatograms from different samples were imported together with 
the respective reference sequence in one project file at one time. The sequences were auto-
matically assembled to the reference sequence. The overview function of the program dis-
played the sequenced fragments as lines and provided an assessment if the full expected 
length of each sample was obtained. Going into detail of the base sequences, the bases were 
displayed as characters – A, T, G and C - as well as chromatograms in the colours green, red, 
black and blue, respectively. The program highlighted variants in comparison to the reference 
sequence automatically with a certain amount of false positive and false negative findings. 
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Thus, all chromatograms were throughout visually investigated and compared with the refer-
ence sequence and each other. Homozygous variants were detected as one peak in a different 
colour on the chromatogram, heterozygous variants with two equally high peaks in different 
colours and insertions or deletions through a shift of the expected sequence alignments. The 
analyses were repeated for each set of samples. The results were recorded first manually and 
then transferred into excel sheets. 
2.4.3. TaqMan Assay 
TaqMan SNP genotyping assays were performed on a 384-well-plate format using a ViiA™ 7 
Real-Time PCR system and analysis was carried out using the QuantStudio™ Real Time PCR 
software v1.1 (Applied Biosystems).193 
The TagMan assay was not performed by the candidate, but by Kasturee Jagirdar and Hilary 
Yong.  
The four additional SNPs that were genotyped using the TaqMan assay consisted of three 
MC1R polymorphisms; rs885479 R163Q, rs1805005 V60L, rs1805009 D294H, and a PGC-1β 
non-coding variant rs251468.  
2.4.4. CoreExome Chip Array 
In respect to the fast-evolving next generation high through put SNP assay, the CoreExome 
Chip array from Illumina was used from 2014 to genotype the samples of the Brisbane cohort 
study and the German cohort study. For the purpose of the present studies a total of 630 
samples from Tübingen and 893 samples from Brisbane were genotyped. This resulted in data 
for more than 500 000 exon and tagging SNP locations per sample. 
The samples were prepared in the lab as described below and submitted to the UQ Centre for 
Clinical Genomics (UQCCG) at the Translational Research Institute (TRI) where the genotyping 
was performed. The data which were provided by UQCCG consisted of binary files in the 
“.bed”, “.bim”, “.fam” format for Plink analysis. 
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2.4.4.1. DNA Preparation and Submission 
Genomic DNA samples which were prepared for genotyping using the Illumina HumanCoreEx-
ome-24 platform, were required to contain a minimum of 2.5ug of DNA with concentrations 
ranging from 100 to 300ng/ul, resulting in a volume between 20 and 25ul dependant on the 
DNA concentration of the sample. 
After DNA extraction from the EDTA blood samples, some of the samples were available in the 
right concentrations, some had higher and a large number of samples had lower concentra-
tions than required. 
Samples with higher concentrations were re-diluted and measured with Nanodrop® until the 
values were in the desired range. 
A total of 435 samples had concentrations below 75ng/ul. Those samples were processed with 
a vacuum concentrator (SpeedVac) as follows. 
A set of 20 selected samples were processed at one time. The samples were placed in 1.5ml 
tubes in a heated centrifuge chamber which was connected to a vacuum pump. The low pres-
sure resulted in a decline of the boiling point and facilitated an evaporation of the DNA sol-
vents. The target volume was calculated by using the equation:  
C1 (ng/ul) x V1 (ul) = C2 (ng/ul) x V2 (ul) 
C1 was the measured concentration, V1 the volume processed on SpeedVac(ul), which was in 
general 150ul, C2 (ng/ul) was the concentration aimed at (120 ng/ul) and V2 (ul), was the esti-
mated target volume. 
The time duration of processing the samples in the SpeedVac ranged from 10 to 40min until 
the volume was equal or less the calculated value. 
The samples were subsequently re-suspended with Buffer AE Elution buffer if necessary to 
reach the exact target volume. The target concentration was measured with a spectropho-
tometer and re-concentrations or re-dilutions were performed if required. 
For quality assessments all samples were measured with NanoDrop™ prior submission and 
the absorbance at A260 as well as the A260/A280 ratio were recorded in excel sheets. 
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For submission the samples were aliquoted in 96-well semi-skirted PCR plates (Axygen Scien-
tific) and sealed with Clear Self-Adhesive Topseal (PerkinElmer). 
An excel sheet which assigned the plate coordinates (Plate No, A01, A02,…) to the sample ID, 
gender information, DNA concentration (ng/ul), Volume (ul) and Date, was submitted along 
with the PCR plates. 
2.4.4.2. Interpretation of the CoreExome Chip Results 
The genotype approach using the Illumina HumanCoreExome BeadChip resulted in raw data 
files and additionally files in a binary format. The raw data were charts with coloured dots 
within the x-axis and y-axis. Genotype information was displayed in one chart per SNP. The 
location of the dots in the chart was determined by fluorescent intensity measurements. They 
indicated the result of each analysed individual at the representative SNP, having either two 
major alleles, one minor and one major allele, or two minor alleles at the respective locus. 
The files in the binary format (“.bed”, “.bim”, “.fam”) included the genotype for each of the 
550,601 markers. The genotype was assigned to the sample IDs and the gender data. The gen-
otype for each marker was given in the format “homozygous genotype” or “no homozygous 
genotype”, coded with 1 or 0, as well as in the format “number of minor alleles”, coded with 
0, 1 and 2. The data was extracted from the files using the program Plink as described below 
in 2.6.1. The data was retrieved as csv file (comma separated values) and was imported in 
other programs such as SPSS and Excel for further analyses. 
2.5. Data Management 
The data management included the sampling, storage and processing of patient data and ma-
terial, the documentation of laboratory work and the storage of electronic files related to this 
work. 
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2.5.1. Patient Data Management 
Patient data used in this work were sampled through three different study protocols.  
The recruitment of the pilot study patients resulted in the following documents and material 
per patient: the patient information and consent, a clinical assessment documentation and a 
patient questionnaire, images and saliva samples. The patients were pseudonymised using 
patient IDs (TU-01, TU-02, TU-03, ….). TU stood for Tübingen and the number represented the 
sequence of patient recruitment. The documents were kept exclusively as paper copies at the 
Eberhard Karls University of Tübingen. Informed consent sheets and the patient identification 
list were kept at the office rooms of the Central German Melanoma Registry, University of 
Tübingen. The information on the assessment and questionnaire files were transferred by the 
PhD candidate as variables into SPSS files using exclusively the patients ID. The pseudonymised 
SPSS files were stored at the University of Queensland and the Eberhard Karls University of 
Tübingen. The patient images were labelled with the patient IDs and stored at the University 
of Queensland and the Eberhard Karls University of Tübingen. The overview images did not 
allow a personal identification of the patients. The patient saliva samples were labelled with 
the Patient ID and transferred to Brisbane. The pseudonymised genotyping results from the 
saliva samples were recorded manually on paper and were then transferred into excel sheets 
and SPSS files. 
The recruitment of the cohort study from Brisbane resulted in the following documents and 
material per patient: the patient information and consent, clinical assessment sheets, a pa-
tient questionnaire, images and saliva samples. The patients were pseudonymised using con-
secutively allocated numbers and the patient’s initials (1AR, 3MM, 4PF, …). The data was trans-
ferred to excel sheets by research assistants. Images, saliva samples as well as the genotyping 
results were stored at the University of Queensland. Copies of the excel sheets with pseudon-
ymised data were stored additionally at the Eberhard Karls University of Tübingen. 
The recruitment of the cohort study from Tübingen resulted in the following documents and 
material per patient: the patient information and consent, clinical assessment sheets, patient 
questionnaire and blood samples. The patients were pseudonymised using either the letter K 
for study participants without a history of melanoma or M for melanoma patients in the com-
bination with consecutively allocated numbers (K1, K2, … M1, M2, …). The paper sheets were 
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stored at the office rooms of the Central German Melanoma Registry, University of Tübingen. 
In 2014 the pseudonymised questionnaires and assessment sheets were scanned and send on 
a web based data cloud of the University Hospital Tübingen to share the data with the PhD 
candidate. The patient identification list and the informed consent sheets remained in Tü-
bingen at all time. Blood samples were labelled with the IDs and were stored initially in Tü-
bingen until they were transferred to Brisbane in 2014. The patients were additionally as-
signed to the Central German Melanoma Registry. A registry extract with melanoma specific 
data of the selected melanoma patients was send electronically to Brisbane in 2015. The dif-
ferent data sources were merged using the Patient IDs as key identifier and stored pseudony-
mised in a SPSS file. 
2.5.2. Documentation of Laboratory Work 
The laboratory work of the PhD candidate was done at two different laboratory institutes in 
Brisbane. In the years 2013 and 2014 the candidate was located at the Institute for Molecular 
Bioscience (IMB) and from 2014 to 2015 at the DRC, TRI in Brisbane. Each work step was doc-
umented by the candidate in a paper lab book at the bench. The lab books were provided by 
the institutes and were archived on site after the departure of the candidate.  
2.5.3. Storage of Electronic Files 
Electronic files related to this work included pseudonymised patient data, result data, docu-
mentation and literature. These electronic files were initially stored at the local hard drive 
allocated to the working group at the Institute for Molecular Bioscience (IMB). They were then 
transferred to the folder of the DRC, TRI. Both locations had regular safety backups performed 
by the institutional information technology services. After the relocation to Germany a VPN 
(virtual private network) connection was established to enable a continuous data exchange. 
In addition, the files were transferred to the hard drive of the Center of Dermatooncology with 
regular backups performed by the information technology service of the University Tübingen. 
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2.6. Statistical Analyses 
The gathered phenotypic, genotypic and disease specific data of the patients, which were used 
for the present work, were processed and analysed using different statistical programs and 
packages. The involved programs included the open source projects Plink194, R195 and the Sib-
pair package, which was programmed by the co-supervisor David Duffy as well as the com-
mercially available programs SPSS and Stata. 
2.6.1. Plink 
Plink is an open-source C/C++ tool set which was developed to perform genome association 
studies.194 The software was downloaded from the URL http://pngu.mgh.harvard.edu/pur-
cell/plink/ and installed at the notebook of the candidate. The command-line program Plink 
was used as a first step to extract the SNPs of interest. Therefore, the single batches of binary 
files, which contained the genotype results from the Illumina CoreExome Chip were loaded 
step by step into the software. Providing a separate txt file of the required SNPs identificators 
a cvs file was generated containing the patient IDs together with gender data and the geno-
type of the requested SNPs. 
2.6.2. Sib-pair 
The software Sib-pair was developed by David Duffy to work with genetic datasets. Along with 
general genetic analyses capabilities the program has a special advantage to deal with related 
study participants for genetic association studies. The software is available from the URL 
https://genepi.qimr.edu.au/staff/davidD/#sib-pair. The Version 1.0 beta, 6.10.2012 was 
downloaded by the candidate and used for association analyses and to perform the genome-
wide association analyses on survival. 
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2.6.3. R 
The R package is an open source program language and at the same time the name of a free 
software package. A free download is available from the internet. The software was used for 
the graphs in Chapter 5.3. and for computing summary statistics and the corresponding forest 
plot in Chapter 5.4.5. 
2.6.4. SPSS 
SPSS (Statistical Package for the Social Sciences) is a Java based software program for statisti-
cal analysis. A software licence was available at the University of Queensland and the Center 
of Dermatooncology in Tübingen. The University of Queensland provided additionally a stu-
dent licence for a time limited use of the software on the candidate´s notebook. The program 
has a graphical user interface, and the data is displayed in analogue to data in excel sheets. 
These features facilitated the necessary steps of merging the data from different sources and 
clearing the data. Different stages of patient recruitment within the Brisbane cohort study and 
manually recorded patient IDs resulted in differing patient IDs in the various data sources. The 
data view as tables was therefore helpful in identifying data mismatches and confirming con-
gruencies. The multiple steps of merging and dividing cohorts for the present work were sup-
ported by the functionality of the program as well. Statistical analyses, such as analyses of 
frequencies, association analyses with fisher’s exact test and Chi square tests, regression mod-
els and survival analyses were carried out as described in the respective chapters. SPSS was 
also used to generate figures such as bar charts and Kaplan Meier survival plots. Due to an 
extended display function for the plots, the presented Kaplan Meier survival plots were built 
using Stata. 
2.6.5. Stata 
The software Stata (Statistics and data) is a software package developed 1985 by the company 
StataCorp.196 A Stata licence was available at the Center of Dermatooncology in Tübingen. The 
software was used to compose Kaplan Meier survival plots with the automated inclusion of a 
number at risk table. The presented p-values of the statistical test were derived from the anal-
yses performed with SPSS.  
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3. Pilot Study with 16 Melanoma Patients from Tübingen 
3.1. Introduction 
A pilot study was initiated as a first step of the PhD project in Tübingen in 2013. The aim was 
to sample clinical data, general information and biomaterial of melanoma patients from Ger-
many in order to compare these data with Australian melanoma patients. The special focus 
was the dermoscopic pattern of naevi in melanoma patients and the comparison of those pat-
terns between metastasized and non-metastasized patients. The study was designed in ac-
cordance with the Brisbane Naevus Morphology Study (NHMRC Project Grant Application: 
APP1004999, Scientific Title: Effects of naevogenesis susceptibility genes and phenotypic cor-
relation with dermoscopic characteristics of naevi – Soyer HP, Sturm RA, Duffy D, Smithers M) 
to enable comparative analyses. The material was then transferred to Australia in order to 
process the samples and to analyse the data. 
3.2. Methods 
3.2.1. Ethics 
The pilot study with the title “Genetik und Nävusmuster bei Melanompatienten“ (English 
translation: “Genetics and naevus pattern in melanoma patients“) was planned in 2013 in Tü-
bingen. A detailed description of the protocol, the planned assessments, a copy of the patient 
information and consent sheet was submitted to the ethic committee of the Eberhard Karls 
University Tübingen. The ethic committee asked for a remission regarding in- and exclusion 
criteria and patient ID. After resolution of the requested issues, the positive ethic vote was 
obtained on the 8th July 2013 with the ethic number 326/2013BO2. 
3.2.2. Study Population and Study Setting 
A total of 16 melanoma patients were included into the study. All patients were recruited 
during their clinical visit in the melanoma outpatient clinic of the University Hospital in Tü-
bingen. The melanoma outpatient clinic belongs to the Department of Dermatology and is 
part of the general outpatient clinic. About 5 000 contacts with melanoma patients were 
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recorded per in the year 2016. Most of the patients are referred after primary excision for the 
secondary excision with the final safety margin and a concomitant sentinel node biopsy. They 
are subsequently included in a structured follow up program which is recommended in Ger-
many and paid by the public and private health insurances. In single cases, such as the first 
case in the pilot study, patients are seen at their first visit with the suspicion of a primary 
melanoma. During the follow up visits the patients get a full body examination to exclude 
secondary melanomas and in-transit or lymph node metastases. Blood examinations and im-
aging procedures are completing the follow up checks. Some of the high-risk patients receive 
adjuvant treatments which are prescribed and monitored by the melanoma clinic. Patients 
who develop metastases and ultimately die of their disease are also seen and treated at the 
clinic either as outpatient or inpatient at the department of dermatology.  
Patients were asked during their visit at the melanoma outpatient clinic by the candidate if 
they would be interested in taking part of a research study. The study procedures and the 
voluntariness of their participation were explained to the patients and a copy of the patient 
information with the patient consent sheet was handed out to the patient. The study specific 
assessments were performed after the patients had given written informed consent. A copy 
of the consent sheet as well as the patient information was handed over to the patient. None 
of the patients had withdrawn their consent. 
3.2.3. Data Collection 
The data collection of the Pilot Study was planned to obtain comprehensive information about 
each patient including the general pigment traits, the number of moles, their sun seeking be-
haviour as well as the personal response to sun exposure, information about their ancestry, 
the family history of melanoma along with their medical history and the collection of germline 
DNA. All these data and materials were gathered within different data collection procedures, 
which are explained in detail below. 
The data collection procedures were organized in four parts after the patient had given writ-
ten informed consent. 
First part was the completion of the physician sheet, which required firstly to collect mela-
noma specific data from the medical records of the patient and secondly a full body examina-
tion of the patient.   
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Details to be recorded by the physician after the full body examination were:  
i. Constitutive skin colour, assessed at the ventral forearm within the categories  
1. Fair, 2. Medium, 3. Olive;  
ii Facultative skin colour, assessed at the dorsal forearm within the categories  
1. Fair, 2. Medium, 3. Olive; 
iii Eye colour, assessed within the categories  
1. Blue/grey, 2. Green/hazel, 3. Brown;  
iv Hair colour, assessed with the categories  
1. Red/red-brown, 2. Blonde, 3. Light brown, 4. Dark brown, 5. Black; 
v Freckling scores, assessed at three body regions, face, dorsal hand and shoulders within 
the categories 1. None, 2. Mild, 3. Moderate, 4. Severe;  
vi Naevus count, recorded within 18 regions at the front and 16 regions at the back and 
summed up to the total naevus body count.  
The 18 regions at the front of the body were: face, ear right, ear left, neck front, palmar 
right, forearm right, upper arm right, chest, abdomen, palmar left, forearm left, upper arm 
left, thigh ventral right, lower leg ventral right, foot right, thigh ventral left, lower leg ventral 
left, foot left. The 16 regions at the back of the body were: head, neck back, dorsal hand left, 
forearm left, upper arm left, back, buttocks, dorsal hand right, forearm right, upper arm 
right, thigh dorsal left, lower leg dorsal left, plantar left, thigh dorsal right, lower leg dorsal 
right, plantar right. Naevi were recorded from a size of 3mm. The last item to be recorded 
was vii the presence of a cutis rhomboidalis nuchae as a sign of chronic sun damage, meas-
ured in three categories, 0, + and ++. 
The second part of the data collection procedures was the imaging of the melanocytic naevi. 
After completion of the body examination and filling out of the physicians sheet the naevi of 
the patient were recorded using a digital computer based dermoscopic imaging system (Foto-
Finder Dermoscope®, Bad Birnbach, Germany). The FotoFinder Dermoscope® is a dermoscope 
system including a hand-held epiluminescence microscopy camera which is connected to a 
computer with the Fotofinder software. The system enables video documentation with follow 
up images of naevi and other skin lesions. The first step was to capture four overview images 
– upper body front, lower body front, upper body back and lower body back – which were 
loaded into the Fotofinder Software. The images were then presented on the computer screen 
and all melanocytic naevi which were chosen to be imaged via dermoscopy were marked and 
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consecutively numbered. In a next step all numbered lesions were imaged with the FotoFinder 
hand-held camera. The moles were imaged with direct skin contact using a disinfectant spray 
to reduce skin reflections. 
Part three of the data collection procedures was a questionnaire which had to be filled out 
by the patients. The questionnaire contained four sets of questions which covered the topics  
i General informations, 
ii Sun exposure,  
iii Skin cancer and moles and 
iv Medications.  
The questions for the patients are listed per area below: 
i General informations – 6 items 
1) Sex: male, female; 2) Date of birth; 3) Place of birth; 4) Ancestry: Western European, South-
ern European, Eastern European, other; 5) Height; 6) Weight. 
ii Sun exposure – 7 items 
1) Where have you been employed: 1. Mainly outdoors, outdoors and indoors, mainly indoors. 
2) Where have your leisure activities been: 1. Mainly outdoors, outdoors and indoors, mainly 
indoors. 
3) During the last year, how much time did you spend outdoors during sunrise and sunset, a. 
on a typical week day, b. on a typical weekend day: 1. Hardly ever (up to one hour), 2. Less 
than 50% of the time (2-4 hours), 3. More than 50% of the time (5 hours and more) 
4) When you have been outside in the sun, on average, how often have you, a. worn sun-
glasses, b. worn a hat, c. applied sunscreen: 1. Never, 2. Less than 50% of the time, 3. More 
than 50% of the time.  
5) If you were exposed to strong sun for the first time in summer for an hour with no protec-
tion would: 1. Always burn, never tan, 2. Burn, then tan, 3. Only tan. 
6) How many times in your life have you had a painful sunburn: 1. Never, 2. Once, 3. 2-3 times, 
4) 4-5 times, 5. More than 10 times. 
7) What SPF of sunscreen are you currently using 
iii Skin cancer and moles – 5 items 
1) What were the location of your melanoma/melanomas and the date of diagnosis 
2) Have you had any other skin cancer in the last two years, a. body region, b. date of diagnoses 
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3) How many moles have you had excised in your lifetime, 1. None, 2. 1-5, 3. 6-10, 4. more 
than 10 
4) Have any of your family members (first or second-degree relatives) ever been diagnosed 
with melanoma 
5) Do any of your immediate family members (parents, siblings, children) have a history of 
more than 50 moles 
iv medications – 2 items 
1) Have you taken the following medications during the past 5 years, a. ASPIRIN (e.g. ASS 100), 
b. Anti-inflammatory medications (e.g. Celebrex, Ibuprofen), c. Steroids (Kortison) (e.g. De-
cortin H, Prednison, Urbason), 1. Never, 2. Occasionally, 3. Less than once a month, 4. 2-3 
times a month, 5. Once a week, 6. 2-3 times a week, 7. 4-7 times a week, 8. Twice or more a 
day. 
2) Other medication: please indicate medications which you take on a regular base and indi-
cate frequency and indication. 
The questionnaires were stored as paper sheets. 
The last part of the data collection procedures was the sampling of saliva with the Oragene 
collection tubes. The patients were requested to provide a 2ml volume of saliva in a collection 
tube if possible. By bending and closing the cap, the storage solution contained within the cap 
was automatically instilled into the tube. Shaking the tube a few times was necessary to en-
sure an optimal mixture and preservation of the genomic DNA. The tubes were labelled with 
the patient ID and stored until they were processed in Australia. 
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3.3. Results 
A total of 16 melanoma patients were collected. The characteristics of the patients are sum-
marized in Table 3. The individual case reports are presented in Appendix 1. 
Most of the patients had stage I or stage II disease at the time of diagnoses and 5 patients had 
stage III or stage IV disease. Two patients had progressive disease and died during follow up. 
The follow up time of the patients was between 2 and 21 years (median = 3.5 years). Nine 
patients were male and 7 patients were female. The age ranged between 18 and 79 years. 
Most patients had a superficial spreading melanoma, followed by the subtype nodular mela-
noma. Other presented melanoma subtypes were lentigo maligna melanoma, acral lentigi-
nous melanoma, dermal melanoma and desmoplastic melanoma, each with one case. The re-
ported tumour thickness ranged from 1.0 mm to 5.0 mm. The patients with progressive dis-
ease had a tumour thickness above 2mm. Only two of the non-metastasized patients, TU-03 
and TU-11 had a thick primary melanoma. Most patients had blue eyes (n=11, 69%), 3 patients 
had green eyes (19%), one brown eyes (6%) and one did not indicate the eye colour. The hair 
colour was brown in 9 patients (56%), blonde in 6 patients (38%) and one patient had black 
hair (6%). Of the five metastasized patients all but one had brown or black hair. The BMI 
ranged from 17.3 to 38.1 (median = 24.3). The total body naevus count ranged from 0 to 364 
naevi (median = 28). The patients with multiple moles, those who had more than 100 mela-
nocytic naevi on their body, were TU-01, TU-3, TU-05 and TU-08. All these four patients were 
non-metastasized patients. The dominant naevus pattern was reticular in 8 patients and un-
specific in 4 patients. Three patients had no predominant naevus type and one patient had no 
naevus at all. Most of the patients (n=8, 50%) indicated they would burn and then tan after 
sun exposure, three patients would only burn (19%), three only tan (19%) and two patients 
skipped the question. The genotyping results were summarized for the gene loci of MC1R and 
exon 5 of PPARGC1B. PPARGC1B is the gene coding for the protein PGC-1b. Variants in MC1R 
were very frequent in this small cohort of melanoma patients. Only 4 patients had no variant 
allele (25%). Three of those four wild type patients were metastasized patients. Detected var-
iants were R160W, R163Q, I155T, R151C, T95M and V60L. The variants R160W and R151C are 
considered as high penetrance alleles in regard to hair and skin colour and marked as “R” 
variants, the variants R163Q, I155T and V60L as low penetrance allele and marked as “r” var-
iants. 197 The variant T95M is a very rare variant. A frequency of 0.002 was reported in a 
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Mediterranean population.198 Of the 12 patients (75%) with MC1R variants, 9 had blue eyes, 
6 blonde hair and 8 indicated they were sun sensitive, with either “burn then tan” or “only 
burn” as a skin reaction after sun exposure.  
Variants at exon 5 of PPARGC1B were rare. Only three patients had one or two variant alleles. 
The detected variants were R226Q and V240I. Two non-metastasized patients and one metas-
tasized patient had a variant. 
 
Table 3: Characteristics of the 16 patients of the pilot study 
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TU-
01 
m 43 SSM 1.65 IIA IIA 3y no blue brown - 364 retic b/t R160W-/- wt 
TU-
02 
f 34 na - na IV 21y no blue blonde - 51 unsp - R160W-/- wt 
TU-
03 
m 59 SSM 2.5 IIA IIA 4y no blue brown 35.8 128 retic b/t wt wt 
TU-
04 
m 17 derm - IIA IIA 6y no green brown 20.5 77 unsp b/t R163Q+/- wt 
TU-
05 
m 76 SSM 1.0 IA IA 6y no blue brown 25.0 123 retic b/t I155T+/- R226Q +/- 
TU-
06 
f 49 SSM 1.1 IB IB 6y no blue blonde 24.8 19 unsp b R151C+/- wt 
TU-
07 
m 75 LMM 1.0 IB IB 3y no blue blonde 31.6 0 na b/t R151C+/- 
T95M+/- 
wt 
TU-
08 
m 28 NM 1.2 IB IB 3y no blue blonde 25.1 170 no  b/t V60L+/- wt 
TU-
09 
f 75 ALM 1.4 IIA IIA 6y no blue blonde 20,8 5 unsp t V60L+/- 
R160W+/- 
wt 
TU-
10 
f 75 SSM 1.0 IA IA 4y no blue brown 29.1 22 retic b R160W+/- wt 
TU-
11 
f 63 desm 2.7 IIA IIA 2y no - brown 28.0 62 no t R160W+/- V240I +/- 
TU-
12 
m 48 SSM 1.2 IB IB 3y no blue blonde 23.8 34 retic b/t R160W+/- wt 
TU-
13 
f 29 na 3.3 IIIB IV 2.5y yes green brown 22.9 22 no b wt wt 
TU-
14 
m 77 SSM 2.4 IIIA IIIA 3y no green brown 38.1 1 retic - wt R226Q +/-
V240I +/- 
TU-
15 
m 61 NM 5.0 IIIA IV 4y yes blue brown - 9 retic b/t wt wt 
TU-
16 
f 18 NM 4.5 IIIA IIIA 3y no brown black 17.3 9 retic t V60L+/- 
R151C+/- 
wt 
*dominant naevus type (>40% naevi belong to one pattern) 
Metastasized patients (stage III/IV) are highlighted in grey, those patients who progressed and died in dark grey. 
at D = at diagnosis 
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3.4. Discussion and Conclusion 
These prospectively included melanoma patients from Tübingen, Germany represent an in 
depth described cohort with comprehensive medical history, the report of behavioural data 
in addition with the phenotype and genotype of the patients. 
The sample size of 16 patients did not allow statistical comparisons. However, the profound 
and systematic view on individual patients allowed a deeper understanding on the different 
personal courses of the disease. Furthermore, the summary of the characteristics resulted in 
a renunciation of the initially hypothesis put forward and formed the base for new research 
questions as discussed below. 
The obtained digital dermoscopic images were classified and a dominant naevus pattern was 
seen in 12 of the 16 patients (75%). This was in accordance to a previously reported rate of a 
pre-dominant global pattern in individuals without a personal history of melanoma.199 How-
ever, this dominant type was based on a threshold of 40% as suggested in the literature. The 
overall variance of different naevus types in the present cohort was high and not distinctive. 
A difference in late and early stage patients was not detectable. In the literature a change in 
naevus pattern was demonstrated with a dermoscopic follow-up imaging study in children and 
young adults. More than half of the observed naevi evolved into different patterns, even from 
atypical naevi into common naevi.200 Another study found an age dependent association of 
naevus pattern and no differences between melanoma patients and controls.201 The high in-
tra-individual variability of naevi as observed in the presented patients as well as the reported 
variation over time in terms of pattern did not encourage to pursue investigations on dermo-
scopic naevus pattern in metastasized and non-metastasized melanoma patients in this work. 
The exploration of the present cohort of melanoma patients did not allow reflection on mela-
noma risk due to the lack of controls, but did allow a comparison of non-metastasized patients 
with patients who had progressive disease and the search for contributing factors.  
High impact factors can be detected even in small numbers, whereas low impact factors need 
to be confirmed in a larger group. In respect to the general frequency of this contributing 
factors one has to consider true positive and false positive findings in small cohorts. 
The main prognostic factor tumour thickness for melanoma progression was clearly revealed 
in this small cohort. All 5 patients with lymph node or distant metastases (stage III and stage 
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IV) had a primary tumour thickness above 2mm, whereas only two of the eleven early stage 
patients had a thick primary. The second clear association of an established factor was the 
histological subtype, with a high rate of nodular melanomas among the late stage patients.  
Host specific characteristics included eye and hair colour, BMI, sun reaction, naevus count 
and the genotype. Brown or black hair seemed to be more common among patients with 
metastatic disease, while there was no difference for hair colour, BMI or the individual reac-
tion of the skin after sun exposure. The total body naevus count was higher among patients 
in early stages. This finding was in accordance with a personal observation of frequently see-
ing metastatic patients in the melanoma outpatient clinic without or with only few melano-
cytic naevi. Variants in PPARGC1B were found in 3 patients without a distinct distribution. 
Variants in MC1R were found in 11 out of the 16 patients, which represented a higher num-
ber than expected compared to the general population. Only one patient among the early 
stage patients had a MC1R wild type compared to three among the five late stage patients. 
Both patients who died had no germline variant at the MC1R loci. These findings were in ac-
cordance to a previously reported survival benefit of patients with MC1R variants by Davies 
et al.202 and lead to the exploration of the prognostic impact of genetic and phenotypic 
markers in a larger cohort. 
In conclusion the completion of the pilot study resulted in a set of extensively well described 
melanoma patients, including early stage and late stage patients. The initial research goal to 
investigate the dermoscopic pattern of melanocytic naevi in metastasized and non-metasta-
sized patients was dropped based on these initial findings. Succeeding research interests in-
cluded the exploration of identified phenotypic and genotypic characteristics of interest, 
such as naevus count, hair colour and MC1R germline variants in a larger German patient co-
hort. 
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3.5. Appendix 1 Case Reports 
Patient TU-01 
The first study participant was a 43-year-old male patient from South Germany with Western 
Europe ancestry and a Malignant Melanoma Stage IIA. 
Medical history: The patient was seen with the suspicion of a superficial spreading melanoma 
on the lower back in August 2013. The histopathology report confirmed the diagnoses and 
described the melanoma as an ulcerated secondary nodular superficial spreading melanoma 
with a tumour thickness of 1.65mm, Clark level IV without an association to a pre-existing 
naevus. Regression areas were described in the specimen and a number of four mitoses per 
mm³ were counted. The patient was referred to a sentinel node biopsy based on the tumour 
thickness of his primary tumour. However, the sentinel was not detectable and the procedure 
was not performed. The patient received an adjuvant treatment with subcutaneous Inter-
feron-alpha 3 MIU 3 times per week from September 2013 to September 2014. The treatment 
duration was shortened due to adverse reactions, such as flue like symptoms, concentration 
disorder, and diminished performance. None of his moles had been excised before. He had no 
other skin cancers and no other medical condition. He was taking occasionally acetylsalicylic 
acid and anti-inflammatory medications. There are no other family members diagnosed with 
melanoma so far, but his father and his brother did have multiple naevi. The patient had been 
participating in clinical follow up visits on a regular basis and he was without recurrence or 
secondary melanoma at the time of last follow up (8th Dec 2016).  
Phenotype: The patient had blue/grey eyes and light brown hair. His constitutive skin colour 
was fair, his facultative skin colour medium. He had mild freckles at the face and the dorsal 
hand, severe freckles at the shoulders and a cutis rhomboidalis at his neck. His total body 
naevus count was 364 (>3 mm) and the area with the largest number of naevi was his back 
with 82 naevi. 
Dermoscopy: A total of 81 naevi were imaged with dermoscopy. The predominant naevus type 
was of reticular pattern with 50 reticular, 8 reticular/globular, 2 globular and 21 unspecific 
pattern. 
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Figure 5: Overview Image upper back with the primary melanoma (No 42) and two naevi cap-
tured with dermoscopy, both with reticular pattern 
Sun behaviour: The patient had been mainly working indoors and his leisure activities were 
located indoors and outdoors. On a typical weekday he would stay less than 50% of the time 
outside while he would be outside in the sun more than 5 hours a day on the weekend. He 
would have protected himself from the sun in less than 50% of the time with sunglasses and 
sunscreen with a protection factor of 25 and never with a hat. If he would have exposed him-
self to the sun unprotected he would have burned and tan. He indicated that he had between 
two and five painful sunburns in his life. 
Genotype:  MC1R: one homozygous variant at R160W was detected which is considered a R 
variant. PGC-1b: none of the assessed 7 SNPs showed a variant 
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Patient TU-02 
The second patient was a 52-year-old woman from South Germany with Western Europe an-
cestry and a Malignant Melanoma Stage IV. 
Medical history: The patient was diagnosed with lymph node metastases in the right groin and 
iliac lymph node metastases in May 1996 at the age of 34. The patient said that three years 
before a mole had been excised at her upper leg without a histopathologic examination. The 
pathology review of 1996 found that 5 of 13 inguinal lymph nodes and 2 of 9 iliac lymph nodes 
were affected with metastases from malignant melanoma. The patient received an adjuvant 
combination treatment with subcutaneous Interferon alpha 60 MIE 3 times a week and 40mg 
Isotretinoin a day. The treatment with Isotretinoin was stopped in August 2001. Interferon 
alpha was continued with 6 MIE until September 2006, the dose was subsequently reduced to 
3MIE 3 times a week and the treatment was terminated in October 2008 after a total period 
of 12 years of adjuvant therapy. More than 10 of her moles had been excised. She had no 
other skin cancer. Her other medical conditions were a Hashimoto Thyreoditis and hay fever. 
Her regular medication was levothyroxine sodium 50mg a day and desloratadine 5mg a day. 
She was taking acetylsalicylic acid and anti-inflammatory drugs on an occasionally base. There 
were no other family members diagnosed with melanoma. She is indicating that her children 
have more than 50 moles. The patient had been participating in clinical follow up visits on a 
regular basis and she was without recurrence or secondary melanoma at the time of last fol-
low up (7th Feb 2017). 
Phenotype: The patient had blue/grey eyes and blonde hair. Her constitutive and her faculta-
tive skin colour were fair. She had mild freckles at the face and the dorsal hand, moderate 
freckles at the shoulders and a cutis rhomboidalis at her neck. Her total body naevus count 
was 51 (>3 mm) and the area with the largest number of naevi was her back with 9 naevi. The 
head, hands and feet were free of naevi. 
Dermoscopy: A total of 11 naevi were imaged with dermoscopy. There was no predominant 
naevus type with 5 reticular and 6 naevi of unspecific pattern. 
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Figure 6: Overview Image upper back and three naevi captured with dermoscopy, one with 
reticular and two with unspecific pattern 
 
Sun behaviour: The patient had been mainly indoors for work as well as for her leisure activi-
ties. On a typical weekday she would have been outside less than one hour and on the week-
end less than 50% of her time. For her sun protection she used sunglasses and sunscreen with 
a protection factor of 50, both of it more than 50% of the time and sometimes she used a hat. 
She remembered more than 10 painful sunburns in her life. 
Genotype: MC1R: one homozygous variant at R160W was detected which is considered a R 
variant. PGC-1b: none of the assessed 7 SNPs showed a variant 
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Patient TU-03 
Patient TU-03 was a 61-year-old man from Kazakhstan with Eastern Europe ancestry and a 
Malignant Melanoma Stage IIA. 
Medical history: The patient was diagnosed with a superficial spreading melanoma on the left 
shoulder in May 2011. The tumour thickness was 2.5mm without ulceration. A sentinel lymph 
node biopsy was performed and no metastases were found. An adjuvant treatment was not 
given to the patient. Between 1 and 5 moles had been excised so far. He had no other skin 
cancers. His other medical condition was a peripheral vascular disease. His regular medication 
was Marcumar. His son was diagnosed with a melanoma in 1999 and both, son and daughter 
have multiple moles. The patient had been participating in clinical follow up visits on a regular 
basis and he was without recurrence or secondary melanoma at the time of last follow up (7th 
Sep 2015). 
Phenotype: The patient had blue/grey eyes and light brown hair. His body height was 172cm 
and his weight was 106kg. His constitutive skin colour was fair, his facultative skin colour me-
dium. He had mild freckles at the face, the dorsal hand and the shoulders and a cutis rhom-
boidalis at his neck. His total body naevus count was 128 (>3 mm) and the area with the largest 
number of naevi was his back with 28 naevi. 
Dermoscopy: A total of 31 naevi were imaged with dermoscopy. The predominant naevus type 
was of reticular pattern with 18 reticular and 13 naevi of unspecific pattern. 
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Figure 7: Overview Image upper back and three naevi captured with dermoscopy, all three 
with reticular pattern 
Sun behaviour: The patient had been working as a welder mainly indoors and his leisure activ-
ities were indoors as well. He would have been less than 50% of his time outside in the sun on 
a weekday as well as on weekends. He never used sun glasses, a hat or sunscreen for sun 
protection. His skin would react with sunburn and tan after sun exposure. He cannot remem-
ber any painful sunburn in his life. 
Genotype: MC1R: wildtype; PGC-1b: none of the assessed 7 SNPs showed a variant 
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Patient TU-04 
Patient TU-04 was a 20-year-old man from South Germany with Western Europe ancestry and 
a Malignant Melanoma Stage IIA. 
Medical history: The patient was diagnosed with a dermal melanoma on the scalp in Decem-
ber 2010. The histopathology report described a suspicious cell clone with nuclear polymor-
phisms and a high proliferation index within a congenital naevus. A comparative genomic hy-
bridisation (CGH) was performed and revealed multiple quantitative chromosomal aberra-
tions which supported the classification of the lesion as malignant melanoma. A sentinel node 
biopsy was performed and three lymph nodes were found without evidence of metastases. 
An adjuvant therapy was not given to the patient. Between 1 and 5 moles had been excised 
in the past. He had no other skin cancers and no other medical condition. No family member 
was affected with melanoma and he indicated that his mother had more than 50 moles on her 
skin. He was taking no regular drugs but occasionally acetylsalicylic acid and anti-inflammatory 
medications. The patient had been participating in clinical follow up visits on a regular basis 
and he was without recurrence or secondary melanoma at the time of last follow up (27th Feb 
2017). 
Phenotype: The patient had green/hazel eyes and light brown hair. His body height was 185cm 
and his weight was 70kg. His constitutive and facultative skin colour was fair. He had no freck-
les at the face, the dorsal hand and the shoulders and no cutis rhomboidalis at his neck. His 
total body naevus count was 77 (>3 mm) and the area with the largest number of naevi was 
his back with 15 naevi, followed by his face with 10 naevi. 
Dermoscopy: A total of 24 naevi were imaged with dermoscopy. There was no predominant 
naevus type with 4 reticular, 3 globular and 17 naevi of unspecific pattern. 
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Figure 8: Overview Image upper back and three naevi captured with dermoscopy with globu-
lar, reticular and unspecific pattern. 
Sun behaviour: The patient had been mainly working indoors and his leisure activities were 
located indoors and outdoors. He would stay less than 50% of the time outside on a typical 
weekday as well as on the weekend. He would have protected himself from the sun in less 
than 50% of the time with sunglasses, a hat and sunscreen with a protection factor of 30. If he 
would have exposed himself to the sun he would have burned and tan. He indicated that he 
had between two and five painful sunburns in his life. 
Genotype: MC1R: R163Q+/-; PGC-1b: none of the assessed 7 SNPs showed a variant 
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Patient TU-05 
Patient TU-05 was a 79-year-old man from Middle Germany with Western Europe ancestry 
and a Malignant Melanoma Stage IA. 
Medical history: The patient was diagnosed with two superficial spreading melanomas in the 
year 2010. The first one was located on the left shoulder with a tumour thickness of 0.3mm 
and the second melanoma was located on the right upper leg and had a tumour thickness of 
1.0mm. Both melanomas were not ulcerated. A sentinel lymph node biopsy was not per-
formed and no adjuvant treatment was given to the patient. He had no excision of naevi in 
the past and no other skin cancer. His other medical conditions were Parkinson´s disease and 
coronary heart disease. His regular medications consisted of Ropinirole 12mg, Asagiline 1mg, 
Furosemide 40mg, Mirtazapine 30mg, Simvastatin 20mg and Fenofibrate 160mg, all on a daily 
base. He was taking occasionally acetylsalicylic acid and anti-inflammatory medications. His 
family members are not affected with melanoma. His children had more than 50 moles on 
their skin. The patient had been participating in clinical follow up visits on a regular basis and 
was without recurrence or secondary melanoma at the time of last follow up (1st Aug 2016). 
Phenotype: The patient had blue/grey eyes and light brown hair. His body height was 171cm 
and his weight was 73kg. He had moderate freckles at the face and the dorsal hand and severe 
freckles at the shoulders. His total body naevus count was 123 (>3 mm) and the area with the 
largest number of naevi was his left ventral thigh with 22 naevi. 
Dermoscopy: A total of 27 naevi were imaged with dermoscopy. The predominant naevus type 
was of reticular pattern with 22 reticular and 5 naevi of unspecific pattern. 
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Figure 9: Overview Image upper back and three naevi captured with dermoscopy, all three 
with reticular pattern 
Sun behaviour: The patient had been working indoors and outdoors and his leisure activities 
were located mainly outdoors. He would have stayed less than 50% of the time outside on a 
typical weekday and on the weekend. He never used sunscreen but protected himself from 
the sun in less than 50% of the time with sunglasses and a hat. If he would have exposed 
himself to the sun unprotected he would have burned and tan. He remembered that he had 
more than 10 painful sunburns in his life. 
Genotype: MC1R: I155T+/-; PGC-1b: Arg226Gln A/G 
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Patient TU-06 
Patient TU-06 was a 52-year-old woman from Austria with Western Europe ancestry and a 
Malignant Melanoma Stage IB. 
Medical history: The patient was diagnosed with a superficial spreading melanoma on the 
right upper arm in May 2010. The melanoma was 1.1mm thick and not ulcerated. A sentinel 
lymph node biopsy was performed with no pathologic findings. An adjuvant treatment was 
not given to the patient. Between 1 and 5 naevi had been excised in the past. No other skin 
cancer was diagnosed. Her other medical conditions were breast cancer and thyroid disease. 
She had been taking tamoxifen and levothyroxine sodium on a daily base. There were no fam-
ily members with melanoma or multiple moles. The patient had been participating in clinical 
follow up visits on a regular basis and was without recurrence or secondary melanoma at the 
time of last follow up (2st Aug 2016). 
Phenotype: The patient had blue/grey eyes and blonde hair. Her body height was 175cm and 
her weight was 76kg. Her constitutive and her facultative skin colour were fair. She had mod-
erate freckles at the face, the dorsal hand, the shoulders and a cutis rhomboidalis at her neck. 
Her total body naevus count was 19 (>3 mm) and the area with the largest number of naevi 
was her back with 4 naevi. The head, hands and feet were free of naevi. 
Dermoscopy: A total of 12 naevi were imaged with dermoscopy. There was no predominant 
naevus type with 3 reticular, 2 reticular/globular and 7 naevi with unspecific pattern. 
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Figure 10: Overview Image upper back and three naevi captured with dermoscopy, one with 
reticular/globular, one with unspecific and one with reticular pattern. 
Sun behaviour: The patient had been mainly indoors for work and her leisure activities were 
located indoors and outdoors. On a typical weekday she would have been less than 2-4 hours 
outside and on the weekend more than 50% of her time. For her sun protection she used 
sunglasses and sunscreen with a protection factor of 50 more than 50% of her time. She never 
used a hat. If she would have exposed herself to the sun unprotected she would have always 
burned. She remembered between 2 and 5 painful sunburns in her life. 
Genotype: MC1R R151C+/-; PGC-1b: none of the assessed 7 SNPs showed a variant 
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Patient TU-07 
Patient TU-07 was a 76-year-old man from South Germany with Western Europe ancestry and 
a Malignant Melanoma Stage IB. 
Medical history: The patient was diagnosed with lentigo maligna melanoma with a tumour 
thickness of 1.0mm on his right forehead in October 2012. A sentinel node biopsy was not 
performed based on the wish of the patient. No adjuvant treatment was given. No moles had 
been excised before. He had no other skin cancers. He had been taking Marcumar due to a 
thrombosis in his medical history. His family members had no history of melanoma and no 
multiple moles. The patient had been participating in clinical follow up visits on a regular basis 
and was without recurrence or secondary melanoma at the time of last follow up (14th Jul 
2015). 
Phenotype: The patient had blue/grey eyes and blonde hair. His body height was 164cm and 
his weight was 85kg. His constitutive and facultative skin colour was fair. He had severe freck-
les at the face and the dorsal hand, mild freckles at the shoulders and a pronounced cutis 
rhomboidalis at his neck. His total body naevus count was zero.  
Dermoscopy: No melanocytic naevi were detected. 
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Figure 11: Overview Image upper back  
 
 
Sun behaviour: The patient had been working indoors and outdoors and had been mainly out-
doors for his leisure activities. On a typical weekday he would have been less than 2-4 hours 
outside in the sun. For his sun protection he used sunglasses and a hat in less than 50% of the 
time. He never used sunscreen. His skin would react with sunburn and tan after unprotected 
sun exposure. He remembered between 2 and 5 painful sunburns in his life. 
Genotype: MC1R R151C+/- T95M+/-; PGC-1b: none of the assessed 7 SNPs showed a variant 
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Patient TU-08 
Patient TU-08 was a 29-year-old man from Saxony with Western Europe ancestry and a Ma-
lignant Melanoma Stage IB. 
Medical history: The patient was diagnosed with a nodular malignant melanoma on his left 
knee in May 2012. The tumour was not ulcerated and 1.2mm thick. A sentinel node biopsy 
was performed with not pathological results. He did not get an adjuvant treatment. Between 
6 and 10 moles had been excised in the past. He had no other skin cancers and no other med-
ical conditions. He was not taking any medications. His mother and his aunt were diagnosed 
with a melanoma as well in the years 2012 and 2013 respectively. His mother has also multiple 
moles. The patient had been participating in clinical follow up visits on a regular basis and he 
was without recurrence or secondary melanoma at the time of last follow up (16th Feb 2015). 
Phenotype: The patient had blue/grey eyes and blonde hair. His body height was 184cm and 
his weight was 85kg. His constitutive skin colour was fair, his facultative skin colour medium. 
He had mild freckles at the face, no freckles at the dorsal hand and no cutis rhomboidalis at 
his neck. His total body naevus count was 170 (>3 mm) and the area with the largest number 
of naevi was his back with 41 naevi, followed by the chest with 25 naevi. 
Dermoscopy: A total of 27 naevi were imaged with dermoscopy. The predominant naevus type 
was of globular pattern with 8 reticular, 2 reticular/globular, 10 globular and 7 naevi of 
unspecific pattern. 
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Figure 12: Overview Image upper back and three naevi captured with dermoscopy, two of 
globular and one of reticular pattern. 
Sun behaviour: The patient had been working mainly indoors and his leisure activities were 
indoors and outdoors. He would have been less than 1 hour outside in the sun on a weekday 
and between 2 and 4 hours on weekends. He never used sun glasses, and less than 50% of the 
time sunscreen (SFP 25-30) and a hat for sun protection. His skin would react with sunburn 
and tan after sun exposure. He remembered 2 to 5 painful sunburns in his life. 
Genotype: MC1R: V60L+/-; PGC-1b: none of the assessed 7 SNPs showed a variant 
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Patient TU-09 
Patient TU-09 was a 77-year-old woman from South Germany with Western Europe ancestry 
and a Malignant Melanoma Stage IIA. 
Medical history: The patient was diagnosed with a acral lentiginous melanoma on her left 
forefinger in January 2011. The tumour was 1.4mm thick and was ulcerated. A sentinel lymph 
node biopsy was performed and no melanoma metastases were found. The patient received 
an adjuvant treatment with subcutaneous interferon alpha 3MIU three times a week from 
June 2011 to January 2012. The treatment was terminated prematurely due to a pronounced 
weight loss. No moles had been excised in the past and the patient had no other history of 
skin cancer. Her other medical conditions were hypertension, atrial fibrillation, chronic ob-
structive pulmonary disease, osteoporosis and a history of an apoplex. She was inhaling tio-
tropium, fluticasone and salmeterol and taking verapamil, candesartan, digitoxin and phen-
procoumon on a daily base. Her family members were not affected with melanoma and none 
of the family members had multiple moles. The patient had been participating in clinical follow 
up visits on a regular basis and she was without recurrence or secondary melanoma at the 
time of last follow up (14th Feb 2017). 
Phenotype: The patient had blue/grey eyes and blonde hair. Her body height was 170cm and 
her weight was 60kg. The constitutive skin colour was fair and her facultative skin colour was 
medium. She had moderate freckles at the face and the shoulder, severe freckles at the dorsal 
hand and a cutis rhomboidalis at her neck. Her total body naevus count was 5 (>3 mm) and 
the area with the largest number of naevi was her back with 3 naevi. The head, hands and feet 
were free of naevi. 
Dermoscopy: A total of 5 naevi were imaged with dermoscopy. There was no predominant 
naevus type with 2 reticular and 3 naevi of unspecific pattern. 
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Figure 13: Overview Image of the lower legs and three naevi captured with dermoscopy, all 
three of unspecific pattern. 
 
Sun behaviour: The patient had been indoors and outdoors for work as well as for her leisure 
activities. She would have been outside between 2 and 4 hours on a typical weekday and on 
the weekend. She never used sunglasses, sunscreen or a hat for her sun protection. If she 
would expose her skin to the sun she indicated that she would only tan. She remembered one 
painful sunburn in her life. 
Genotype: MC1R: V60L+/- R160W+/-; PGC-1b: none of the assessed 7 SNPs showed a variant 
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Patient TU-10 
Patient TU-10 was a 77-year-old woman from South Germany with Western Europe ancestry 
and a Malignant Melanoma Stage IA. 
Medical history: The patient was diagnosed with a superficial spreading melanoma on her 
right calf in November 2011. The tumour was 1.0mm thick and not ulcerated. She was referred 
to sentinel node biopsy and no melanoma metastases were found in the lymph node. No ad-
juvant treatment was given to the patient. She had between one and five moles excised in the 
past and had no other skin cancer. She had no other medical condition and was taking no 
medications. No family members were affected with melanoma but her son had multiple 
moles. The patient had been participating in clinical follow up visits on a regular basis and he 
was without recurrence or secondary melanoma at the time of last follow up (19th Oct 2015). 
Phenotype: The patient had blue/grey eyes and light brown hair. Her body height was 154cm 
and her weight was 69kg. Her constitutive skin colour was fair and her facultative skin colour 
was medium. She had moderate freckles at the face, the dorsal hand, the shoulders and a 
pronounced cutis rhomboidalis at her neck. Her total body naevus count was 22 (>3 mm) and 
the areas with the largest number of naevi were her back and her left dorsal lower leg with 4 
naevi each.  
Dermoscopy: A total of 18 naevi were imaged with dermoscopy. The predominant naevus type 
was of reticular pattern with 10 reticular, 1 reticular/globular and 7 naevi of unspecific 
pattern. 
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Figure 14: Overview Image upper back and three naevi captured with dermoscopy, all three 
of reticular pattern. 
 
Sun behaviour: The patient had been mainly outdoors for her leisure activities. On a typical 
weekday she would have been 2-4 hours outside and on the weekend less than one hour of 
her time. For her sun protection she never used sunglasses. After sun exposure her skin would 
always have burned but not tanned. She remembered between 2 and 5 painful sunburns in 
her life. 
Genotype: MC1R: R160W+/-; PGC-1b: none of the assessed 7 SNPs showed a variant 
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Patient TU-11 
Patient TU-11 was a 63-year-old woman from Croatia with Southern Europe ancestry and a 
Malignant Melanoma Stage IIA. 
Medical history: The patient was diagnosed with a desmoplastic malignant melanoma on her 
left cheek in April 2013. The tumour was 2.7mm thick and not ulcerated. In July 2013 a sentinel 
lymph biopsy was performed and none of the two extirpated lymph nodes was affected with 
melanoma metastases. The patient did not receive adjuvant treatment. She had between one 
and five moles excised in the past and no other skin cancer. Her other medical conditions were 
hypertension and depression. She was taking citalopram and candesartane daily and acetyl-
salicylic acid less than once a month. None of her family members had a history of melanoma. 
Her children and siblings had multiple moles. The patient had been participating in clinical 
follow up visits on a regular basis and she was without recurrence or secondary melanoma at 
the time of last follow up (19th Oct 2015). 
Phenotype: The patient had light brown hair. Her body height was 158cm and her weight was 
70kg. Her constitutive and her facultative skin colour were fair. She had no freckles at the face, 
the dorsal hand and the shoulders and no cutis rhomboidalis at her neck. Her total body nae-
vus count was 62 (>3 mm) and the area with the largest number of naevi was her back with 
18 naevi. 
Dermoscopy: A total of 11 naevi were imaged with dermoscopy. There was no predominant 
naevus type with 5 reticular, 1 reticular/globular and 5 naevi of unspecific pattern. 
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Figure 15: Overview Image upper back and three naevi captured with dermoscopy, two of 
reticular and one of reticular/globular pattern. 
 
Sun behaviour: The patient had been mainly indoors for work and had been indoors and out-
doors for her leisure activities. She would have been less than 50% of her time outside during 
the week and on the weekend. For her sun protection she never used sunglasses and a hat in 
less than 50% of the time. After exposure to the sun she would always tan. She remembered 
between 5 and 10 painful sunburns in her life. 
Genotype: MC1R: R160W+/-; PGC-1b: Val240Ile A/G heterozygous 
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Patient TU-12 
Patient TU-12 was a 48-year-old man from South Germany with Western Europe ancestry and 
a Malignant Melanoma Stage IB. 
Medical history: The patient was diagnosed with a superficial spreading melanoma on his left 
abdomen in June 2013. The tumour was initially reported to be 1,2mm thick. In a second his-
topathology assessment the tumour thickness was reported to be 0.9mm, with a Clark level 
of III, focal regression, no ulceration, no mitoses and an association to a pre-existing naevus 
was observed. A sentinel lymph node biopsy revealed no pathologic findings. The patient re-
ceived no adjuvant treatment. The patient had no other skin cancer and no moles had been 
excised in the past. He had no other medical conditions and no medications. His family mem-
bers were not affected by a melanoma and had not multiple moles. The patient had been 
participating in clinical follow up visits on a regular basis and he was without recurrence or 
secondary melanoma at the time of last follow up (4th Oct 2016). 
Phenotype: The patient had blue/grey eyes and blonde hair. His body height was 182cm and 
his weight was 79kg. His constitutive skin colour was fair and his facultative skin colour was 
medium. He had moderate freckles at the face, the dorsal hand and the shoulders and a cutis 
rhomboidalis at his neck. His total body naevus count was 34 (>3 mm) and the area with the 
largest number of naevi was his back with 18 naevi. The head, hands and feet were free of 
naevi. 
Dermoscopy: A total of 12 naevi were imaged with dermoscopy. The predominant naevus type 
was of reticular pattern with 8 reticular, 1 reticular/globular and 3 naevi of unspecific pattern. 
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Figure 16: Overview Image upper back and three naevi captured with dermoscopy, all three 
of reticular pattern. 
 
Sun behaviour: The patient had been working indoors and outdoors and his leisure activities 
were located mainly outdoors. He would stay between 2 and 4 hours outside on a typical 
weekday as well as on the weekend. He would have protected himself from the sun in less 
than 50% of the time with sunglasses, a hat and sunscreen with a protection factor of 20. If he 
would have exposed himself to the sun he would have burned and tan. He indicated that he 
had between two and five painful sunburns in his life. 
Genotype: MC1R: R160W+/-, PGC-1b: none of the assessed 7 SNPs showed a variant 
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Patient TU-13 
Patient TU-13 was a 31-year-old woman from South Germany with Western Europe ancestry 
and a Malignant Melanoma Stage IV. 
Medical history: The patient was diagnosed with a 3.3mm thick melanoma on the left upper 
arm in September 2011. The patient said that it had been a fast-growing black nodule on a 
small naevus. She had shown it to several physicians in a time period of two and a half years 
before it got excised. In October 2011 a sentinel lymph node biopsy was performed and mel-
anoma metastases were found in two lymph nodes. An adjuvant treatment with subcutaneous 
interferon alpha 3 MIE three times a week was given to the patient over a period of 1.5 years 
until April 2013. In August 2013 multiple new distant metastases were detected in the lungs, 
liver, bones and she had a solitary brain metastasis. Her tumour was BRAF V600E positive. As 
a single mother she decided for a standard treatment outside a clinical trial in proximity to her 
home city. She received vemurafenib 960mg and ibandronic acid 50mg daily. Her brain me-
tastasis was treated with stereotactic radiotherapy. In November 2011 she had a mixed re-
sponse with a reduced size of the lung and liver lesions but with multiple new brain metasta-
ses. A whole brain radiation therapy was performed and a combination treatment with vemu-
rafenib and dabrafenib was started in December 2013. In January 2014 she had a deterioration 
of her general condition and a progressive disease. A polychemotherapy with carboplatin AUC 
6, 900mg and paclitaxel 225mg/m², 360mg was started on the 10th January 2014 and sched-
uled every 4 weeks. The patient died on the 4th March 2014. 
She had no other skin cancers. Her regular medication was sumatriptan once a week for mi-
graine. She had no family members with melanoma. Her sister and her brother had multiple 
moles. 
Phenotype: The patient had green/hazel eyes and dark brown hair. Her body height was 
155cm and her weight was 55kg. Her constitutive and her facultative skin colour were fair. She 
had no freckles at the face, the dorsal hand and the shoulders and no cutis rhomboidalis at 
her neck. Her total body naevus count was 22 (>3 mm) and the area with the largest number 
of naevi was her chest with 5 naevi. 
Dermoscopy: A total of 10 naevi were imaged with dermoscopy. The predominant naevus type 
was of unspecific pattern with 4 reticular, 1 globular and 5 naevi of unspecific pattern. 
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Figure 17: Overview Image upper back and three naevi captured with dermoscopy, two of 
unspecific and one of reticular pattern. 
Sun behaviour: The patient had been mainly indoors for work as well as for her leisure activi-
ties. On a typical weekday and on the weekend, she would have been less than one hour out-
side. For her sun protection she used sunglasses and sunscreen with a protection factor of 50, 
both of it less than 50% of the time and she never used a hat. She would always burn and 
never tan after sun exposure. She remembered no painful sunburns in her life. 
Genotype: MC1R: wildtype; PGC-1b: none of the assessed 7 SNPs showed a variant 
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Patient TU-14 
Patient TU-14 was a 78-year-old man from South Germany with Western Europe ancestry and 
a Malignant Melanoma Stage IIIA. 
Medical history: The patient was diagnosed with a secondary nodular, superficial spreading 
melanoma on this right flank in January 2013. The tumour was 2.4mm thick and not ulcerated. 
A Sentinel lymph node biopsy revealed one affected lymph node. In March 2013 a completing 
lymph node dissection of the right axilla was performed. An adjuvant treatment was not given 
to the patient. He had no excisions of moles before and no other skin cancer. His other medical 
conditions were hypertension, atrial fibrillation, chronic obstructive pulmonary disease, coro-
nary heart disease and thyroid hypofunction. His medication was valsartan 80mg, levothyrox-
ine sodium 100ug, magnesium, tiotropium, torasemide, verapamil, metamizol and phenpro-
coumon. He had no family members with melanoma or multiple moles. The patient had been 
participating in clinical follow up visits on a regular basis and he was without recurrence or 
secondary melanoma at the time of last follow up (29th Sep 2016). 
Phenotype: The patient had green/hazel eyes and dark brown hair. His body height was 170cm 
and his weight was 110kg. His constitutive and facultative skin colour was medium. He had 
mild freckles at the face, the dorsal hand and the shoulders and a cutis rhomboidalis at his 
neck. His total body naevus count was 1 (>3 mm). The naevus was located on his abdomen. 
Dermoscopy: One naevus was imaged with dermoscopy. It was of reticular pattern. 
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Figure 18: Overview Image upper back and one naevus captured with dermoscopy with retic-
ular pattern. 
 
Sun behaviour: The patient had been working as a carpenter and caretaker indoors and out-
doors. His leisure activities were located mainly outdoors. He would stay between 2 and 4 
hours outside on a typical weekday as well as on the weekend. He would have protected him-
self from the sun in less than 50% of the time with sunglasses, more than 50% of the time with 
a hat and never used sunscreen.  
Genotype: MC1R: wt +/+ ; PGC-1b: Arg226Gln A/G homozygous, Val240Ile A/G homozygous 
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Patient TU-15 
Patient TU-15 was a 65-year-old man born in Siberia with Western Europe ancestry and a Ma-
lignant Melanoma Stage IV. 
Medical history: The patient was diagnosed with a 5.0mm thick nodular melanoma on this 
right upper arm in March 2010. He had a positive lymph node and received completing lymph 
node dissection in May 2010. An adjuvant treatment with subcutaneous Interferon alpha 
3MIE three times a week was initiated in November 2010. In May 2013 a subcutaneous in-
transit metastasis was resected, followed by resection of lung metastases and lymph node 
metastases of the hilum. Multiple new distant metastases were diagnosed in August 2013. His 
mutation status was BRAF negative. He was screened for two clinical trials but failed to meet 
the inclusion criteria. Chemotherapy with dacarbazine was initiated in October 2013. The 
brain metastasis was treated with stereotactic radiation in November 2013. Follow up inves-
tigation in January 2014 showed a mixed response and a therapy with ipilimumab was recom-
mended and scheduled for February 2014. The patient died on the 25th January 2014. 
He had no other skin cancers. His other medical conditions were deep vein thrombosis, pul-
monary embolism and diabetes mellitus. He had no family members with melanoma or mul-
tiple moles.  
Phenotype: The patient had blue/grey eyes and light brown hair. His constitutive skin colour 
was fair and his facultative skin colour was medium. He had no freckles at the face and the 
dorsal hand and mild freckles at the shoulders and no cutis rhomboidalis at his neck. His total 
body naevus count was 9 (>3 mm).  
Dermoscopy: A total of 9 naevi were imaged with dermoscopy. The predominant naevus type 
was of reticular pattern with 8 reticular and one naevus of unspecific pattern. 
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Figure 19: Overview Image upper back and three naevi captured with dermoscopy, all three 
of reticular pattern. 
Sun behaviour: The patient had been working as a cheesemaker mainly indoors and his leisure 
activities were located mainly indoors as well. He would stay between 2 and 4 hours outside 
on a typical weekday as well as on the weekend. He never used sun glasses, a hat or sunscreen 
for sun protection. He would have reacted with burn and tan to unprotected sun exposure. 
He remembered between 2 and 5 painful sunburns in his life.  
Genotype: MC1R: wildtype; PGC-1b: of the assessed 7 SNPs there was no variant detectable 
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Patient TU-16 
Patient TU-16 was an 18-year-old girl born in Stuttgart with Middle East Ancestry and a Malig-
nant Melanoma Stage IIIA. 
Medical history: The patient was diagnosed with a melanoma on her left shoulder in January 
2013. She said the lesion had been growing in a time period of 6-8 months. The histopathology 
report described an abnormal spitzoid melanocytic lesion which was classified as nodular mel-
anoma with a tumour thickness of 4.5mm. The patient was referred to sentinel lymph node 
biopsy and two HMB 45 positive cells were found in the lymph node. An adjuvant treatment 
with subcutaneous interferon alpha 3MIE three times a week was given to the patient. She 
had no excisions of moles before and no other skin cancer. Her other medical condition was a 
thyroid disease and she took levothyroxine sodium on a daily base. Her family members were 
not affected with melanoma and had no multiple moles. The patient had been participating in 
clinical follow up visits on a regular basis and she was without recurrence or secondary mela-
noma at the time of last follow up (28th Oct 2015). 
Phenotype: The patient had brown eyes and black hair. Her body height was 165cm and her 
weight was 47kg. Her constitutive and her facultative skin colour were olive. She had no freck-
les at the face, the dorsal hand and the shoulders and no cutis rhomboidalis at her neck. Her 
total body naevus count was 9 (>3 mm) and the area with the largest number of naevi was her 
left lower leg with 2 naevi. 
Dermoscopy: A total of 7 naevi were imaged with dermoscopy. The predominant naevus type 
was of reticular pattern with 5 reticular, 1 reticular/globular and 1 naevus of globular pattern. 
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Figure 20: Overview Image upper back and three naevi captured with dermoscopy, one of 
globular and two of reticular pattern. 
Sun behaviour: The patient had been mainly indoors for work as well as for her leisure activi-
ties. She spent 3 years of her life in Melbourne, Australia at the age of 13 to 15. On a typical 
weekday and on the weekend, she would have been less than 50% of her time outside. For 
her sun protection she used sunglasses and a hat less than 50% of the time and sunscreen 
with a protection factor of 50 more than 50% of the time. She would always tan after sun 
exposure. She remembered no painful sunburn in her life. 
Genotype: MC1R: V60L+/- R151C+/-; PGC-1b: none of the assessed 7 SNPs showed a variant 
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3.7. Appendix 2 Questionnaires Sample 
Clinical assessment, physicians sheet, page 1 
 
Clinical assessment, physicians sheet, page 2 
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Questionnaire, patients sheet, page 1 
 
Questionnaire, patients sheet, page 2 
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4. Comparison of Early and Late Stage Melanoma Patients from Tübingen 
4.1. Introduction 
About 80% of all melanoma patients are cured today. More than half of all patients never 
experience metastatic disease, and a significant proportion of those who do develop metas-
tases are cured with surgical and medical treatments. To date, mainly tumour specific factors 
which promote progression have been investigated in order to predict and understand the 
individual course of disease. The thickness of the primary tumour, irrespective of the histology 
and the general size, is the most important established factor and is included in the AJCC stag-
ing classification. Other tumour specific factors are the presence of ulceration and mitoses in 
the primary tumour and the evidence of skin, lymph node or distant metastases. Serum lactate 
dehydrogenase (LDH) is a host biomarker with prognostic impact203 and is included in the AJCC 
staging system for sub classification in Stage IV. 
While it is clear which individuals are at risk to develop melanoma and which types of mela-
noma – the thick and ulcerated ones- tend to progress, it has been rarely investigated if there 
is a specific phenotype of patients who are at risk of developing progressive disease or if there 
is a specific protective phenotype.  
The aim of the following analyses was to explore if there are any differences between early 
and late stage melanoma patients – those patients who are cured and those who develop 
metastases. 
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4.2. Methods 
Three different approaches were used to investigate phenotype and genotype differences be-
tween early and late stage melanoma patients. These were the comparison of non-metasta-
sized and metastasized patients (Stage I/II and Stage III/IV at end of follow up), the comparison 
of patients who survived and those who died and the calculation of survival probabilities ac-
cording to the respective variables with single variables and in a genome wide approach. 
To compare the phenotype and genotype characteristics between early and late stage mela-
noma patients a dataset was created. The data was set up with a SPSS sheet and was extracted 
from the cohort of the study „Hereditary defects and cutaneous malignant melanoma“, which 
was approved by the ethics committee from Tübingen on the 12th December 2007, the ethics 
number was 376/2007B01. For the purpose of this analysis all melanoma patients were in-
cluded and the control patients were excluded. The last update of follow up data including 
survival dates was performed on the 13th December 2016.  
The patient recruitment and data management were described in Methods, Chapter 2. 
Variables of interest were patient specific and tumour specific data. These were: 
i. general traits of the patients, in detail: sex, age, BMI, ancestry, hair colour, eye colour, skin 
type Fitzpatrick, skin reaction to UV exposure, naevus count, dysplastic naevus count, UV dam-
age und field cancerosis (the presence of multiple confluent actinic keratoses as a sign of 
chronic sun damage) 
ii medical history and family history of the patients, in detail: history of a secondary cancer, 
history of psoriasis, family history of melanoma, family history of cancer,  
iii sun behaviour of the patients, in detail: sunburns in childhood, usage of sunbeds, frequency 
of sun holidays, usage of sunscreen, occupational and leisure sun exposure,  
iv genetic data, in detail: the presence of a germline variant within MC1R, PGC-1a and PGC-
1b, including a deeper analysis with data of the MC1R locus and a set of 356 384 chip array 
derived variants, and 
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v tumour specific data, in detail: histology of primary tumour, tumour thickness, tumour lo-
calisation, Clark level, presence of ulceration, presence of regression and the association to 
naevi. 
The counts for the variables were calculated with SPSS. For ordinal and nominal variables, the 
numbers and percentages were extracted from the frequency tables. The missing values were 
indicated and classified with na. The valid percentages, which did not include missing cases, 
were quoted in the tables. For metric variables, such as age and BMI, the median, standard 
deviation and the minimum and maximum values (range) was displayed.  
Comparisons between metastasized and non-metastasized patients – Stage I/II and Stage III/IV 
were made with crosstab calculations. For ordinal and nominal variables, the associations 
were tested with a two-sided Pearson Chi-Square test.  
To select the appropriate statistical test for comparisons of the metric variables age and BMI 
the distribution of the frequencies was tested for both variables using a histogram with a nor-
mal distribution curve. The variable “age” showed a bimodal distribution while the variable 
“BMI” had a normal distribution. 
Therefore, the Mann-Whitney U test, a nonparametric test for two independent samples was 
chosen for the variable “age”. The significance level to reject the null hypothesis was set to 
0.05. 
For the variable “BMI”, a parametric test, the t-test of equality of means, an independent 
sample test, was chosen. The equal variance was not assumed and the p-value was presented 
for a two-tailed test. The significance level to reject the null hypothesis was set to 0.05. 
The survival analyses were calculated with the Kaplan Meier method. The survival time was 
calculated between the date of first diagnoses and the date of last follow up. All cases with 
death of another reason and patients who were still alive at the time of last follow up were 
censored. The significance was tested pooled over strata and the log rank (Mantel-Cox) test 
was used to test if the null hypothesis could be rejected. The significance level to reject the 
null hypothesis was set to 0.05. 
For the genome wide approach, the survival analyses were performed on 356 384 genetic  
variants distributed over all 23 chromosomes. The rare SNPs with a minor allele frequency 
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below 0.1 were kept for the analysis in order to not miss rare variants with a high impact. The 
variants with the highest significance levels were further analysed to filter artefactual results. 
4.3. Results 
4.3.1. Cohort Description 
A total of 556 patients with a history of malignant melanoma were included into the anal-
yses. The majority of patients (n=365) were without metastases at the end of follow up and 
were classified as Stage I or Stage II disease according to the tumour thickness and proper-
ties of the primary tumour. The other 191 patients were either initially metastasized or de-
veloped metastases during the time of follow up. They were classified as Stage III or Stage IV 
with the evidence of regional or distant metastases respectively. 
The median time of follow up was 8 years for all 556 patients. Patients with Stage I or Stage 
II had a follow up time of 9 years and patients who were Stage III or Stage IV had a median 
follow up time of 8 years at the time of databank closure (Dec 2016). Patients who survived 
or died of other causes had a median follow up time of 9 years, whereas patients who died 
of melanoma had a median follow up time of 4 years. 
Of the 556 patients, 44.6% were female and 55.4% male. The majority of patients had Ger-
man parents, only 6.8% of the patients had another ancestry. The median age was 59 years, 
the youngest patient was 17, the oldest 91 years old. The birthdate was available for all pa-
tients. The age distribution showed two peaks, one around 50 years and one around 70 
years (Figure 21a). The data for both height and weight was available for 526 patients. The 
mean BMI was 27 and the curve was normally distributed (Figure 21b). 
The age and BMI distribution between early and late stage melanoma patients were similar 
(Figure 21c+d). 
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Figure 21: Age and BMI distribution within the complete cohort (a and b) and among early (blue) and 
late (green) stage patients (c and d) 
 
Pigment traits, naevus count and UV damage 
The general characteristics, pigment traits, naevus count and UV damage are summarized in 
Table 4. Hair colour was the only variable with showed a significant difference between early 
and late stage patients. All other variables were similar between early and late stage patients. 
The characteristics of the complete cohort were as follows. Only few patients had red or black 
hair, with 6% and 5.9% respectively. The majority of patients had either brown (44.3%) or 
blonde (43.8%) hair. Most patients were blue-eyed with 39.5%, followed by patients with 
brown eyes (24.1%), grey (19.9%) or green (16.5%) eyes. The most common skin type accord-
ing to the Fitzpatrick scale among the patients was skin type II with 56.5%, followed by skin 
type III (35.7%) and skin type I (6.4%). None of the patients had a Fitzpatrick skin type IV, V or 
a b 
c d 
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VI. Almost half of the patients indicated their skin reaction after sun exposure as “mostly 
burned, light tan” (49.3%), followed by “seldom burned, strong tan” (23.6%), “always burned, 
no tan” (17.6%) and only 9.5% reported they would never burn and always tan. About one 
third of the patients (35.7%) had between 11 and 30 naevi on their body, 24.2% had up to 10 
naevi, followed by 19% with a total body naevus count of 31-50 naevi. Only 6.9% of the pa-
tients had more than 100 naevi on their body. The vast majority of patients (80.4%) had no 
dysplastic naevus, 1-5 dysplastic naevi were reported for 17.3% of patients and only few pa-
tients had 6-10 (1%), 11-20 (0.8%) or more than 20 (0.4%) dysplastic naevi on their body. The 
three categories for UV damage, none, light and severe were almost evenly distributed among 
the population with 26.1%, 37.3% and 36.7% respectively. Only very view patients (2.3%) had 
a field cancerisation. 
The hair colour was recorded for 546 patients with 10 missing values, the eye colour was rec-
orded for 552 patients with 4 missing values. The skin type was not recorded for 71 patients 
and the skin reaction was missing for 6 patients. The naevus count was almost completely 
available with 2 missing values, the dysplastic naevus count was not available for 77 patients, 
data regarding UV damage was missing for 65 patients and regarding the presence of a field 
cancerisation on the capillitium for 85 patients. 
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Table 4: Comparison of general and pigment traits between early and late stage melanoma patients. 
 All pts St I/II St III/IV p* 
 n % n % n %  
Total, n 556 100 365 100 191 100  
Sex 
female 
male 
 
248 
308 
 
44.6 
55.4 
 
159 
206 
 
43.6 
56.4 
 
89 
102 
 
46.6 
53.4 
0.494 
Age median 
range 
59  
17-91 
 58 
17-91 
 59 
19-89 
 0.173 
BMI median 
range 
26 
17-70 
 26 
17-70 
 26 
18-42 
 0.993 
German parents 
yes 
others 
na 
 
508 
37 
11 
 
93.2 
6.8 
 
335 
23 
7 
 
93.6 
6.4 
 
173 
14 
4 
 
92.5 
7.5 
0.640 
Hair colour 
red 
blonde 
brown 
black 
na 
 
33 
239 
242 
32 
10 
 
6.0 
43.8 
44.3 
5.9 
 
21 
170 
143 
25 
6 
 
5.8 
47.4 
39.8 
7.0 
 
12 
69 
99 
7 
4 
 
6.4 
36.9 
52.9 
3.7 
0.018 
Eye colour 
blue 
grey 
green 
brown 
na 
 
218 
110 
91 
133 
4 
 
39.5 
19.9 
16.5 
24.1 
 
141 
70 
66 
85 
3 
 
39.0 
19.3 
18.2 
23.5 
 
77 
40 
25 
48 
1 
 
40.5 
21.1 
13.2 
25.3 
0.499 
Skin type (Fitzpatrick) n, % 
I 
II 
III 
IV 
V 
na 
 
31 
274 
173 
6 
1 
71 
 
6.4 
56.5 
35.7 
1.2 
0.2 
 
18 
178 
121 
4 
1 
43 
 
5.6 
55.3 
37.6 
1.2 
0.3 
 
13 
96 
52 
2 
0 
28 
 
8.0 
58.9 
31.9 
1.2 
0 
0.610 
Skin reaction  
always burned, no tan 
mostly burned, light tan 
seldom burned, strong tan 
never burned, always tan 
na 
 
97 
271 
130 
52 
6 
 
17.6 
49.3 
23.6 
9.5 
 
62 
178 
86 
36 
3 
 
17.1 
49.2 
23.8 
9.9 
 
35 
93 
44 
16 
3 
 
18.6 
49.5 
23.4 
8.5 
0.933 
UV damage 
none 
light 
severe 
na 
 
128 
183 
180 
65 
 
26.1 
37.3 
36.7 
 
82 
112 
133 
38 
 
25.1 
34.3 
40.7 
 
46 
71 
47 
27 
 
28.0 
43.3 
28.7 
0.070 
Field cancerization 
yes 
no 
na 
 
11 
460 
85 
 
2.3 
97.7 
 
10 
300 
55 
 
3.2 
96.8 
 
1 
160 
30 
 
0.6 
99.4 
0.076 
Naevus count 
0-10 
11-30 
31-50 
51-100 
>100 
na 
 
134 
198 
105 
79 
38 
2 
 
24.2 
35.7 
19.0 
14.3 
6.9 
 
93 
122 
74 
51 
25 
0 
 
25.5 
33.4 
20.3 
14.0 
6.8 
 
41 
76 
31 
28 
13 
2 
 
21.7 
40.2 
16.4 
14.8 
6.9 
0.495 
Dysplastic naevus count 
0 
1-5 
6-10 
11-20 
more than 20 
na 
 
385 
83 
5 
4 
2 
77 
 
80.4 
17.3 
1.0 
0.8 
0.4 
 
250 
61 
4 
2 
1 
47 
 
78.6 
19.2 
1.3 
0.6 
0.3 
 
135 
22 
1 
2 
1 
30 
 
83.9 
13.7 
0.6 
1.2 
0.6 
0.496 
*Pearson Chi-Square Asymp.Sig (2-sided) 
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Personal and family medical history 
The data is summarized in Table 5. There were no significant differences between early and 
late stage melanoma patients. A small subset of patients with 6.7% reported a history of a 
second cancer in addition to the malignant melanoma. The history of psoriasis was rare with 
3.9%. A family history of melanoma affecting first degree relatives was reported for 5.4% of 
patients. When taken all cancer types together, more than half of the patients (52.9%) had a 
history of cancer in their families. 
The information about the personal history of a second cancer was available for all patients. 
Data regarding the history of psoriasis, the family history of melanoma and the family history 
of cancer was missing in 21, 19 and 21 cases respectively.  
 
Table 5: Comparison of the medical history between early and late stage melanoma patients 
 All pts St I/II St III/IV p* 
 n % n % n %  
Total, n 556 100 365 100 191 100  
Second cancer 
yes 
no 
na 
 
37 
519 
0 
 
6.7 
93.3 
 
26 
339 
0 
 
7.1 
92.9 
 
11 
180 
0 
 
5.8 
94.2 
0.540 
History of Psoriasis 
yes 
no 
na 
 
21 
514 
21 
 
3.9 
96.1 
 
15 
337 
13 
 
4.3 
95.7 
 
6 
177 
8 
 
3.3 
96.7 
0.579 
Family history of MM 
yes 
no 
na 
 
29 
508 
19 
 
5.4 
94.6 
 
23 
332 
10 
 
6.5 
93.5 
 
6 
176 
9 
 
3.3 
96.7 
0.123 
Family history of Cancer 
yes 
no 
na 
 
283 
252 
21 
 
52.9 
47.1 
 
195 
156 
14 
 
55.6 
44.4 
 
88 
96 
7 
 
47.8 
52.2 
0.089 
*Pearson Chi-Square Asymp.Sig (2-sided) 
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Sun behaviour data 
The data is summarized in Table 6. There was no significant difference between early and late 
stage melanoma patients. The majority of patients experienced one sunburn per year in their 
childhood (44.6%), followed by 24.7% of patients who had less than one sunburn per year and 
those patients with sunburns several times a year (22.0%). Less than 10% of the patients re-
membered no sunburn in their childhood (8.7%). The use of sunbeds was very rare among the 
melanoma patients from Tübingen. Nearly 90% indicated they would never visit a solarium. 
Less than 10% used sunbeds occasionally and only around 4% of the patients visited a solarium 
on a regular base, either a few weeks before the holiday, monthly or on a weekly base. About 
one third of the patients noted they would never go on sun holidays. Most of the patients 
went less than one time a year (37.0%) or one to twice a year (24.9%) on sun holidays. Around 
5% of the patients went on sun holidays more frequently during the year. Most patients ap-
plied sunscreen either several times a week (35.1%) or on a daily base (20.8%). Around one 
third indicated they would seldom use sunscreen and 10.8% stated they never use sunscreen. 
About half of the patients were solely located indoors during their working hours. Around 30% 
of the patients spent up to two hours a day outside, with 10.0% less than 30min a day, 11.8% 
of the patients 30-60min a day and 9.8% one to two hours a day respectively. Around 20% of 
the patients spent more than 2 hours outside during their occupation, with 6.7% of the pa-
tients spending 2-4 hours a day outside, 5.5% of patients with 4-6 hours a day and 6.7% with 
more than 6 hours a day. In terms of leisure sun exposure, the majority of patients spent 2-4 
hours a day outside (33.2%), followed by 26.0% of patients who spent 1-2 hours outside, 17% 
spent 30-60min outside, 14.4% spent 4-6 hours outside, 5.0% spent less than 30 min a day 
outside, 3.5% of the patients more than 6 hours a day. Only 0.9% of patients stated they would 
stay completely indoors during their leisure time. 
Questionnaire based information of the sun behaviour was recorded for all melanoma pa-
tients in 6 categories: the frequency of sunburns during childhood, the use of sunbeds, the 
frequency of sun holidays during the year, the regular use of sunscreen and the estimated 
time of occupational and leisure sun exposure. Missing values were apparent in 5 to 15 cases 
of the 556 patients per category.  
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Table 6: Comparison of the sun behaviour between early and late stage melanoma patients 
 All pts St I/II St III/IV p* 
 n % n % n %  
Total, n 556 100 365 100 191 100  
Sunburns (age < 20 ys) 
no sunburns 
less than 1x/year 
1x/year 
several times a year 
na 
 
48 
136 
246 
121 
5 
 
8.7 
24.7 
44.6 
22.0 
 
28 
93 
161 
80 
3 
 
7.7 
25.7 
44.5 
22.1 
 
20 
43 
85 
41 
2 
 
10.6 
22.8 
45.0 
21.7 
0.658 
Use of Solarium 
never 
occasional 
few weeks before holiday 
less than 1x/month 
monthly 
weekly 
na 
 
476 
48 
8 
2 
6 
6 
10 
 
87.2 
8.8 
1.5 
0.4 
1.1 
1.1 
 
309 
35 
5 
2 
5 
3 
6 
 
86.1 
9.7 
1.4 
0.6 
1.4 
0.8 
 
167 
13 
3 
1 
3 
4 
 
89.3 
7.0 
1.6 
0.5 
1.6 
0.578 
Sun holidays 
never 
less than 1x/year 
1-2x/year 
2x/year 
more frequent than 
2x/year 
na 
 
182 
204 
137 
15 
13 
5 
 
33.0 
37.0 
24.9 
2.7 
2.4 
 
114 
133 
96 
11 
9 
2 
 
31.4 
36.6 
26.4 
3.0 
2.5 
 
68 
71 
41 
4 
4 
3 
 
36.2 
37.8 
21.8 
2.1 
2.1 
0.662 
Use of sunscreens 
never 
seldom 
several times a week  
daily 
na 
 
59 
182 
192 
114 
9 
 
10.8 
33.3 
35.1 
20.8 
 
33 
111 
136 
80 
5 
 
9.2 
30.8 
37.8 
22.2 
 
26 
71 
56 
34 
4 
 
13.9 
38.0 
29.9 
18.2 
0.056 
Occupational sun expo-
sure 
only indoors 
less than 30 min a day 
30-60 min a day 
1-2 hours a day 
2-4 hours a day 
4-6 hours a day 
more than 6 hours a day 
na 
 
268 
54 
64 
53 
36 
30 
36 
15 
 
49.5 
10.0 
11.8 
9.8 
6.7 
5.5 
6.7 
 
170 
39 
42 
39 
28 
14 
25 
8 
 
47.6 
10.9 
11.8 
10.9 
7.8 
3.9 
7.0 
 
98 
15 
22 
14 
8 
16 
11 
7 
 
53.3 
8.2 
12.0 
7.6 
4.3 
8.7 
6.0 
0.105 
Leisure sun exposure 
only indoors 
less than 30 min a day 
30-60 min a day 
1-2 hours a day 
2-4 hours a day 
4-6 hours a day 
more than 6 hours a day 
na 
 
5 
27 
92 
141 
180 
78 
19 
14 
 
0.9 
5.0 
17.0 
26.0 
33.2 
14.4 
3.5 
 
5 
18 
55 
94 
119 
52 
14 
8 
 
1.4 
5.0 
15.4 
26.3 
33.3 
14.6 
3.9 
 
0 
9 
37 
47 
61 
26 
5 
6 
 
0 
4.9 
20.0 
25.4 
33.0 
14.1 
2.7 
0.583 
*Pearson Chi-Square Asymp.Sig (2-sided) 
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Genetic data 
The presence of one or more germline variants was assessed for all 556 patients in the genes 
coding for MC1R, PGC-1a and PGC-1b. The majority of patients had one or more variants in 
the gene coding for MC1R (77.3%), 22.7% of the patients had two wild type alleles. The overall 
presence of any MC1R variant was not different between stage I/II and stage III/IV patients. 
The sub-analyses of MC1R variants – distinguishing between r-variants, R-variants and wt var-
iants, revealed significant differences as described later and presented in (Figure 25). A variant 
in the gene coding for PGC-1a was less frequently observed, 87.2% had a wild type, 12.8% of 
the patients had one or more variants. The gene coding for PGC-1b was without any variants 
in 76.8% of the melanoma patients, 23.2% had one or more variants (Table 7). 
Table 7: Comparison of genetic variants between early and late stage melanoma patients 
 All pts St I/II St III/IV p* 
 n % n % n %  
Total, n 556 100 365 100 191 100  
MC1R** 
wt 
variant 
na 
 
126 
430 
 
22.7 
77.3 
 
85 
280 
 
23.3 
76.7 
 
41 
150 
 
21.5 
78.5 
0.626 
MC1R r alleles 
0 
1 
2 
 
288 
217 
51 
 
51.8 
39.0 
9.2 
 
187 
134 
44 
 
51.2 
36.7 
12.1 
 
101 
83 
7 
 
52.9 
43.5 
3.7 
0.004 
MC1R R alleles 
0 
1 
2 
 
310 
207 
39 
 
55.8 
37.2 
7.0 
 
207 
132 
26 
 
56.7 
36.2 
7.1 
 
103 
75 
13 
 
53.9 
39.3 
6.8 
0.772 
MC1R WT alleles 
0 
1 
2 
 
174 
256 
126 
 
31.3 
46.0 
22.7 
 
126 
154 
85 
 
34.5 
42.2 
23.3 
 
48 
102 
41 
 
25.1 
53.4 
21.5 
0.028 
MC1R Genotype 
WT/WT 
WT/r 
WT/R 
r/r 
r/R 
R/R 
 
126 
133 
123 
51 
84 
39 
 
22.7 
23.9 
22.1 
9.2 
15.1 
7.0 
 
85 
78 
76 
44 
56 
26 
 
23.3 
21.4 
20.8 
12.1 
15.3 
7.1 
 
41 
55 
47 
7 
28 
13 
 
21.5 
28.8 
24.6 
3.7 
14.7 
6.8 
0.019 
PGC-1a 
wt 
variant 
na  
 
485 
71 
 
87.2 
12.8 
 
319 
46 
 
87.4 
12.6 
 
166 
25 
 
86.9 
13.1 
0.870 
PGC-1b 
wt 
variant 
na 
 
427 
129 
 
76.8 
23.2 
 
281 
84 
 
77.0 
23.0 
 
146 
45 
 
76.4 
23.6 
0.885 
*Pearson Chi-Square Asymp.Sig (2-sided) 
**deeper analyses with data of the MC1R locus were performed, considering the numbers of r, R or WT alleles 
respectively, and the specific MC1R genotype 
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Tumour specific data 
The tumour specific data are presented in Table 8. The differences between early and late 
stage patients are discussed in the next chapter. The median tumour thickness of all mela-
noma patients was 1.5mm. The category 1.01mm to 2.0mm was most frequent with 41.0%, 
followed by the categories below 1mm and 2.01-4mm with 24.5% and 24.3%. A tumour thick-
ness of above 4mm was recorded for 10.2% of patients. The main subtype was superficial 
spreading melanoma with 61.2%, followed by 17.9% of patients with nodular melanoma. Len-
tigo maligna melanoma was about as frequent as acral lentiginous melanoma with 5.2% and 
5.6%. Other melanoma subtypes were summarized with 10.2% of cases. Most melanomas 
were localized on the trunk (38.3%), followed by the lower extremities (26.8%), the upper 
extremities (18.2%) and the head and neck region (15.2%). Other localisations were recorded 
in 1.5% of the cases. A primary melanoma was not detectable in 4.2% of the melanoma pa-
tients. These patients were initially diagnosed with melanoma metastases and were summa-
rized as patients with unknown primary. A Clark level 4 was found in 70.8% of the cases, fol-
lowed by 17.7% with Clark level 3. Few melanomas had a Clark level 2 (7.1%) or Clark level 5 
(4.3%) and no Clark level 1 was recorded in this cohort. The histopathology report described 
ulceration in 72.5% of the cases and signs of regression in 14.2% of the melanoma specimens. 
An association to a pre-existing naevus was reported for 19.5% of melanomas (Table 8).  
Tumour specific data were recorded for each melanoma patient. Missing cases were found as 
follows: The tumour thickness was missing in 37 cases, the melanoma subtype in 54 cases, the 
primary localisation in 23 cases. The presence or absence of an unknown primary tumour was 
specified in all but in 14 cases. Details of the histopathology report such as indication of the 
Clark level, presence of ulceration, signs of regression and an association of the melanoma to 
a pre-existing naevus were missing in 93, 112, 126 and 135 cases respectively. 
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Table 8: Comparison of tumour specific data between early and late stage melanoma patients 
 All pts St I/II St III/IV p* 
 n % n % n %  
Total, n 556 100 365 100 191 100  
Tumour thickness 
median 
 
<1,0mm 
1,01-2,0mm 
2,01-4mm 
>4mm 
na 
 
1.5mm 
 
127 
213 
126 
53 
37 
 
 
 
24.5 
41.0 
24.3 
10.2 
 
1.3mm 
 
108 
156 
68 
30 
3 
 
 
 
29.8 
43.1 
18.8 
8.3 
 
2.1mm 
 
19 
57 
58 
23 
34 
 
 
 
12.1 
36.3 
36.9 
14.6 
 
<0.001 
 
<0.001 
Histology 
SSM 
NM 
LMM 
ALM 
others 
na 
 
307 
90 
26 
28 
51 
54 
 
55.2 
16.2 
4.7 
5.0 
9.2 
 
224 
51 
21 
16 
35 
18 
 
64.6 
14.7 
6.1 
4.6 
10.1 
 
83 
39 
5 
12 
16 
36 
 
53.5 
25.2 
3.2 
7.7 
10.3 
0.016 
Localisation 
head and neck 
trunk 
upper extremities 
lower extremities 
others 
na 
 
81 
204 
97 
143 
8 
23 
 
15.2 
38.3 
18.2 
26.8 
1.5 
 
46 
150 
76 
90 
3 
0 
 
12.6 
41.1 
20.8 
24.7 
0.8 
 
35 
54 
21 
53 
5 
23 
 
20.8 
32.1 
12.5 
31.5 
3.0 
0.002 
Clark level 
2 
3 
4 
5 
na 
 
33 
82 
328 
20 
93 
 
7.1 
17.7 
70.8 
4.3 
 
31 
67 
220 
11 
36 
 
9.4 
20.4 
66.9 
3.3 
 
2 
15 
108 
9 
57 
 
1.5 
11.2 
80.6 
6.7 
<0.001 
Ulceration 
yes 
no 
na 
 
122 
322 
112 
 
27.5 
72.5 
 
63 
239 
63 
 
20.9 
79.1 
 
59 
83 
49 
 
41.5 
58.5 
<0.001 
Regression 
yes 
no 
na 
 
61 
369 
126 
 
14.2 
85.8 
 
47 
252 
66 
 
15.7 
84.3 
 
14 
117 
60 
 
10.7 
89.3 
0.169 
Naevus-associated MM 
yes 
no 
na 
 
82 
339 
135 
 
19.5 
80.5 
 
60 
234 
71 
 
20.4 
79.6 
 
22 
105 
64 
 
17.3 
82.7 
0.463 
*Pearson Chi-Square Asymp.Sig (2-sided) 
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4.3.2. Stage I/II compared with Stage III/IV 
The cohort of melanoma patients from Tübingen consisted of 556 patients and was split into 
two groups to compare phenotypes, sun behaviour and tumour specific data between early 
and advanced melanoma patients. Early melanoma patients, who were diagnosed with stage 
I or stage II disease and who did not progress over the time period of follow up, formed the 
first group of 365 patients. Advanced melanoma patients, who were either initially diagnosed 
with stage III/stage IV or who progressed and were classified stage III or stage IV at the end of 
follow up, formed the second group of 191 patients. 
The comparison between the two groups in regard of their general data, pigment traits, signs 
of UV damage and naevus counts are summarized in Table 4. The advanced patients group 
consisted of slightly more female patients compared to the early stage group (46.6% versus 
43.6%), but the difference was not significant. The median age, the BMI and the ancestry were 
similar between the two groups. The median age was 58 and 59 years respectively and the 
BMI 26 in both groups. More than 90% of patients had German parents with 93.6% in the early 
stage group and 92.5% in the late stage group. 
A significant difference was observed in regard of the hair colour between the two groups. 
Patients with blonde hair were more likely to have early stage melanoma, whereas more pa-
tients with brown hair had late stage disease. The frequency of blonde hair was 47.4% in the 
early stage group compared to 36.9% in the late stage group, whereas 39.8% had brown hair 
in the early stage group compared to 52.9% in the late stage group. This difference was signif-
icant with a p-value of 0.018 (Figure 22a). The other pigment traits eye colour and skin type 
were similar between both groups. No difference was observed between the skin reaction 
after sun exposure of early versus late stage melanoma patients (Figure 22d). The total body 
naevus count was recorded in 5 categories. The category 11-30 total body naevus count was 
most frequent in both groups with 33.4% in early stage and 40.2% in late stage melanoma 
patients. The distribution between the categories was similar in both cohorts with no signifi-
cant differences (Figure 22e). Slightly more patients with early stage melanoma disease had a 
report of dysplastic naevi on their body. While 83.9% of late stage melanoma had no dysplastic 
naevi, 78.6% of early stage melanoma patients were documented having no dysplastic naevi 
on their body. However, the differences were not statistically significant (Figure 22f). 
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Figure 22: Bar charts displaying the pigment traits of the cohort; a. Hair colour; b. Eye colour; c. Skin 
type; d. Skin reaction; e. Naevus count; f. Dysplastic Naevus count 
a b 
e f 
c d 
p=0.018 
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Data recorded in regard of the medical history of the patients were  
i. the presence of a second cancer other than melanoma 
ii. the personal history of psoriasis 
iii. the family history of melanoma and 
iv. the family history of other cancer types. 
None of the variables showed significant differences between the two groups (Table 5). 
Slightly more patients of the early stage group were affected with a second cancer comprising 
7.1% of early stage patients compared to 5.8% of late stage melanoma patients with a second 
cancer other than melanoma. A history of psoriasis was slightly more frequent in early stage 
melanoma patients with 4.3% versus 3.3%. A positive family history of melanoma was more 
frequent in the early stage patients with 6.5% compared to 3.3% of patients in the late stage 
group. Likewise, more patients of the early stage group had a family member with any other 
cancer type. These were 55.6% compared to 47.8% of late stage patients with a positive family 
history of cancer (Figure 23). 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Bar charts displaying the medical history of the cohort; a. Personal history of a second can-
cer; b. Personal history of psoriasis; c. Family history of melanoma; d. Family history of cancer 
a b 
c d 
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Sun behaviour and UV damage data were compared between the two groups. These data 
consisted of eight different variables: the recall of sunburns in childhood and adolescence, the 
use of sun beds, frequency of sun holidays, usage of sunscreen, occupational sun exposure, 
leisure sun exposure, UV damage and field cancerisation. None of the single variables showed 
significant differences between the early stage melanoma patients and the late stage mela-
noma patients (Table 6). 
Slightly more patients of the late stage group compared to the early stage group indicated 
they never got sunburned at the age below 20 years (10.6% versus 7.7%). Patients of the early 
stage group indicated more frequently they got less than 1x/year burned. The other categories 
1x/year and several times a year had the same percentage with 44.5% versus 45.0% and 22.1% 
versus 21.7% respectively (Figure 24a). 
Likewise, slightly more of the late stage patient group reported they would never use sun beds 
with 89.3% compared to 86.1% of the early melanoma stage patients and fewer late stage 
patients used sun beds occasionally compared to early stage patients. The categories few 
weeks before holiday, less than 1x/month, monthly and weekly shared nearly the same per-
centage in both groups (Figure 24b). 
Accordingly, more late stage patients never went on sun holidays with 36.2% compared to 
31.4% of the early stage patients (Figure 24c). 
The sunscreen use was lower among the late stage melanoma patients. The percentage of 
patients who never used sunscreen was 13.9% compared to 9.2% among the early stage mel-
anoma patients. Most of the early stage patients (37.8%) reported they would use sunscreen 
several times a week while this was reported by 29.9% of the late stage patients, who most 
frequently indicated (38.0%) they would seldom use sunscreen. These differences reached a 
borderline p-value of 0.056 (Figure 24d). 
There was no statistical difference between the two groups concerning the occupational sun 
exposure as well as the leisure sun exposure. Regarding the occupational sun exposure, the 
proportion of patients working exclusively indoors was higher among the late stage patients 
with 53.3% compared to 47.6% of the early stage patients. The leisure sun exposure was nearly 
identical between the two groups (Figure 24 e+f). 
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Severe UV damage was more frequent in early stage melanoma patients with 40.7% versus 
28.7% of late stage melanoma patients with severe UV damage. Late stage melanoma patients 
were more likely to have no or light UV damage (Figure 24g). 
Likewise, a field cancerization on the head was more frequent in early stage patients with 3.2% 
compared to a frequency of 0.6% in late stage melanoma patients (Figure 24 h). However, 
these differences were not statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 continued on next page 
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Figure 24: Bar charts displaying data on sun behaviour and UV damage of the cohort; a. History of 
sunburns; b. Use of sun beds; c. Sun holidays; d. Use of sunscreen; e. Occupational sun exposure; f. 
Leisure sun exposure; g. UV damage; h. Field cancerisation. 
The frequency of genetic germline variants coding for the genes MC1R, PGC-1a and PGC-1b 
was not significantly different between early stage and late stage melanoma patients. MC1R 
variants were common, 78.5% of the late stage patients and 76.7% of the early stage patients 
had at least one variant. Further exploration of the type of MC1R variants revealed significant 
differences between the two groups (Figure 25). 
e f 
g h 
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Stage III/IV patients were more likely to have one r-allele and less likely to have two r-alleles 
compared to Stage I/II patients. Patients with no WT allele were more frequent among Stage 
I/II patients. The distribution of R-alleles was similar between the two groups. The MC1R gen-
otypes WT/WT, r/r, r/R and R/R were significantly more frequent among Stage I/II, while the 
genotypes WT/r and WT/R were more frequent among Stage III/IV patients (p=0.019). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Bar charts displaying a. wildtype versus the presence of at least one variant at the coding 
region for MC1R; b. the distribution of MC1R genotypes; c. the presence of MC1R r-alleles; c. the pres-
ence of MC1R R-alleles and e. the presence of MC1R WT-alleles in stage I/II versus stage III/IV patients 
 
 
a b 
c p=0.004 p=0.028 d e 
p=0.019 
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Variants in the gene coding for PGC-1a were seen in 12.6% of the early stage patients com-
pared to 13.1% of the late stage patients. Variants in the gene coding for PGC-1b were slightly 
more frequent with 23.0% in early stage and 23.6% in late stage melanoma patients (Figure 
26). 
 
 
 
 
 
 
 
 
 
 
Figure 26: Bar charts displaying genetic data: wildtype versus the presence of at least one variant at 
the coding regions for a. PGC-1a and b. PGC-1b in stage I/II versus stage III/IV patients 
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The following tumour specific data were compared between the two groups: tumour thick-
ness, histology, localisation of the primary tumour, Clark level, ulceration of the primary, signs 
of regression and the existence of naevus residues in the histological specimen  
(Table 8). 
The median tumour thickness was 2.1mm in the late stage group compared to 1.3mm in the 
early stage group. This difference was significant with a p-value of <0.001 (Figure 27a). Most 
patients among the early stage group had a tumour thickness between 1.01 and 2.0mm 
(43.1%) followed by 29.8% of patients with a tumour thickness below 1.0mm. Interestingly 
still 30 patients (8.3%) had a tumour thickness of above 4mm without developing any metas-
tases. In parallel 19 patients (12.1%) of the late stage group had initially a low risk tumour with 
a tumour thickness below 1mm.  
The frequent subtype superficial spreading melanoma was more prevalent among the early 
stage patients with 64.6% compared to 53.5% among the late stage patients (Figure 27b). 
Likewise, 6.1% of early stage patients had a lentigo maligna melanoma compared to 3.2% of 
late stage patients. The subtypes nodular melanoma and acral lentiginous melanoma were 
more frequent among the late stage patients with 25.2% versus 14.7% and 7.7% versus 4.6% 
respectively (p= 0.016).  
The localisation head and neck and lower extremities were more frequent among late stage 
patients with 20.8% versus 12.6% and 31.5% versus 24.7% respectively (Figure 27c). The most 
common localisation among the early stage patients was the trunk with 41.1% compared to 
32.1% among late stage patients (p=0.002). 
Per definition all cases with unknown primary were included in the late stage group where 
they contributed with 12.3% of all cases (Figure 27d). 
Early stage patients had lower Clark levels compared to late stage patients (Figure 27e). The 
majority of late stage patients (80.6%) had a Clark level 4 compared to 66.9% of early stage 
patients (p=<0.001).  
Ulcerated primaries were reported in 20.9% of the cases among early stage melanomas com-
pared to 41.5% of the tumours of late stage patients (p=<0.001) (Figure 27f). 
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Signs of regression were reported more frequently in early stage patients with 15.7% com-
pared to 10.7% in specimens of late stage patients (Figure 27g). This difference was not signif-
icant with a p-value of 0.169. An association with a pre-existing naevus was seen in about one 
fifth in both groups, slightly more in early stage melanoma patients (20.4%) compared to late 
stage patients (17.3%) (Figure 27h). The difference was not significant (p=0.463). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27 continued on next page 
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Figure 27: Bar charts displaying the tumour specific data of the cohort; a. Tumour thickness; b. Histol-
ogy; c. Localisation; d. Unknown primary; e. Clark level; f. Ulceration, g. Regression, h. Naevus associ-
ated melanoma 
 
 
 
 
 
  
e f 
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p=<0.001 p=<0.001 
Dr. med. Annette Pflugfelder  Phenotypes and Genotypes of Melanoma Patients 
 
123 
 
4.3.3. Melanoma Survivors compared with Fatalities 
In a next step those patients who survived were compared to those who died of melanoma, 
independent of the stage of their disease. This was done to focus on those patients who did 
not only enter a prognostic unfavourable stage but who ultimately died of their disease. 
Of all 556 melanoma patients, 64 patients died from melanoma at the end of the follow up 
time and 492 patients were still alive or died of other causes. All previously assessed variables 
were analysed between these two groups of patients, the melanoma survivors and those who 
died. 
General data, data pigment traits and the total body naevus count of the patients are summa-
rized in Table 9.  
The gender distribution was similar between the two groups. Patients who died were slightly 
younger with a median age of 54 compared to 60, but this difference was not significant. Pa-
tients of both groups had the same median BMI of 26. The percentage of patients with German 
parents was 93.4% and 92.1% in the two groups. 
Blonde-haired patients were more prevalent among survivors than among those who died, 
whereas patients with brown hair were most common among patients who died. However, 
this difference was not significant (p= 0.848). 
The eye colour was similar between both groups, notably for patients with blue, grey and 
brown eyes. Patients with green eyes were less frequent among patients who died of mela-
noma than among those who survived (10.9% versus 17.2%), however this was based on small 
numbers. Overall the difference of the eye colour between the cohorts was not significant 
(p=0.605). 
A Fitzpatrick skin type II was most frequent among those patients who died with 69.6% com-
pared to 54.8% of patients among the survivors. Among patients who survived a slightly higher 
proportion had skin type III with 37.1% compared to 25.0% among those who died. Again, this 
was not significant (p= 0.290) 
According to the distribution of the skin type, more patients among the survivors had a higher 
tanning ability. Fewer patients among those who survived indicated they would always burned 
or mostly burned and have a light tan after sun exposure compared to those who died in the 
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course of their disease (17.2% versus 21.0% and 48.8% versus 53.2% respectively). Accord-
ingly, 24.4% of the survivors stated they would seldom burned with a strong tan compared to 
17.7% of those who died and 9.6% indicated they would never burned and always tan com-
pared to 8.1%. The differences were not significant (p=0.608). 
Severe UV damage was less frequent among melanoma patients who died with 28.1% versus 
37.8% of patients with severe UV damage among patients who survived (p=0.286). 
In line with this none of the melanoma patients who died had a field cancerisation with the 
presence of multiple actinic keratosis compared to 11 patients among those who survived 
(p=0.213). 
The distribution of the 5 different naevus count categories was similar between those mela-
noma patients who survived and those who died. The same was true for the count of dysplas-
tic naevi. 
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Table 9: Comparison of general and pigment traits between patients who survived and patients who 
died from melanoma 
 All pts Alive or dead of 
other cause 
Died from 
melanoma 
p* 
 n % n % n %  
Total, n 556 100 492 100 64 100  
Sex 
female 
male 
 
248 
308 
 
44.6 
55.4 
 
219 
273 
 
44.5 
55.5 
 
29 
35 
 
45.3 
54.7 
0.904 
Age 
median, range 
 
59,  
17-91 
  
60 
17 - 91 
  
54 
19 - 70 
 0.294 
BMI 
median, range 
26,  
17-70 
 26 
17 - 70 
 26 
18 - 42 
 0.705 
German parents 
yes 
others 
na 
 
508 
37 
11 
 
93.2 
6.8 
 
450 
32 
10 
 
93.4 
6.6 
 
58 
5 
1 
 
92.1 
7.9 
0.700 
Hair colour 
red 
blonde 
brown 
black 
na 
 
33 
239 
242 
32 
10 
 
6.0 
43.8 
44.3 
5.9 
 
29 
215 
212 
29 
7 
 
6.0 
44.3 
43.7 
6.0 
 
4 
24 
30 
3 
 
6.6 
39.3 
49.2 
4.9 
0.848 
Eye colour 
blue 
grey 
green 
brown 
na 
 
218 
110 
91 
133 
4 
 
39.5 
19.9 
16.5 
24.1 
 
192 
95 
84 
117 
4 
 
39.3 
19.5 
17.2 
24.0 
 
26 
15 
7 
16 
 
40.6 
23.4 
10.9 
25.0 
0.605 
Skin type (Fitzpatrick) n, % 
I 
II 
III 
IV 
V 
na 
 
31 
274 
173 
6 
1 
71 
 
6.4 
56.5 
35.7 
1.2 
0.2 
 
28 
235 
159 
6 
1 
63 
 
6.5 
54.8 
37.1 
1.4 
0.2 
 
3 
39 
14 
0 
0 
8 
 
5.4 
69.6 
25.0 
0 
0 
0.290 
Skin reaction  
always burned, no tan 
mostly burned, light tan 
seldom burned, strong tan 
never burned, always tan 
na 
 
97 
271 
130 
52 
6 
 
17.6 
49.3 
23.6 
9.5 
 
84 
238 
119 
47 
4 
 
17.2 
48.8 
24.4 
9.6 
 
13 
33 
11 
5 
2 
 
21.0 
53.2 
17.7 
8.1 
0.608 
UV damage 
none 
light 
severe 
na 
 
128 
183 
180 
65 
 
26.1 
37.3 
36.7 
 
113 
157 
164 
58 
 
26.0 
36.2 
37.8 
 
15 
26 
16 
7 
 
26.3 
45.6 
28.1 
0.286 
Field cancerosis 
yes 
no 
na 
 
11 
460 
85 
 
2.3 
97.7 
 
11 
403 
78 
 
2.7 
97.3 
 
0 
57 
7 
 
100 
0 
0.213 
Naevus count 
0-10 
11-30 
31-50 
51-100 
>100 
na 
 
134 
198 
105 
79 
38 
2 
 
24.2 
35.7 
19.0 
14.3 
6.9 
 
124 
173 
94 
67 
32 
2 
 
25.3 
35.3 
19.2 
13.7 
6.5 
 
10 
25 
11 
12 
6 
0 
 
15.6 
39.1 
17.2 
18.8 
9.4 
0.376 
Dysplastic naevus count 
0 
1-5 
6-10 
11-20 
more than 20 
na 
 
385 
83 
5 
4 
2 
77 
 
80.4 
17.3 
1.0 
0.8 
0.4 
 
342 
71 
5 
4 
2 
68 
 
80.7 
16.7 
1.2 
0.9 
0.5 
 
43 
12 
0 
0 
0 
9 
 
78.2 
21.8 
0.701 
*Pearson Chi-Square Asymp.Sig (2-sided) 
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Data on the medical history of the patients and the medical family history are presented in 
Table 10. No significant differences were observed between the groups. 
Of the 64 patients who died from melanoma 6.3% had a second cancer and 3.2% had a history 
of psoriasis. In the group of the 492 survivors there were 6.7% who had a second cancer and 
4.0% with a personal history of psoriasis.  
A positive family history of melanoma was reported by 3.3% of patients who died from mela-
noma and by 5.7% of the survivors. 
Around half of the patients had a family member with a positive history of any other type of 
cancer, slightly more among the survivors with 53.8% compared to 45.9% among those pa-
tients who died (Table 10). 
 
 
Table 10: Comparison of the medical history between patients who survived and patients who died 
from melanoma 
 All pts Alive or dead of 
other cause 
died from 
melanoma 
p* 
 n % n % n %  
Total, n 556 100 492 100 64 100  
Second cancer 
yes 
no 
na 
 
37 
519 
0 
 
6.7 
93.3 
 
33 
459 
0 
 
6.7 
93.3 
 
4 
60 
0 
 
6.3 
93.8 
0.890 
History of Psoriasis 
yes 
no 
na 
 
21 
514 
21 
 
3.9 
96.1 
 
19 
454 
19 
 
4.0 
96.0 
 
2 
60 
2 
 
3.2 
96.8 
0.763 
Family history of MM 
yes 
no 
na 
 
29 
508 
19 
 
5.4 
94.6 
 
27 
450 
15 
 
5.7 
94.3 
 
2 
58 
4 
 
3.3 
96.7 
0.452 
Family history of Cancer 
yes 
no 
na 
 
283 
252 
21 
 
52.9 
47.1 
 
255 
219 
18 
 
53.8 
46.2 
 
28 
33 
3 
 
45.9 
54.1 
0.245 
*Pearson Chi-Square Asymp.Sig (2-sided) 
 
 
Dr. med. Annette Pflugfelder  Phenotypes and Genotypes of Melanoma Patients 
 
127 
 
Sun behaviour data of melanoma patients who died at the end of the follow up time compared 
to those who survived are presented in Table 11. There were no significant differences be-
tween the two groups. 
Around half of the patients among the survivors and among those who died from melanoma 
indicated they got sunburned once a year, 22.4% and 18.8% respectively got sunburned sev-
eral times a year, 25.3% and 20.3% less than once a year and 8.6% versus 9.4% never got 
sunburned. The usage of sunbeds was uncommon among melanoma patients, 87.4% of the 
survivors and 85.5% of those who died never went to a solarium. About one third of the mel-
anoma patients indicated they would never go on sun holidays, 33.6% of the survivors and 
28.6% of those who died of melanoma, 36.9% and 38.1% went less than one time a year, 
24.6% and 27.0% between one to two times a year, 2.7% and 3.2% two times a year, and 2.3% 
versus 3.2% stated they would go more frequently than two times a year on a sun holiday. 
Regular sunscreen use was slightly less common among those patients who died. Among those 
patients who died 12.9% used sunscreen on a daily base compared to 21.9% among the sur-
vivors, 33.9% versus 35.3% used sunscreen several times a week. The majority of patients who 
later died of melanoma used seldom or never sunscreen with 45.2% and 8.1% compared to 
31.8% and 11.1%. About half of the patients spent their work hours completely indoors, 
slightly more patients who died with 56.7% compared to 48.6% of those who survived. The 
categories less than 30 min a day, 30-60 min a day, 1-2 hours a day, 2-4 hours a day, 4-6 hours 
a day and more than 6 hours a day were evenly distributed among both groups. The same 
similar distribution was true for the leisure sun exposure. Very few patients, 5 among the sur-
vivors and none of those who died spent their leisure time completely indoors, 5.0% versus 
4.8% spend less than 30min a day outside, 17.1% and 15.9% were 30-60min a day outside, 
26.1% and 25.4% between 1 and 2 hours, 32.6% and 38.1% between 2 and 4 hours, 14.2% 
versus 15.9% between 4 and 6 hours and 19 patients (4%) of the survivors were more than 6 
hours a day outside. This was stated by none of the patients who died. 
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Table 11: Comparison of the sun behaviour between patients who survived and patients who died from 
melanoma 
 All pts Alive or dead of 
other cause 
died from 
melanoma 
p* 
 n % n % n %  
Total, n 556 100 492 100 64 100  
Sunburns (age < 20 ys) 
no sunburns 
less than 1x/year 
1x/year 
several times a year 
na 
 
48 
136 
246 
121 
5 
 
8.7 
24.7 
44.6 
22.0 
 
42 
123 
213 
109 
5 
 
8.6 
25.3 
43.7 
22.4 
 
6 
13 
33 
12 
 
9.4 
20.3 
51.6 
18.8 
0.634 
Use of Solarium 
never 
occasional 
few weeks before holiday 
less than 1x/month 
monthly 
weekly 
na 
 
476 
48 
8 
2 
6 
6 
10 
 
87.2 
8.8 
1.5 
0.4 
1.1 
1.1 
 
423 
41 
7 
2 
6 
5 
8 
 
87.4 
8.5 
1.4 
0.4 
1.2 
1.0 
 
 
53 
7 
1 
0 
0 
1 
2 
 
85.5 
11.3 
1.6 
0 
0 
1.6 
0.886 
Sun holidays 
never 
less than 1x/year 
1-2x/year 
2x/year 
more frequent than 2x/year 
na 
 
182 
204 
137 
15 
13 
5 
 
33.0 
37.0 
24.9 
2.7 
2.4 
 
164 
180 
120 
13 
11 
4 
 
33.6 
36.9 
24.6 
2.7 
2.3 
 
18 
24 
17 
2 
2 
1 
 
28.6 
38.1 
27.0 
3.2 
3.2 
0.934 
Use of sunscreen 
never 
seldom 
several times a week  
daily 
na 
 
59 
182 
192 
114 
9 
 
10.8 
33.3 
35.1 
20.8 
 
54 
154 
171 
106 
7 
 
11.1 
31.8 
35.3 
21.9 
 
5 
28 
21 
8 
2 
 
8.1 
45.2 
33.9 
12.9 
0.133 
Occupational sun exposure 
only indoors 
less than 30 min a day 
30-60 min a day 
1-2 hours a day 
2-4 hours a day 
4-6 hours a day 
more than 6 hours a day 
na 
 
268 
54 
64 
53 
36 
30 
36 
15 
 
49.5 
10.0 
11.8 
9.8 
6.7 
5.5 
6.7 
 
234 
49 
54 
50 
32 
29 
33 
11 
 
48.6 
10.2 
11.2 
10.4 
6.7 
6.0 
6.9 
 
34 
5 
10 
3 
4 
1 
3 
4 
 
56.7 
8.3 
16.7 
5.0 
6.7 
1.7 
5.0 
0.434 
Leisure sun exposure 
only indoors 
less than 30 min a day 
30-60 min a day 
1-2 hours a day 
2-4 hours a day 
4-6 hours a day 
more than 6 hours a day 
na 
 
5 
27 
92 
141 
180 
78 
19 
14 
 
0.9 
5.0 
17.0 
26.0 
33.2 
14.4 
3.5 
 
5 
24 
82 
125 
156 
68 
19 
13 
 
1.0 
5.0 
17.1 
26.1 
32.6 
14.2 
4.0 
 
0 
3 
10 
16 
24 
10 
0 
1 
 
0 
4.8 
15.9 
25.4 
38.1 
15.9 
0 
0.698 
*Pearson Chi-Square Asymp.Sig (2-sided) 
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Genetic data of those patients who died compared to those who survived are presented in 
Table 12. There was no significant difference between the two groups. Slightly more of the 
fatalities had a wild type at the MC1R locus with 28.1% compared to 22.0% but this difference 
was not significant. Further exploration of MC1R variants, considering r alleles, R alleles and 
the different MC1R genotypes revealed no significant differences as well.  
Among the patients who died from melanoma 85.9% had no variant at the coding gene for 
PGC-1a and 79.7% had no variant at the coding gene for PGC-1b, compared to 87.4% and 
76.4% respectively. 
Table 12: Comparison of genetic variants between patients who survived and patients who died from 
melanoma 
 All pts Alive or dead of 
other cause 
died from 
melanoma 
p 
 n % n % n %  
Total, n 556 100 492 100 64 100  
MC1R** 
wt 
variant 
na 
 
126 
430 
 
22.7 
77.3 
 
108 
384 
 
22.0 
78.0 
 
18 
46 
 
28.1 
71.9 
0.267 
MC1R r alleles 
0 
1 
2 
 
288 
217 
51 
 
51.8 
39.0 
9.2 
 
248 
195 
49 
 
50.4 
39.6 
10.0 
 
40 
22 
2 
 
62.5 
34.4 
3.1 
0.087 
MC1R R alleles 
0 
1 
2 
 
310 
207 
39 
 
55.8 
37.2 
7.0 
 
276 
181 
35 
 
56.1 
36.8 
7.1 
 
34 
26 
4 
 
53.1 
40.6 
6.3 
0.829 
MC1R WT alleles 
0 
1 
2 
 
174 
256 
126 
 
31.3 
46.0 
22.7 
 
160 
224 
108 
 
32.5 
45.5 
22.0 
 
14 
32 
18 
 
21.9 
50.0 
28.1 
0.197 
MC1R Genotype 
WT/WT 
WT/r 
WT/R 
r/r 
r/R 
R/R 
 
126 
133 
123 
51 
84 
39 
 
22.7 
23.9 
22.1 
9.2 
15.1 
7.0 
 
108 
119 
105 
49 
76 
35 
 
22.0 
24.2 
21.3 
10.0 
15.4 
7.1 
 
18 
14 
18 
2 
8 
4 
 
28.1 
21.9 
28.1 
3.1 
12.5 
6.3 
0.355 
PGC-1a 
wt 
variant 
na  
 
485 
71 
 
87.2 
12.8 
 
430 
62 
 
87.4 
12.6 
 
55 
9 
 
85.9 
14.1 
0.742 
PGC-1b 
wt 
variant 
na 
 
427 
129 
 
76.8 
23.2 
 
376 
116 
 
76.4 
23.6 
 
51 
13 
 
79.7 
20.3 
0.561 
*Pearson Chi-Square Asymp.Sig (2-sided) 
**deeper analyses with data of the MC1R locus were performed, considering the numbers of r, R or WT alleles 
respectively, and the specific MC1R genotype 
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Tumour specific data of the melanoma patients are summarized in Table 9 for both groups. A 
significant difference between the two groups was observed for the variables ”history of an 
unknown primary” and “ulceration of the primary tumour” (Table 13). 
Patients who died from melanoma had a median tumour thickness of 1.9mm compared to 
1.5mm among the survivors. The proportion of thick melanomas above 4mm and of melano-
mas between 2.01 and 4mm tumour thickness was higher in comparison to the group of mel-
anoma survivors with 16.4% versus 9.5% and 32.7% versus to 23.3%. Tumours with a thickness 
between 1.01mm and 2.0mm were most frequent among the survivors with 42.0% compared 
to 32.7% among patients who died of their melanoma. Still 18.2% (10 patients) among those 
who died had an initially favourable tumour thickness below 1mm. 
The distribution of melanoma subtypes was similar between both groups. Superficial spread-
ing melanoma was most frequent with 61.1% among the survivors and 61.5% among those 
who died. There were slightly more patients with nodular melanomas among those who died 
with 23.1% versus 17.3% among the survivors, the same was true for acral lentiginous mela-
nomas with 7.7% versus 5.3%. Only one patient (1.9%) of those who died had a lentigo maligna 
melanoma compared to 5.6% of the survivors. 
The localisation of the primary tumour did not differ significantly between the two groups. 
The trunk was the most common localisation with 41.4% among those who died and 37.9% 
among the survivors, followed by the lower extremities with 27.6% and 26.7%, head and neck 
with 15.5% and 15.2% and the upper extremities with 12.1% versus 18.9%. 
A primary tumour was not detectable in 9.4% of those patients who ultimately died of their 
disease while only 3.6% of those who survived were diagnosed with an unknown primary. This 
difference was significant with a p-value of 0.030. 
Patients who died had higher Clark levels. Clark level 4 was reported for 84.4% in this group 
compared to 69.4% among the survivors. Primary tumours of the survivors had more fre-
quently a Clark level 3 or Clark level 2 with 18.7% versus 8.9% and 7.7% versus 2.2% compared 
to patients from the fatality group. 
An ulcerated primary was found in nearly half of those patients who died (48.1%) compared 
to only 24.7% of patients who survived. This difference was significant with a p-value of 0.001. 
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Signs of regression in the histological specimen were more often observed among the survi-
vors, with 14.8% compared to 9.1% among patients who died. 
Remains of a pre-existing naevus were found in a similar proportion in both groups with 19.6% 
among survivors and 18.2% among the group with fatalities. 
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Table 13: Comparison of tumour specific data between patients who survived and patients who died 
from melanoma 
 All pts Alive or dead of other 
cause 
died from 
melanoma 
p* 
 n % n % n %  
Total, n 556 100 492 100 64 100  
Tumour thickness 
median 
 
<1,0mm 
1,01-2,0mm 
2,01-4mm 
>4mm 
na 
 
1.5mm 
 
127 
213 
126 
53 
37 
 
 
 
24.5 
41.0 
24.3 
10.2 
 
1.5mm 
 
117 
195 
108 
44 
28 
 
 
 
25.2 
42.0 
23.3 
9.5 
 
1.9mm 
 
10 
18 
18 
9 
9 
 
 
 
18.2 
32.7 
32.7 
16.4 
 
0.106 
 
0.461 
Histology 
SSM 
NM 
LMM 
ALM 
others 
na 
 
307 
90 
26 
28 
51 
54 
 
61.2 
17.9 
5.2 
5.6 
10.2 
 
275 
78 
25 
24 
48 
42 
 
61.1 
17.3 
5.6 
5.3 
10.7 
 
 
32 
12 
1 
4 
3 
12 
 
61.5 
23.1 
1.9 
7.7 
5.8 
0.461 
Localisation 
head and neck 
trunk 
upper extremities 
lower extremities 
others 
na 
 
81 
204 
97 
143 
8 
23 
 
15.2 
38.3 
18.2 
26.8 
1.5 
 
72 
180 
90 
127 
6 
17 
 
15.2 
37.9 
18.9 
26.7 
1.3 
 
9 
24 
7 
16 
2 
6 
 
15.5 
41.4 
12.1 
27.6 
3.4 
0.530 
Unknown primary 
yes 
no 
na 
 
23 
519 
14 
 
4.2 
95.8 
 
17 
461 
14 
 
3.6 
96.4 
 
6 
58 
0 
 
9.4 
90.6 
0.030 
Clark level 
2 
3 
4 
5 
na 
 
33 
82 
328 
20 
93 
 
7.1 
17.7 
70.8 
4.3 
 
32 
78 
290 
18 
74 
 
7.7 
18.7 
69.4 
4.3 
 
1 
4 
38 
2 
19 
 
2.2 
8.9 
84.4 
4.4 
0.159 
Ulceration 
yes 
no 
na 
 
122 
322 
112 
 
27.5 
72.5 
 
97 
295 
100 
 
24.7 
75.3 
 
25 
27 
12 
 
48.1 
51.9 
0.001 
Regression 
yes 
no 
na 
 
61 
369 
126 
 
14.2 
85.8 
 
57 
329 
106 
 
14.8 
85.2 
 
4 
40 
20 
 
9.1 
90.9 
0.307 
Naevus-associated MM 
yes 
no 
na 
 
82 
339 
135 
 
19.5 
80.5 
 
74 
303 
115 
 
19.6 
80.4 
 
8 
36 
20 
 
18.2 
81.8 
0.819 
*Pearson Chi-Square Asymp.Sig (2-sided) 
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4.3.4. Survival Analyses 
Survival analyses were performed in order to examine the impact of phenotypes and geno-
types on the survival probabilities in a time dependent manner. 
4.3.4.1. Survival Analyses with previously assessed Variables 
The survival probabilities of the 556 melanoma patients were tested for each of the above 
assessed variables. Significant results in the log rank test, pooled over strata were found for 
two of the variables. These were the tumour specific variables “Ulceration of the primary” and 
“Unknown primary”. Patients with an ulcerated primary tumour had an impaired survival 
probability (p=0.001) (Figure 30c) as well as patients with unknown primary at the time of 
initial diagnoses (p=0.008) (Figure 30d). 
Using the log rank test with pairwise comparison, additionally six variables showed significant 
results. This was the variable tumour thickness, with an impaired survival of patients with a 
tumour thickness >4mm compared to those with melanomas between 1.01 and 2.0mm 
(p=0.040) (Figure 30a). 
Among the general and pigment traits, patients with a Skin type II had an impaired survival 
probability compared to patients with Skin type III (p=0.032). The difference in survival prob-
abilities remained significant after dichotomization of the variable in Skin type I and II versus 
Skin type III, IV and V (p=0.031). 
Among the variables regarding sun behaviour, patients had better survival probabilities who 
used sunscreen daily in summer compared to those who seldom used sunscreen (p=0.030) 
and who had a leisure sun exposure of 4-6 hours compared to 2-4 hours (p=0.050). However, 
dichotomizing of these two variables resulted in not significant differences, indicating the pre-
viously detected differences were driven by small subset numbers.  
In regard to the MC1R genotypes patients with a r/r genotype had a better survival compared 
to WT/R types (P=0.040) and patients with two MC1R r-alleles had a better survival than pa-
tients with no MC1R r-alleles (p=0.049) (Figure 31b). 
The remaining log rank test results (pooled over strata) of the Kaplan Meier survival analyses 
were as follows: 
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The assessed variables of general and pigment traits were gender, with no significant differ-
ences between males and females (p=0.884), age (p=0.089), BMI (p=0.498), German ancestry 
(p=0.630), Hair colour (p=0.908), Eye colour (p=0.616), Skin type (p=0.244), Skin reaction 
(p=0.600), UV damage (p=0.407), Field cancerosis (p=0.262), Naevus count (p=0.439) and Dys-
plastic naevus count (p=0.675). 
The variables concerning medical history were the personal history of a second cancer 
(p=0.841), the personal history of psoriasis (p=0.649), the family history of melanoma 
(p=0.566) and the family history of cancer (p=0.275), all without impact on melanoma specific 
survival. 
The sun behaviour data were the frequency of sunburns at the age below 20 years (p=0.469), 
the use of sunbeds (p=0.904), the frequency of sun holidays (p=0.862), the use of sunscreen 
(p=0.114), the occupational sun exposure (p=0.528) and the leisure sun exposure (p=0.775). 
All variables showed no significant results in the pooled over strata test. 
Survival analyses with the genetic variables presence of any variant compared to wildtype of 
MC1R (p=0.333), PPARGC1A (p=0.825) and PPARGC1B (p=0.579) showed no survival differ-
ences. The number of MC1R r alleles, MC1R R alleles or MC1R WT alleles and the MC1R Gen-
otype were likewise without significant difference in the log rank pooled over strata test. 
4.3.4.2. Genome-Wide Survival Analyses 
In order to screen for genetic markers which might influence survival among the cohort of 
melanoma patients, all available genetic variants across the 23 chromosomes of each individ-
ual melanoma patient were assessed in a genome-wide analyses. The ten variants with the 
most significant results were further investigated. All variants were single nucleotide polymor-
phisms (SNPs). Four of these SNPs were located in chromosome 1, three in chromosome 10, 
two in chromosome 4 and one in chromosome 8. All of these 10 SNPs yielded a p-value ≤ 1e-
5 and one SNP reached genome wide significance with a p-value of 1e-10.204,205 The results of 
the genome-wide association analysis (GWAS) were illustrated in a Manhattan plot (Figure 
28). 
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Figure 28: Manhattan Plot illustrating the genome-wide association analyses across all 23 chromo-
somes for melanoma-specific survival in 556 melanoma patients. The top ten SNPs are presented in 
red dots with the respective rs numbers (black: most likely artefactual finding, red: potential relevance) 
The top 10 SNPs were further explored in regard to their relation to known gene loci, their 
reported minor allele frequency in dbSNP and the observed frequency of homozygous and 
heterozygous individuals in the cohort, as described below. 
The SNP rs12416395 is located on chromosome 10 and had a reported minor allele of A=0.206. 
Among the 556 melanoma patients, 77 were heterozygous (A/C) and one patient who died of 
melanoma was homozygous (A/A). The significant result was driven by this single event. There 
was no survival difference between wildtype and heterozygous patients at this locus (log rank 
test p=0.179). The SNP rs183135544, likewise located on chromosome 10, with a reported 
minor allele frequency of A=0.003, was found among 11 patients. One patient was homozy-
gous (A/A) and died of melanoma and 10 patients were heterozygous (A/G). Again, the signif-
icant result was driven by a single case. The SNP rs7551288 is an intron variant of the gene 
DHCR24 located on chromosome 1 with a reported MAF of G=0.386. Homozygous patients 
(n=96) had the worst survival outcome, wildtype patients (n=176) the best outcome, hetero-
zygous patients (n=284) were in between. The SNP rs12146110 is again located on chromo-
some 1 and is an intron variant of the gene USH2A. The minor allele frequency was A=0.212, 
17 patients were homozygous and 171 patients heterozygous. Homozygous patients had an 
impaired survival and all homozygous patients who entered Stage IV died of their disease. The 
rs12416395 
rs7551288 
rs183135544 
rs12146110 rs13146736 
rs1993585 rs1007271 
rs11247940 
exm850364 rs12545000 
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SNP rs12545000 is located on chromosome 8, the minor allele frequency was C=0.126. The 
significant result was driven by a single case with one homozygous patient who died. The SNP 
rs11247940 is located on chromosome 1 and the minor allele frequency was C=0.255. Again, 
the significant result was driven by a single case. The variant exm850364 is a rare variant lo-
cated on chromosome 10. Only one patient was heterozygous and this patient died. SNP 
rs1993585 is located on chromosome 4 with a minor allele frequency of A=0.226. One homo-
zygous patient died and the 95 heterozygous patients had a significant impaired survival com-
pared to the wildtype patients. SNP rs1007271 is located on chromosome 1 and had a re-
ported minor allele frequency of A=0.472. Heterozygous patients (n=251) had the same sur-
vival probabilities than wildtype patients (n=248), however homozygous patients (n=57) had 
a significant impaired survival (17 events). SNP rs13146736 is located on chromosome 4, the 
minor allele frequency was T=0.382. Heterozygous patients had an impaired survival com-
pared to wildtype patients, however the homozygous patients had a not coherent improved 
survival probability, yet driven only by two events. The result was not significant in stage IV.  
In total 4 SNPs, rs7551288, rs12146110, rs1993585 and rs1007271 were selected as poten-
tially relevant candidates. 
4.3.4.3. Survival Plots of Selected Variables 
Specific phenotype and genotype variables were selected to illustrate the respective survival 
probabilities using a Kaplan Meier plot. The first variable was the phenotype variable “Total 
body naevus count” as core variable of the second hypothesis of this thesis. Furthermore, 
variables which were significant or were close to significance in the primary association anal-
yses stage I/II versus stage III/IV were selected. These were the variables Tumour thickness, 
Histology, Localisation, Unknown primary, Clark level, Ulceration, Hair colour, Use of sun-
screen and UV damage. Additionally, the variables Gender and BMI were chosen, as they have 
been described previously in the literature having a prognostic impact on melanoma survival. 
Finally, the survival curves with significant results in the pairwise comparisons, skin type and 
MC1R r-allele and the curves for the SNPs with potential relevance derived from the genome-
wide association analyses were selected and presented in Figure 31. 
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The survival curves for the selected host specific variables are presented in Figure 29, the tu-
mour specific variables are shown in Figure 30. 
The survival probabilities for patients with a total body naevus count below 30 naevi com-
pared to patients with a naevus count above 30 naevi are presented in Figure 29a. 
The curves overlap with some slight difference 4 years after initial diagnoses, favouring pa-
tients with few naevi. Using the log rank test this difference was not statistically significant 
(p=0.501). Hair colour had no impact on the survival probabilities as shown in Figure 29b. Pa-
tients with regular use of sunscreen had a slightly better survival, however this was not statis-
tically significant (p=0.128) (Figure 29c). The same was true for patients with severe sun dam-
age compared to those with light and with no sun damage (p=0.407) (Figure 29d). All patients 
with the presence of a field cancerisation on the head survived or died of other causes, while 
all those patients who died from melanoma had no field cancerisation. The survival plot is not 
presented as all cases were censored and no statistical test could be performed. Female and 
male patients had the same survival probabilities with overlapping survival curves as shown 
in Figure 29e (p=0.884). No survival differences were seen for obese versus not obese patients 
with a BMI threshold of 30 (Figure 29f). 
The survival probabilities based on tumour specific factors are presented in Figure 30. The 
survival curves break up as expected for patients with melanomas of the different tumour 
thickness groups <1mm, 1.01-2mm, 2.01-4mm, >4mm. The survival difference was not statis-
tically significant in the pooled over strata test (p=0.110) but was significant in the pairwise 
comparison (p= 0.040) (Figure 30a). The related factor of the histologically diagnosed depth 
of penetration, the Clark level showed as well no significance in the overall comparison 
(p=0.273). An ulceration of the primary tumour was associated with a significant decrease of 
the survival probability as shown in Figure 30c (p=0.001). Patients who were diagnosed initially 
with metastases of an unknown primary had impaired survival probabilities compared to 
those with a known primary (Figure 30d, p=0.008). The survival curves of patients stratified 
for the melanoma subtype did split up as expected but reached no statistical significance (Fig-
ure 30e, p=0.576). The different body localisations of the primary tumour showed no impact 
on survival probabilities as illustrated in Figure 30f (p=0.604).   
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Figure 29: Survival probabilities for patients stratified for host specific variables, a. Total body naevus 
count, b. Hair colour, c. Use of sunscreen, d. UV damage, e. Gender and f. Body mass index. 
a. Total body naevus number b. Hair colour 
f. Body mass Index 
c. Use of sunscreen d. UV damage 
e. Gender 
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Figure 30: Survival probabilities for patients stratified for tumour specific variables:  a. Tumour thick-
ness, b. Clark level, c. Ulceration, d. Unknown primary, e. Histology and f. Localisation.  
a. Tumour thickness b. Clark level 
c. Ulceration 
e. Histology f. Localisation 
d. Unknown primary 
p=0.001 
p=0.040 
Pairwise comparison 
p=0.008 
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Figure 31: Survival probabilities for patients stratified for a. skin type, b. the presence of a MC1R r-
allele and for the four SNPs of potential relevance: c. rs7551288, d. rs12146110, e. rs1993585 and  
f. rs1007271 
p=0.049 
Log rank pairwise comparison: 0 versus 2 r alleles 
p=0.031 
Log rank overall comparisons 
P<0.001 
Log rank overall comparisons 
P<0.001 
Log rank overall comparisons 
P<0.001 
Log rank overall comparisons 
a. Skin type b. MC1R r-allele 
c. rs7551288 d. rs12146110 
f. rs1007271 e. rs1993585 
P<0.001 
Log rank overall comparisons 
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The Kaplan Meier curves of subsequent analyses, including the pairwise log rank test, the 
deeper MC1R analyses and of the SNPs derived from the genome-wide association analyses 
are presented in Figure 31. The survival probabilities of patients according to their skin type 
yielded a significant result in the pairwise comparison which remained significant after dichot-
omization of the variable. Patients with a lighter skin type I or II had a worse outcome com-
pared to darker pigmented patients with skin type III or IV (p=0.031) (Figure 31a). The deeper 
analyses of the MC1R variants, distinguishing between R-alleles and r-alleles among the pa-
tients, revealed a significant increasing survival benefit for patients with one or two r-allele(s) 
(p=0.049) (Figure 31b).  
The survival curves presented for the four SNPs rs7551288 (Figure 31c), rs12146110 (Figure 
31d), rs1993585 (Figure 31e) and rs1007271 (Figure 31f) revealed diminished survival proba-
bilities of patients homozygous for the respective minor allele variant for all four SNPs. A split 
up of the survival curves between wildtype patients and heterozygous patients was addition-
ally apparent for the first three SNPs rs7551288, rs12146110 and rs1993585, indicating an 
additive effect. However, the latter one included only one homozygous patient. The fourth 
SNP rs1007271 showed only an impact on survival for patients with two minor alleles. The two 
most interesting SNPs rs7551288 and rs12146110 had both additionally an impact on survival 
among patients in stage IV (Figure 32). 
 
 
 
 
 
 
 
 
 
Figure 32: Survival probabilities in Stage IV for patients with the different genotypes at the two best 
SNPs a. rs7551288 and b. rs12146110 
a. rs7551288, Survival St IV 
Months after Stage IV diagnosis 
P<0.001 
Log rank overall comparisons 
b. rs12146110, Survival St IV 
P<0.001 
Log rank overall comparisons 
Months after Stage IV diagnosis 
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4.4. Discussion 
The presented analyses compared the characteristics of early and late stage melanoma pa-
tients with an initial focus on phenotypic characteristics and sun behaviour data. Established 
melanoma specific factors were investigated as well. In a second step SNP array derived ge-
netic markers were additionally analysed in a genome-wide approach. The cohort consisted 
of 556 melanoma patients who were recruited during their regular appointments in the mel-
anoma outpatient clinic at the University Hospital Tübingen. 
The initial hypothesis was that late stage melanoma patients, those patients who ultimately 
die of their disease would have less naevi than early stage melanoma patients. This was based 
on a personal observation. This hypothesis was not confirmed in the present cohort. The nae-
vus count between patients who were classified as stage I/II patients at last follow up com-
pared to patients who were classified as stage III/IV patients was similar. The same was true 
for patients who died of melanoma compared to those who survived. The survival curves of 
patients with low versus high naevus count were not significantly different. This result is in 
contradiction to the reported survival benefit for melanoma patients with high naevus num-
bers by Ribero et al. in 2015.59 However, the validity of this result was questioned by Autier et 
al. in respect to statistical concerns and a possible overdiagnosis of screen-detected indolent 
melanomas.60 The authors cited a work published by Levell et al. which was investigating a 
diagnostic drift towards a classification of benign lesions as early melanomas.206 This trend 
was explained by subjective criteria in the histological diagnoses in early lesions and the in-
creasing cautiousness of medical practitioners due to the legal consequences of a wrong diag-
nosis. The assumption that the previously reported survival benefit for patients with a high 
naevus count was driven by a dilution of patients with actual benign lesions might be sup-
ported by the presented data. The cohort from Tübingen comprised relatively few patients 
with early melanomas as discussed later. 
Overall, the characteristics between early and late stage patients in the presented cohort were 
remarkably consistent. This was seen for personal and family medical history data as well as 
for general, pigment traits and the initially assessed genetic markers of the patients. Hair col-
our was the only trait which was significantly different between early and late melanoma pa-
tients. Blonde patients were more frequent among stage I/II patients while brown haired pa-
tients formed the largest sub-group among stage III/IV patients. However, this difference was 
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not significant between those patients who died from melanoma compared to those who sur-
vived and likewise not significant in the Kaplan Meier survival analyses. Moreover, there was 
even a trend for an impaired outcome for patients with blond/red hair compared to those 
with brown/black hair. This finding went with the impaired survival of patients with skin type 
II compared to patients with darker skin type III, which was significant in the pairwise log rank 
test. Contradicting results were previously reported by Davies et al. showing a more favoura-
ble outcome for patients with blond hair compared to brown/black hair and for patients hav-
ing a MC1R variant.202 While the favourable outcome of fair pigmented individuals was not 
confirmed within the present cohort, an increasing benefit for patients having one or two 
MC1R r-allele(s) was shown. Likewise, patients having a MC1R WT/WT genotype were more 
frequent among the fatalities with 28% compared to 22% among those who survived, which 
was in line with the paper published by Davies et al. It is interesting to observe here an exclu-
sive survival benefit for patients with the r allele. This benefit is suggestive to be independent 
of pigmentation traits considering the impaired outcome of light skinned patients in the pre-
sent cohort. The small r variants do not as much influence pigmentation traits compared to 
the R variants. The high penetrance R alleles have shown to have a combined odds ratio for 
red hair of 63.3 (95% CI 31.9-139.6) compared to the significantly lower odds ratios for r alleles 
of 5.1 (95% CI 2.5-11.3).148,207 Possible explanations for the observed survival differences 
might be a protective biologic effect of the r allele in metastatic disease, e.g. via an improved 
immune response. Another cause might be the promotion of less aggressive melanomas in 
patients having a MC1R r allele. 
The sun behaviour data was not significantly different between early and late stage patients 
and between survivors and fatalities. However, a trend for less chronic UV damage was ob-
served among the fatalities. None of the patients who died had a field cancerisation, a condi-
tion caused by cumulative sun exposure, compared to 2.7% among those who survived. Se-
vere UV damage was likewise more frequent among those who survived with 38% compared 
to 28% among those who died. A potential benefit of UV exposure in melanoma patients de-
rived by high Vitamin D levels has been suggested before208, supporting the favourable out-
come of patients with UV damage in the present cohort. However, the results still have to be 
interpreted with caution as potential confounders of the observed associations have not been 
examined. 
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Tumour specific markers were investigated in analogy to the other variables. As expected, the 
established prognostic factors such as tumour thickness of the primary, histology, localisation, 
the presence of an unknown primary, Clark level and ulceration showed a highly significant 
different distribution between stage I/II and stage III/IV patients. However, after comparing 
the patients who ultimately died of their disease with those who survived only two factors 
remained statistically significant. These factors were ulceration and the presence of an un-
known primary. This is surprising and requires a closer look on the investigated cohort. Low 
risk patients with a tumour thickness below 1mm were usually not seen at the University Hos-
pital and relatively few of these patients were therefore included in the present cohort study. 
However, patients with additional risk factors or those who progressed in spite of their thin 
tumours were followed up in the hospital. This resulted in an unexpected high number of pa-
tients with stage III/IV disease (n=19) and fatalities (n=10) among the 127 patients with a tu-
mour thickness below 1mm. On the other side more patients than expected survived among 
those with a tumour thickness above 4mm. A possible explanation is the fact that patients 
with rapidly progressive disease were less likely to be followed up in the outpatient clinic, 
where the patient recruitment for this cohort study was done, but were rather seen as in-
patients. Thus, the present cohort represented a cohort of patients excluding a share of indo-
lent melanomas and a part of those with rapidly progressive disease. This specific cohort com-
position did not facilitate the detection of the established prognostic markers between the 
groups. 
As a last step the influence of survival probabilities by genetic germline variants in the patients 
was explored using more than 300 000 SNPs in a genome-wide approach. Of the 10 most sig-
nificant SNPs a set of four SNPs were selected as potentially relevant prognostic variants based 
on allele frequency and consistency of the minor allele effects. The SNPs rs7551288, 
rs12146110 and rs1007271 are located on chromosome 1, rs1993585 on chromosome 4. Two 
SNPs are intron variants of known genes, rs7551288 lies in the gene DHCR24 and rs12146110 
belongs to the gene USH2A. These two SNPs did both have not only an impact on overall sur-
vival in the complete cohort but also among the patients who developed metastatic disease. 
The USH2A protein is associated with the Usher syndrome, a disease characterized by im-
paired hearing and visual loss due to retinitis pigmentosa.209 A link to melanoma or cancer has 
not been described so far. The DHCR24 gene is coding for the 3beta-hydroxysterol delta24-
reductase (DHCR24), an enzyme involved in cholesterol synthesis.210 Expression levels of 
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DHCR24 were found to be upregulated in higher grade urothelial carcinoma211 and in mela-
noma metastases.212 The progression promoting effect of the protein DHCR24 was found to 
be associated with protection against oxidative stress-induced apoptosis.212 The observed in-
tronic variant rs7551288 might regulate the expression of the protein and thereby influence 
survival and maybe also response to systemic treatments. The variant is common with a minor 
allele frequency of 39%. Heterozygous patients had an impaired survival, a worse outcome 
was observed in patients with two minor alleles and all homozygous patients who entered 
stage IV died of melanoma. 
4.5. Conclusions 
In conclusion the hypothesis that patients with high naevus number are more frequent among 
early stage melanoma patients and survivors was not confirmed in this cohort of patients from 
Germany. 
The absence of an ulcerated primary tumour and the presence of an MC1R r allele were asso-
ciated with an improved survival. 
A genome-wide association study revealed four potentially relevant variants predicting sur-
vival outcome in melanoma patients. The intronic variant rs7551288 is located in the gene 
DHCR24. DHCR24 is a protein shown to protect against oxidative stress-induced apoptosis un-
derpinning the potential relevance for melanoma progression and prognosis. 
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5. Comparison of an Australian and German Melanoma Cohort 
5.1. Introduction 
Melanoma is common among fair skinned populations with the highest reported incidence 
rates in Australia and New Zealand, both countries on the southern hemisphere with intense 
daily UV radiation and with inhabitants of European origin.23 European populations have lower 
incidence and mortality rates compared to Australia and New Zealand.3 
Two independent cohorts of melanoma patients of two regions, one from Europe and one 
from Australia were selected for comparative analyses. Both cohorts consisted of patients 
with similar Western European ancestry and similar socioeconomic background. Both cohorts 
were drawn from populations with a similar lifestyle in a western culture but with one major 
difference: the intensity of the environmental UV radiation. Brisbane is a city located in a sub-
tropical region, at southern latitude 27° with an average between 6 and 9 hours sun a day 
around the year. In contrast Tübingen is located in a tempered climate zone at northern lati-
tude 48° and has an average of 2 hours sun in the winter months and only a period of 2 months 
with 8 hours sun a day.213 
The aim of the following analyses was to compare the general characteristics, sun behaviour 
data and tumour specific variables of the two cohorts with different environmental sun expo-
sure levels. 
5.2. Methods 
The methods related to the establishment of the two patient cohorts, such as patient recruit-
ment and data management are described in chapter 2. 
In order to perform comparative analyses between the Australian and the German cohort of 
melanoma patients, a shared SPSS file was created. The complete set of melanoma patients 
from each cohort was selected to be merged into one file.  
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The following variables were chosen for comparisons: 
General characteristics  
• Sex 
• Age 
• BMI 
• Ancestry 
• Hair colour 
• Eye colour 
• Skin reaction 
• Total body naevus count 
• Family history of melanoma 
Sun behaviour  
• Sunburns 
• Use of sunscreen 
Genetic data 
• MC1R 
• PGC-1a 
• PGC-1b 
Tumour specific data 
• Tumour thickness 
• Multiple melanomas* 
• Histology 
• Localisation 
• Clark level 
• Ulceration 
• Regression 
• Naevus-associated melanoma 
*in case of multiple melanomas, the tumour specific data of the thickest primary melanoma were recorded 
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Variables which had not the same values where adapted to enable combined analyses as de-
scribed below. 
Hair colour: The variable of the Brisbane cohort had 5 values: red, fair, light brown, dark brown 
and black. In Tübingen the values were red, blonde, brown and black. The values light and 
dark brown were combined to brown for the matched variable with the 4 values red, blonde, 
brown and black. 
Eye colour: The variable of the Tübingen cohort had 4 values and distinguished between blue, 
grey, green and brown. In Brisbane the values were blue/grey, green/hazel and brown. The 
matched variable had 3 values blue/grey, green/hazel and brown. 
Skin reaction: The variable of the Tübingen cohort had 4 values: 1. Always burned, no tan, 2. 
Mostly burned, light tan, 3. Seldom burned, strong tan and 4. Never burned, always tan. The 
two values “mostly burned, light tan” and “seldom burned, strong tan” were combined to one 
value “burn then tan” to match the 3 values of the Brisbane cohort: always burn and never 
tan, burn then tan, only tan. 
Total body naevus count: The variable of the Brisbane cohort was a metric variable with the 
absolute naevus number, counting naevi from a size of 5mm. In Tübingen naevi were reported 
from a size of 3mm. The variable of the Tübingen cohort was categorized in 5 groups: 0-10, 
11-30, 31-50, 51-100 and more than 100. The same categories were used to group the variable 
naevus count for patients of the Brisbane cohort.  
Family history melanoma: The variables of the Brisbane cohort had 3 values and distinguished 
between first and second-degree relatives. The variable in Tübingen did only refer to second 
degree relatives. The matched variable had only 2 values: First degree relatives with mela-
noma and no first-degree relatives with melanoma. 
Sunscreen usage: The variable of the Tübingen cohort had 4 values: never, seldom, several 
times a week and daily. Variable 3 and 4 were merged to the value more than 50% of the time. 
The matched variable had the 3 values of the Brisbane cohort: never, less than 50% and more 
than 50% of the time with sunscreen usage. 
Sunburns: The patients of the Tübingen cohort were asked how many sunburns they had per 
year, while the patients in Brisbane were asked for painful sunburns in their lifetime. The 
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variable was therefore not directly transferable and only the information if the patient ever 
experienced sunburns was kept. The matched variable had two values: no, the patient never 
got sunburned, yes, the patient got sunburned before. 
SPSS was used to calculate the frequencies and percentages of the selected variables. The 
missing variables were indicated with na. The given percentages were calculated without miss-
ing cases. The median was calculated for the metric variables, age, BMI and tumour thickness.  
Comparisons between the two cohorts were made with crosstabs for the ordinal and nominal 
variables. A two-sided Pearson Chi-Square test was used to test if the null hypothesis could be 
rejected. 
The normally distributed metric variables BMI and tumour thickness were compared between 
the cohorts using the parametric t-test of equality of means.  
The bimodal distributed metric variable age was compared with the nonparametric Mann-
Whitney U test. The significance level to reject the null hypothesis was 0.05 for all statistical 
tests. 
5.3. Results 
Comparison of general baseline data and pigmentation traits  
A total of 1010 melanoma patients were analysed. The general and pigment characteristics 
are presented in Table 14. Male patients were more frequent in both cohorts with 246 male 
patients of 454 patients in Brisbane and 308 male patients of 556 patients in Tübingen. The 
median age of all patients was 58 with a range from 14 to 91 years. The median age was bal-
anced between the two cohorts with 57.5 and 59 years in Brisbane and Tübingen respectively. 
The body mass index (BMI) was higher in Brisbane with 27.45 versus 26.25 in Tübingen. This 
difference was significant with a p-value of 0.003. The vast majority of patients were of Euro-
pean ancestry. Only 6 patients (1.4%) from Brisbane and only 2 patients (0.4%) from Tübingen 
had another ancestry. The majority of patients from Brisbane were of British/Irish origin while 
most patients from Tübingen had German parents (data not shown). Brown hair colour was 
the most frequent hair phenotype in both cohorts with 59.5% and 44.3% of patients from 
Brisbane and from Tübingen respectively. Patients with blonde hair were about as frequent as 
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patients with brown hair in Tübingen with 43.8%, whereas only 20.4% of patients had blonde 
hair in Brisbane. However, the percentage of patients with red hair was more than doubled in 
the Brisbane cohort with 16.4% compared to 6% in Tübingen (Figure 33a). Patients with 
green/hazel eyes were more frequent in Brisbane with 27.5% compared to 16.5% of patients 
with green eyes in Tübingen. The percentage of patients with blue/grey eyes was similar be-
tween the cohorts with 58.4% and 59.4% in Brisbane and Tübingen respectively. Less patients 
had brown eyes in Brisbane (14.1%) compared to Tübingen (24.1%). In terms of skin reaction 
few patients of both cohorts indicated their skin would only tan after sun exposure. About half 
of the patients from Brisbane (49.0%) stated their skin reaction as “burn then tan” and 43.2% 
of the patients as “always burn, never tan”. This most sun sensitive category “always burn, 
never tan” was only chosen by 17.6% of melanoma patients from Tübingen to describe their 
skin reaction, while the majority of the patients from Tübingen (72.9%) indicated they would 
“burn then tan” (Figure 33c). The distribution of the 5 different total body naevus count cate-
gories was similar between the patients from Brisbane and the patients from Tübingen. The 
category “between 11 and 30 naevi” was most common with 37.5% of patients from Brisbane 
and 35.7% of patients from Tübingen. However, the comparison of this variable has a limita-
tion as only naevi from 5mm were counted in Brisbane while all naevi from 3mm size were 
counted in Tübingen. A positive family history of melanoma was reported by 37.3% of patients 
from Brisbane while only 5.4% of patients from Tübingen had a first degree relative with a 
malignant melanoma (Figure 33d). 
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Table 14: Comparison of general traits between melanoma patients from Brisbane and Tübingen 
 All pts  Brisbane  Tübingen  p* 
 n % n % n %  
Total, n 1010 100 454 100 556 100  
Sex 
female 
male 
 
456 
554 
 
45.1 
54.9 
 
208 
246 
 
45.8 
54.2 
 
248 
308 
 
44.6 
55.4 
0.701 
Age 
median, range 
 
58 
14 - 91 
  
57.5 
14 - 88 
  
59 
17 - 91 
  
0.061 
BMI 
median, range 
 
26.66 
16.90 – 
69.92 
  
27.45 
16.90 – 
56.77 
  
26.25 
17.16 – 
69.92 
 0.003 
European ancestry 
yes 
others 
na 
 
949 
8 
53 
 
99.2 
0.8 
 
411 
6 
37 
 
98.6 
1.4 
 
538 
2 
16 
 
99.6 
0.4 
0.072 
Hair colour 
red 
blonde 
brown 
black 
na 
 
107 
331 
511 
49 
12 
 
10.7 
33.2 
51.2 
4.9 
 
74 
92 
269 
17 
2 
 
16.4 
20.4 
59.5 
3.8 
 
33 
239 
242 
32 
10 
 
6.0 
43.8 
44.3 
5.9 
<0.001 
Eye colour 
blue/grey 
green/hazel 
brown 
na 
 
593 
216 
197 
4 
 
58.9 
21.5 
19.6 
 
265 
125 
64 
 
 
58.4 
27.5 
14.1 
 
328 
91 
133 
4 
 
59.4 
16.5 
24.1 
<0.001 
Skin reaction  
always burn, never tan 
burn then tan 
only tan 
na 
 
291 
621 
87 
11 
 
29.1 
62.2 
8.7 
 
194 
220 
35 
5 
 
43.2 
49.0 
7.8 
 
97 
401 
52 
6 
 
17.6 
72.9 
9.5 
<0.001 
Naevus count** 
0-10 
11-30 
31-50 
51-100 
>100 
na 
 
244 
368 
184 
145 
66 
3 
 
24.2 
36.5 
18.3 
14.4 
6.6 
 
110 
170 
79 
66 
28 
1 
 
24.3 
37.5 
17.4 
14.6 
6.2 
 
134 
198 
105 
79 
38 
2 
 
24.2 
35.7 
19.0 
14.3 
6.9 
0.948 
Family history of mela-
noma 
yes(1st degree relatives) 
no  
na 
 
 
197 
791 
22 
 
 
19.9 
80.1 
 
 
168 
283 
3 
 
 
37.3 
62.7 
 
 
29 
508 
19 
 
 
5.4 
94.6 
<0.001 
*Pearson Chi-Square Asymp.Sig (2-sided) 
**Naevi were recorded from 5mm size in Brisbane and from 3mm size in Tübingen 
 
 
 
 
Dr. med. Annette Pflugfelder  Phenotypes and Genotypes of Melanoma Patients 
 
152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: Bar charts illustrating the different frequencies of a. hair colour, b. eye colour, c. skin reac-
tion after sun exposure, d. positive family history of melanoma, e. history of sunburns and f. use of 
sunscreen in melanoma patients from Brisbane compared to Tübingen. 
 
a 
c
 
b
 
d
 
e
 
f
 
p=<0.001 p=<0.001 
p=<0.001 p=<0.001 
p=<0.001 p=<0.001 
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Comparison of sun behaviour data  
The history of sunburns and data concerning the use of sunscreen was available for both co-
horts of melanoma patients from Brisbane and Tübingen. The data is presented in Table 15. 
The majority of patients from both cohorts indicated they had experienced sunburns in their 
life. Those who never got sunburned were significantly more frequent among the melanoma 
patients from Tübingen, with 8.7% compared to 2.9% of the patients from Brisbane (Figure 
33e). Around 10% of all patients never used sunscreen. Most of the patients from Australia 
used sunscreen more than 50% of their time (45.1%) while the majority of the patients from 
Tübingen were applying sunscreen in less than 50% of their time (68.4%)  
(Figure 33f).  
 
Table 15: Comparison of sun behaviour between melanoma patients from Brisbane and Tübingen 
 All pts  Brisbane  Tübingen  p* 
 n % n % n %  
Total, n 1010 100 454 100 556 100  
History of sunburns 
no 
yes 
na 
 
61 
939 
10 
 
6.1 
93.9 
 
13 
436 
5 
 
2.9 
97.1 
 
48 
503 
5 
 
8.7 
91.3 
<0.001 
Usage of sunscreen 
never 
<50% of time 
>50% of time 
na 
 
108 
568 
314 
20 
 
10.9 
57.4 
31.7 
 
 
49 
194 
200 
11 
 
11.1 
43.8 
45.1 
 
 
59 
374 
114 
9 
 
10.8 
68.4 
20.8 
 
<0.001 
*Pearson Chi-Square Asymp.Sig (2-sided) 
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Comparison of genetic data 
A principal component analysis was performed to investigate the population structure of the 
two cohorts.214 The plot illustrates the ethnical background of the study participants, with PC2 
corresponding to North-South and PC1 to East-West in Europe. The plot revealed a partly 
overlapping but distinct population structure between the melanoma patients from Brisbane 
and the patients from Tübingen (Figure 34). 
 
Figure 34: Principal component analysis of the melanoma patients from Brisbane (blue) and Tübingen 
(green). The variables PC1 and PC2 were calculated using the FlashPCA2 package in R. 29 cases were 
excluded due to missing or outliner values. 
 
Genetic data was compared for the MC1R, PGC-1a and PGC-1b locus. The data is presented in 
Table 16. A significant difference was detected between patients from Brisbane and patients 
from Tübingen for the locus MC1R and PGC-1a, but not for PGC-1b. Much more patients from 
Brisbane had at least one variants in the gene locus coding for MC1R (87.6%) compared to 
patients from Tübingen with a least one MC1R variant (77.3%). A deeper analysis of the MC1R 
genotype revealed similar percentages of patients with the WT/r, WT/R and r/r genotype, 
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however the r/R and R/R genotypes were significantly more frequent among the patients from 
Brisbane and the WT/WT genotype was more frequent among the patients from Tübingen 
(p<0.001). This was also reflected by the counts for R-alleles and WT alleles with huge differ-
ences between the two cohorts (p<0.001) and a still significant but less pronounced difference 
between r-alleles counts (p=0.069). The frequency of patients with one or more germline var-
iants in the gene coding for PGC-1a was higher in patients from Tübingen than in patients from 
Brisbane (12.8% versus 8.8%). Variants in the gene coding for PGC-1b were as frequent in Tü-
bingen as in Brisbane with 76.8% compared to 77.0%. 
Table 16: Comparison of genetic data between melanoma patients from Brisbane and Tübingen 
 All pts  Brisbane  Tübingen  p* 
 n % n % n %  
Total, n 1010 100 454 100 556 100  
MC1R** 
wt 
variant 
na 
 
182 
826 
2 
 
18.1 
81.9 
 
56 
396 
2 
 
12.4 
87.6 
 
126 
430 
 
22.7 
77.3 
<0.001 
MC1R r alleles 
0 
1 
2 
na 
 
496 
426 
86 
2 
 
49.2 
42.3 
8.5 
 
208 
209 
35 
2 
 
46.0 
46.2 
7.7 
 
288 
217 
51 
 
51.8 
39.0 
9.2 
0.069 
MC1R R alleles 
0 
1 
2 
na 
 
504 
413 
91 
2 
 
50.0 
41.0 
9.0 
 
194 
206 
52 
2 
 
42.9 
45.6 
11.5 
 
310 
207 
39 
 
55.8 
37.2 
7.0 
<0.001 
MC1R WT alleles 
0 
1 
2 
na 
 
367 
459 
182 
2 
 
36.4 
45.5 
18.1 
 
193 
203 
56 
2 
 
42.7 
44.9 
12.4 
 
174 
256 
126 
 
31.3 
46.0 
22.7 
<0.001 
MC1R Genotype 
WT/WT 
WT/r 
WT/R 
r/r 
r/R 
R/R 
na 
 
182 
236 
223 
86 
190 
91 
2 
 
18.1 
23.4 
22.1 
8.5 
18.8 
9.0 
 
56 
103 
100 
35 
106 
52 
2 
 
12.4 
22.8 
22.1 
7.7 
23.5 
11.5 
 
126 
133 
123 
51 
84 
39 
 
22.7 
23.9 
22.1 
9.2 
15.1 
7.0 
<0.001 
PGC-1a 
wt 
variant 
na  
 
898 
111 
1 
 
89 
11 
 
413 
40 
1 
 
91.2 
8.8 
 
485 
71 
 
87.2 
12.8 
0.047 
PGC-1b 
wt 
variant 
na 
 
776 
233 
1 
 
76.9 
23.1 
 
349 
104 
1 
 
77.0 
23.0 
 
427 
129 
 
76.8 
23.2 
0.927 
*Pearson Chi-Square, Exact Sig. (2-sided) 
**deeper analyses with data of the MC1R locus were performed, considering the numbers of r, R or WT alleles 
respectively, and the specific MC1R genotype 
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Comparison of tumour specific data  
Melanoma specific data was available for both cohorts in 8 categories. These categories were 
the tumour thickness, the history of multiple melanomas in one patient, the histologic subtype 
of the melanoma, the localisation on the body, the Clark level, the presence of ulceration, 
signs of regression and of naevus remnants in the histopathological specimen of the primary 
melanoma. The data is presented in Table 17. 
Significant differences were apparent between the two cohorts of melanoma patients from 
Brisbane and from Tübingen in all of these categories apart from the category localisation of 
the primary. Around 40% of the patients had their melanoma on the trunk in both cohorts, 
followed by one quarter of patients with a melanoma on the lower extremities, about 20% on 
the upper extremities and about 15% at the head and neck (Figure 35a).  
The median tumour thickness was 1mm in the cohort of patients from Brisbane compared to 
1.5mm in Tübingen. Accordingly, more than half of the patients from Brisbane had thin mela-
nomas with a tumour thickness below 1mm compared to only 24.5% of patients from Tü-
bingen. Most patients from Tübingen had a melanoma with a tumour thickness between 1.01 
and 2mm (41.0%). The proportion of thick melanomas above 4mm was similar between the 
cohorts with 8.5% in Brisbane and 10.2% in Tübingen (Figure 35b). 
A Clark level 1 was diagnosed in 34.1% of patients from Brisbane but in none of the patients 
from Tübingen. The majority of patients from Tübingen had a Clark level 4 (70.8%), followed 
by a Clark level 3 (17.7%) and a Clark level 2 (7.1%). Patients from Brisbane had a more evenly 
distribution with 23.4% Clark level 2, 13.2% Clark level 3 and 25.5% Clark level 4. The rate of 
patients with Clark level 5 melanomas was around 4% in both cohorts. 
The most frequent histologic subtype was superficial spreading melanoma with 69.2% among 
the patients from Brisbane and 61.2% among patients from Tübingen. The second frequent 
type was nodular melanoma with 13.5% in Brisbane and 17.9% in Tübingen. The subtype len-
tigo maligna melanoma was much more frequent in Brisbane with 12% compared to 5.2%, 
whereas acral lentiginous melanoma was more frequent in Tübingen with 5.6% compared to 
2.3% in Brisbane (Figure 35c). 
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Table 17: Comparison of tumour specific data between melanoma patients from Brisbane and Tü-
bingen 
 All pts  Brisbane  Tübingen  p* 
 n % n % n %  
Total, n 1010 100 454 100 556 100  
Tumour thickness 
median 
 
<1,0mm 
1,01-2,0mm 
2,01-4mm 
>4mm 
na 
 
1.35 
 
259 
278 
165 
75 
233 
 
 
 
33.3 
35.8 
21.2 
9.7 
 
1.00 
 
132 
65 
39 
22 
196 
 
 
 
51.2 
25.2 
15.1 
8.5 
 
1.50 
 
127 
213 
126 
53 
37 
 
 
 
24.5 
41.0 
24.3 
10.2 
 
<0.001 
 
<0.001 
Multiple Melanomas 
yes 
no 
na 
 
251 
754 
5 
 
25.0 
75.0 
 
236 
213 
5 
 
52.6 
47.4 
 
15 
541 
 
2.7 
97.3 
<0.001 
Histology 
SSM 
NM 
LMM 
ALM 
others 
na 
 
491 
126 
58 
34 
59 
242 
 
63.9 
16.4 
7.6 
4.4 
7.7 
 
184 
36 
32 
6 
8 
188 
 
69.2 
13.5 
12.0 
2.3 
3.0 
 
307 
90 
26 
28 
51 
54 
 
61.2 
17.9 
5.2 
5.6 
10.2 
<0.001 
Localisation 
head and neck 
trunk 
upper extremities 
lower extremities 
mucosa 
na 
 
135 
363 
167 
234 
8 
103 
 
14.9 
40.0 
18.4 
25.8 
0.9 
 
 
54 
159 
70 
91  
0 
80 
 
14.4 
42.5 
18.7 
24.3 
0 
 
81 
204 
97 
143 
8 
23 
 
15.2 
38.3 
18.2 
26.8 
1.5 
0.123 
Clark level 
1 
2 
3 
4 
5 
na 
 
127 
120 
131 
423 
34 
175 
 
15.2 
14.4 
15.7 
50.7 
4.1 
 
127 
87 
49 
95 
14 
82 
 
34.1 
23.4 
13.2 
25.5 
3.8 
 
0 
33 
82 
328 
20 
93 
 
0 
7.1 
17.7 
70.8 
4.3 
<0.001 
Ulceration 
yes 
no 
na 
 
164 
578 
268 
 
22.1 
77.9 
 
42 
256 
156 
 
14.1 
85.9 
 
122 
322 
112 
 
27.5 
72.5 
<0.001 
Regression 
yes 
no 
na 
 
202 
516 
292 
 
28.1 
71.9 
 
141 
147 
166 
 
49.0 
51.0 
 
61 
369 
126 
 
14.2 
85.8 
<0.001 
Naevus-associated MM 
yes 
no 
na 
 
228 
472 
310 
 
32.6 
67.4 
 
146 
133 
175 
 
52.3 
47.7 
 
82 
339 
135 
 
19.5 
80.5 
<0.001 
*Pearson Chi-Square Asymp.Sig (2-sided) 
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Ulcerated melanomas which represent a subclass entity with an impaired prognosis, were 
more frequent in patients from Tübingen, with 27.5% compared to 14.1% patients with ulcer-
ated primaries in Brisbane (Figure 35d). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Bar charts illustrating the different frequencies of a. the localisation, b. the tumour thickness of the 
primary, grouped in 4 categories, c. the histological subtype, and d. the presence of ulceration in the primary 
tumour in melanoma patients from Brisbane compared to Tübingen.  
 
 
 
 
a 
c
 
b
 
d
 
p=<0.001 
p=<0.001 p=<0.001 
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The most striking difference was the proportion of patients with a history of multiple primary 
melanomas. More than half of the patients of the cohort from Brisbane (52.6%) had a history 
of multiple melanomas compared to only 2.7% of patients from Tübingen (Figure 36a). 
A remarkable difference was also seen in the frequency of melanomas with signs of regres-
sion. About half of the melanoma patients from Brisbane (49.0%) had a melanoma with re-
gression compared to 14.2% of melanoma patients from Tübingen (Figure 36b). 
Another divergent variable was the presence of naevus remnants in the histopathological 
specimen. More than half of the patients from Brisbane (52.3%) had a naevus associated mel-
anoma compared to 19.5% of patients from Tübingen (Figure 36c).  
The results of the last two variables had a limitation due to a notable amount of missing values, 
which were 292 missing values for the variable ´Regression´ and 310 missing values for the 
variable ´Naevus associated melanoma´. 
The data in regard to the number of melanomas in each individual patient however was nearly 
complete, with 5 missing values for the Brisbane cohort and no missing values for the Tü-
bingen cohort. 
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Figure 36: Bar charts illustrating the different frequencies of a. multiple melanomas, b. presence of 
regression in the primary tumour and c. Naevus associated melanoma in patients from Brisbane com-
pared to Tübingen. 
a 
b
 
c
  
p=<0.001 
p=<0.001 
p=<0.001 
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5.3.1. Results after Exclusion of In Situ Melanoma Cases 
A bias between the cohorts from Brisbane and from Tübingen was the fact that patients with 
in situ melanomas were included in the Brisbane cohort while those patients were not in-
cluded in Tübingen. In order to test the validity of the described results, the analyses were 
repeated after the exclusion of 127 melanoma in situ cases from Brisbane. The total number 
of analysed melanoma patients was thus 883, including 327 patients from Brisbane and 556 
patients from Tübingen. 
The comparison of the general characteristics resulted again in a significant difference be-
tween the cohorts for the variables BMI, Hair colour, Eye colour, Skin reaction and Family his-
tory of melanoma (Table 18). The median age was 56 after exclusion of in situ cases compared 
to 57.5 years including in situ cases. The median BMI with 27 remained constant after exclu-
sion of patients with a melanoma in situ. 
The share of patients with low naevus numbers went up after exclusion of those patients with 
in situ cases. The lowest category with 0-10 naevi from 5mm size had a share of 26.7% com-
pared to previous 24.3% and 38.7% of patients were within the second category (11-30 naevi) 
after exclusion of the in-situ cases compared to 36.8% before. 
Patients with an ancestry other than European were more frequent in the Brisbane cohort 
after exclusion of in situ melanoma cases. The difference towards the Tübingen cohort 
reached significance (p=0.048). 
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Table 18: Comparison of general traits between melanoma patients from Brisbane and Tübingen, after 
exclusion of in situ cases 
 All pts  Brisbane  Tübingen  p* 
 n % n % n %  
Total, n 883 100 327 100 556 100  
Sex 
female 
male 
 
400 
483 
 
45.3 
54.7 
 
152 
175 
 
46.5 
53.5 
 
248 
308 
 
44.6 
55.4 
0.588 
Age 
median, range 
 
58 
14-91 
  
56 
14-88 
  
59 
17-91 
  
0.061 
BMI 
median, range 
 
26.57 
16.90-
69.92 
  
27.36 
16.90-
54.09 
  
26.25 
17.16 – 
69.92 
  
0.003 
European ancestry 
yes 
others 
na 
 
834 
7 
42 
 
99.2 
.8 
 
296 
5 
26 
 
98.3 
1.7 
 
538 
2 
16 
 
99.6 
0.4 
0.048 
Hair colour 
red 
blonde 
brown 
black 
na 
 
89 
305 
433 
45 
11 
 
10.2 
35.0 
49.7 
5.2 
 
56 
66 
191 
13 
1 
 
17.2 
20.2 
58.6 
4.0 
 
33 
239 
242 
32 
10 
 
6.0 
43.8 
44.3 
5.9 
<0.001 
 
Eye colour 
blue/grey 
green/hazel 
brown 
na 
 
526 
173 
180 
4 
 
59.8 
19.7 
20.5 
 
198 
82 
47 
0 
 
60.6 
25.1 
14.4 
 
328 
91 
133 
4 
 
59.4 
16.5 
24.1 
<0.001 
 
Skin reaction  
always burn, never tan 
burn then tan 
only tan 
na 
 
236 
560 
78 
9 
 
27.0 
64.1 
8.9 
 
139 
159 
26 
3 
 
42.9 
49.1 
8.0 
 
97 
401 
52 
6 
 
17.6 
72.9 
9.5 
<0.001 
 
Naevus count** 
0-10 
11-30 
31-50 
51-100 
>100 
na 
 
221 
324 
159 
120 
56 
3 
 
25.1 
36.8 
18.1 
13.6 
6.4 
 
87 
126 
54 
41 
18 
1 
 
26.7 
38.7 
16.6 
12.6 
5.5 
 
134 
198 
105 
79 
38 
2 
 
24.2 
35.7 
19.0 
14.3 
6.9 
0.621 
Family history of mela-
noma 
yes(1st degree relatives) 
no  
na 
 
 
146 
716 
21 
 
 
16.9 
83.1 
 
 
117 
208 
2 
 
 
36.0 
64.0 
 
 
29 
508 
19 
 
 
5.4 
94.6 
<0.001 
 
*Pearson Chi-Square Asymp.Sig (2-sided) 
**Naevi were recorded from 5mm size in Brisbane and from 3mm size in Tübingen 
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The exclusion of in situ melanoma cases had no influence on the results regarding sun be-
haviour data between the two cohorts (Table 19). 
 
Table 19: Comparison of sun behaviour between melanoma patients from Brisbane and Tübingen, af-
ter exclusion of in situ cases 
 All pts  Brisbane  Tübingen  p* 
 n % n % n %  
Total, n 883 100 327 100 556 100  
History of sunburns 
no 
yes 
na 
 
57 
817 
9 
 
6.5 
93.5 
 
9 
314 
4 
 
2.8 
97.2 
 
48 
503 
5 
 
8.7 
91.3 
0.001 
Usage of sunscreen 
never 
<50% of time 
>50% of time 
na 
 
92 
510 
264 
17 
 
10.6 
58.9 
30.5 
 
33 
136 
150 
8 
 
10.3 
42.6 
47.0 
 
59 
374 
114 
9 
 
10.8 
68.4 
20.8 
 
<0.001 
*Pearson Chi-Square Asymp.Sig (2-sided) 
 
The results of the genetic data comparisons after exclusion of in situ cases are presented in 
(Table 20). PGC-1a variants reached a slightly higher frequency among the Brisbane cohort 
after exclusion of the in-situ cases. This finding levelled up to the percentage of patients with 
PGC-1a variants in the Tübingen cohort. The difference was not significant anymore with a p-
value of 0.182. The percentages of patients with at least one PGC-1b variants did not alter 
remarkably with the exclusion of in situ cases and was not significant. The count of at least 
one MC1R variant was still significantly different between the groups (p=0.002). The same was 
true for the MC1R genotype, the count for WT alleles and for R alleles. However, the r allele 
frequency was not significantly different between the two cohorts any more, with 9.2% of 
patients having two r alleles in both groups and around half of each group without any r allele 
(p=0.219). 
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Table 20: Comparison of genetic data between melanoma patients from Brisbane and Tübingen, af-
ter exclusion of in situ cases 
 All pts  Brisbane  Tübingen  p* 
 n % n % n %  
Total, n 883 100 327 100 556 100  
MC1R** 
wt 
variant 
na 
 
172 
710 
1 
 
19.5 
80.5 
 
46 
280 
1 
 
14.1 
85.9 
 
126 
430 
 
22.7 
77.3 
0.002 
MC1R r alleles 
0 
1 
2 
na 
 
438 
363 
81 
1 
 
49.7 
41.2 
9.2 
 
150 
146 
30 
1 
 
46.0 
44.8 
9.2 
 
288 
217 
51 
 
51.8 
39.0 
9.2 
0.219 
MC1R R alleles 
0 
1 
2 
na 
 
459 
345 
78 
1 
 
52.0 
39.1 
8.8 
 
149 
138 
39 
1 
 
45.7 
42.3 
12.0 
 
310 
207 
39 
 
55.8 
37.2 
7.0 
0.004 
MC1R WT alleles 
0 
1 
2 
na 
 
316 
394 
172 
1 
 
35.8 
44.7 
19.5 
 
142 
138 
46 
1 
 
43.6 
42.3 
14.1 
 
174 
256 
126 
 
31.3 
46.0 
22.7 
<0.001 
MC1R Genotype 
WT/WT 
WT/r 
WT/R 
r/r 
r/R 
R/R 
na 
 
172 
206 
188 
81 
157 
78 
1 
 
19.5 
23.4 
21.3 
9.2 
17.8 
8.8 
 
46 
73 
65 
30 
73 
39 
1 
 
14.1 
22.4 
19.9 
9.2 
22.4 
12.0 
 
126 
133 
123 
51 
84 
39 
 
22.7 
23.9 
22.1 
9.2 
15.1 
7.0 
0.001 
PGC-1a 
wt 
variant 
na  
 
780 
103 
0 
 
88.3 
11.7 
 
295 
32 
0 
 
90.2 
9.8 
 
485 
71 
0 
 
87.2 
12.8 
0.182 
PGC-1b 
wt 
variant 
na 
 
677 
206 
0 
 
76.7 
23.3 
 
250 
77 
0 
 
76.5 
23.5 
 
427 
129 
0 
 
76.8 
23.2 
0.907 
*Pearson Chi-Square Asymp.Sig (2-sided) 
**deeper analyses with data of the MC1R locus were performed, considering the numbers of r, R or WT alleles 
respectively, and the specific MC1R genotype 
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The tumour specific data were compared for the two cohorts after exclusion of in situ mela-
noma cases. The results are presented in Table 21.  
All variables which were significant in the analyses with the whole cohort remained significant 
after the exclusion of the 127 in situ melanoma cases. These were the seven variables tumour 
thickness, multiple melanomas, histology, Clark level, ulceration, regression, naevus associ-
ated melanoma. 
As expected the median tumour thickness increased from 1.00 to 1.10mm. The presence of 
multiple melanomas was less frequent after the exclusion of in situ cases with 43.5% com-
pared to 52.6%. The difference was still highly significant compared to the 2.7% of multiple 
melanoma cases in Tübingen. The histological subtype nodular melanoma had a higher per-
centage among the Brisbane cohort while lentigo maligna melanomas were less frequent after 
the exclusion of in situ cases. The difference was still significant compared to Tübingen. 
The presence of an ulcerated primary went up as expected after the exclusion of in situ cases. 
The difference between the cohorts Brisbane and Tübingen was less pronounced but still sig-
nificant. The percentage of primary tumours with signs of regression was nearly the same after 
exclusion of in situ melanomas. Naevus-associated melanomas were less frequent after the 
exclusion of in situ cases. However, the difference between the cohorts Brisbane and Tübingen 
was still highly significant. 
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Table 21: Comparison of tumour specific data between melanoma patients from Brisbane and Tü-
bingen, after exclusion of in situ cases 
 All pts  Brisbane  Tübingen  p* 
 n % n % n %  
Total, n 883 100 327 100 556 100  
Tumour thickness 
median 
 
<1,0 mm 
1,01-2,0 mm 
2,01-4 mm 
>4 mm 
na 
 
1.40 
 
236 
272 
162 
74 
139 
 
 
 
31.7 
36.6 
21.8 
9.9 
 
1.10 
 
109 
59 
36 
21 
102 
 
 
 
48.4 
26.2 
16.0 
9.3 
 
1.50 
 
127 
213 
126 
53 
37 
 
 
 
24.5 
41.0 
24.3 
10.2 
 
<0.001 
 
<0.001 
 
Multiple Melanomas 
yes 
no 
na 
 
155 
723 
5 
 
17.7 
82.3 
 
140 
182 
5 
 
43.5 
56.5 
 
15 
541 
 
2.7 
97.3 
<0.001 
 
Histology 
SSM 
NM 
LMM 
ALM 
others 
na 
 
429 
126 
32 
34 
58 
204 
 
63.2 
18.6 
4.7 
5.0 
8.5 
 
122 
36 
6 
6 
7 
150 
 
68.9 
20.3 
3.4 
3.4 
4.0 
 
307 
90 
26 
28 
51 
54 
 
61.2 
17.9 
5.2 
5.6 
10.2 
0.046 
Localisation 
head and neck 
trunk 
upper extremities 
lower extremities 
mucosa 
na 
 
111 
308 
143 
214 
8 
99 
 
14.2 
39.3 
18.2 
27.3 
1.0 
 
30 
104 
46 
71 
0 
76 
 
12.0 
41.4 
18.3 
28.3 
0 
 
81 
204 
97 
143 
8 
23 
 
15.2 
38.3 
18.2 
26.8 
1.5 
0.231 
Clark level 
1 
2 
3 
4 
5 
na 
 
0 
120 
131 
423 
34 
175 
 
0 
16.9 
18.5 
59.7 
4.8 
 
0 
87 
49 
95 
14 
82 
 
0 
35.5 
20.0 
38.8 
5.7 
 
0 
33 
82 
328 
20 
93 
 
0 
7.1 
17.7 
70.8 
4.3 
<0.001 
 
Ulceration 
yes 
no 
na 
 
163 
491 
229 
 
24.9 
75.1 
 
41 
169 
117 
 
19.5 
80.5 
 
122 
322 
112 
 
27.5 
72.5 
0.028 
Regression 
yes 
no 
na 
 
158 
465 
260 
 
25.4 
74.6 
 
97 
96 
134 
 
50.3 
49.7 
 
61 
369 
126 
 
14.2 
85.8 
<0.001 
Naevus-associated MM 
yes 
no 
na 
 
162 
447 
274 
 
26.6 
73.4 
 
80 
108 
139 
 
42.6 
57.4 
 
82 
339 
135 
 
19.5 
80.5 
<0.001 
 
*Pearson Chi-Square Asymp.Sig (2-sided) 
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5.4. Discussion 
The present analyses were based on a two cohorts of melanoma patients, comprising 454 
patients from Brisbane and 556 patients from Tübingen. Both cohorts were collected in hos-
pital based outpatient clinics. Age and gender were well balanced between the groups. Pa-
tients from Australia had a higher body mass index (BMI) with 27.45 compared to those from 
Germany (26.25). The lower median BMI for patients in Germany compared to Australia was 
in accordance with recently published data for BMI measures in the general population of 70 
different countries. Australians were reported with a higher BMI compared to Germans.215  
The comparison of two patient cohorts derived from a) Australia, where the inhabitants have 
a pre-dominant British/Irish ancestry and b) from South Germany with primarily German 
origin revealed some expected phenotype differences. Individuals with red hair and green 
eyes were much more common among Australian melanoma patients, while more German 
patients had blond hair. Much more patients from Australia were sun sensitive and indicated 
they would always burn and never tan compared to the German melanoma patients. This pre-
condition along with the higher environmental UV exposure in Australia gave a plausible ex-
planation of the higher rate of sunburns in the personal history of Australian melanoma pa-
tients compared to the German patients. The much more frequent use of sunscreen among 
the Australian melanoma patients could be interpreted based on the higher need of a sun 
sensitive group in a high UV exposure environment compared to the German group. Another 
explanation is the positive result of the intensive public sun prevention campaigns in Australia, 
which were introduced in the 1980is and which resulted in a broad public acceptance of sun 
protection.216 
The different frequencies of MC1R variants in the two cohorts are in accordance with the dif-
ferent ancestries. MC1R variants are found more frequently in individuals with a British/Irish 
family background compared to individuals from middle Europe. The overall frequency of 
MC1R variants in both cohorts was high. This is in accordance with the increased melanoma 
risk for individuals with MC1R variants.217  
First degree family members with a positive history of a melanoma were reported from more 
than a third of the Australian melanoma patients (37.3%) compared to only 5.4% of the Ger-
man melanoma patients. This huge difference is reflected by the higher incidence rates in 
Australia in general. The high proportion of familial melanoma in Australia compared to 
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Germany is questioning the often claimed genetic background of these cases and does rather 
point towards an environmental effect of UV light as carcinogen in these families. 
The tumour specific parameters were remarkably different between the Australian and the 
German melanoma patients. The median tumour thickness was 1.0mm in the Australian co-
hort compared to 1.5mm in the German cohort. While the thick melanomas were equally fre-
quent in both groups the share of thin melanomas was much higher in the Brisbane cohort. 
This finding might be biased by the fact that patients with in situ melanomas and with thin 
melanomas were less likely included in the German cohort.  
The subtypes superficial spreading melanoma (SSM) and lentigo maligna melanoma (LMM) 
were more frequent among Australian patients, whereas nodular melanoma (NM) and acral 
lentiginous melanomas (ALM) were more frequent among German patients. These findings 
correlate with the fact that SSM and LMM belong to the sun induced melanomas while NM 
and ALM are not considered to be sun induced.1 Furthermore NM and ALM define the sub-
groups with an impaired prognosis compared to SSM and LMM. 
Ulceration of the primary is an unfavourable primary tumour characteristic and was again 
more common in the German cohort. In contrast primary melanomas with more favourable 
prognostic characteristics, such as naevus associated melanoma218 and melanomas with signs 
of regression53 where more frequent among Australian patients. 
An extreme difference of patients with multiple primary melanomas (MPM) was observed be-
tween the two cohorts. About half of the melanoma patients from Brisbane (52.6%) had more 
than one melanoma compared to only 2.7% of patients with multiple melanomas from Tü-
bingen. This extreme difference can be partially explained by the study inclusion procedure of 
the Brisbane cohort. A special interest in multiple melanoma patients in the working group 
resulted in an intended oversampling of these patients. In the literature, a varying range of 
melanoma patients who develop secondary melanomas were reported. Studies based on Eu-
ropean populations published between 2010 and 2017 found between 3% and 6.5% of pa-
tients with MPM. A share of 6.5% patients with multiple melanomas was calculated in 2253 
patients drawn from the German Central Malignant Melanoma Registry (Gassenmaier et al. 
2017, submitted). A Swiss study reported a rate of 4.6% MPM219, an Italian study found 6% 
MPM cases220 and a large study from the Netherlands including 42,733 patients from a 
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national, population-based Cancer Registry found 3% patients with two or more melano-
mas.221 Another study from the Netherlands focussed on risk factors for multiple melanoma 
and found cumulative sun exposure and a high naevus density as main contributing risk factors 
for the 4.7% reported cases of MPM.222 Studies from the States and from Canada reported 
between 1.9% and 10% MPM cases. The oldest study retrieved was from 1979 with 5.3% 
MPM223, a study from 2005 with 4,484 patients reported 8.6%224, a small cohort study of 354 
patients described 8% MPM and was published in 2006.225 A study from 2010 with 2,506 mel-
anoma patients found only 1.9% of multiple melanoma cases. Analyses revealed a significant 
association of MPM with older age and the diagnoses of a superficial spreading melanoma.226 
Three small cohort studies found 7.7%, 5% and 10% of MPM.55,227,228 A large study from 2012 
based on 208,289 patients found a rate of 3.3% MPM, another large study from 2015 including 
16,570 patients found a rate of 7.3% MPM.229,230 In the latter study risk factors associated with 
MPM were older age, male, white and having a partner. Four studies from Australia were 
found with reported rates between 2.9% and 17.8% of MPM cases. One study from Sydney 
was published in 1982 with 2.9% MPM among 90 melanoma patients.54 Another report from 
Sydney including 5,250 patients diagnosed between 1983 and 1999 found a rate of 6% MPM.56 
A report from Queensland found a rate of 7% among 29,908 patients diagnosed between 1995 
and 2008.56 Another cohort from Queensland comprising 1,068 patients found a rate of 17.8% 
MPM and a positive association with elder age and males.231 Overall, the rates of MPM in 
different continents showed remarkable differences. Higher rates were more likely seen in 
smaller cohorts, in those from more recent years and in cohorts from countries with a higher 
UV exposure. Smaller cohorts have generally a higher risk of a selection bias which could ex-
plain an unexpected high or low observed “out-of-range” value. The consistent high rate of 
MPM in small cohorts however is more likely explained by the fact that those smaller cohorts 
tend to be closer observed and to be included in a high quality follow up with a higher chance 
of finding true secondary melanomas as well as over-diagnosed melanomas, both resulting in 
higher MPM numbers. An increase of MPM rates in recent years might be explained by the 
generally rising incidence numbers of melanoma. The report of higher MPM rates in regions 
with higher UV exposure is setting a light on the impact of UV as carcinogen rather than on a 
genetic predisposition for the development of MPM. 
The prognostic impact of MPM is still unclear and conflicting results are reported. While some 
studies found an impaired survival probability for patients with multiple melanomas221,231,232 
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other studies reported a survival benefit for patients with MPM in general56 or for those MPM 
with thick tumours.57 Survival data were not yet available for the melanoma patients from 
Brisbane but were available for the patients from Tübingen. None of the 15 patients with mul-
tiple melanomas of the cohort of 556 patients died or progressed during follow up. Thus, the 
present data point towards a more favourable prognosis for patients with multiple melano-
mas. 
Overall, the rate of prognostic favourable tumours was higher among the Brisbane cohort. 
These more favourable melanomas might include a share of screen detected and indolent 
melanomas as a result of the successfully conducted secondary prevention campaigns. UV 
exposure is the most likely cause for the higher rate of prognostic favourable tumours. How-
ever, this rate of prognostic favourable melanomas is perishing among the general high inci-
dence rate caused by UV light. The increasing incidence rates of skin cancer worldwide was 
linked to changed leisure activities and altered sun seeking behaviour of the western popula-
tions after world war II. This resulted in a higher risk of UV induced damages of the unpro-
tected skin. However, a generally higher UV exposure caused by a less protective atmosphere 
is another likely cause for the worldwide skin cancer epidemic of the last decades. Ozone de-
pletion as a cause for the epidemic in skin cancer was mentioned by A. Woodcock, a Respira-
tory Physician in an editorial233, but received little attention by Dermatologists so far. One 
report was published in 1993 discussing the expected increase of melanoma incidence due to 
the reduction of ozone in the stratosphere.234 The higher incidence rates of melanoma in New 
Zealand compared to Australia is noteworthy. Based on the countries latitude a lower mela-
noma risk would be expected. The higher incidence and mortality rates compared to Aus-
tralia24 might be influenced as well by the close proximity to the Antarctic ozone hole. More-
over the recovering of the ozone layer might have contributed to the reported decline in inci-
dence rates in Australia in 2015.25 The healing in the Antarctic ozone layer was published last 
year and was traced back to the banning of industrial chlorofluorocarbons as a result of the 
Montreal Protocol, established in 1987 by the United Nations.235  
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Conclusions 
The comparison of melanoma patients from two countries with different environmental sun 
exposure revealed clear differences.  
Melanoma patients from Brisbane had more often primary tumours with favourable prognos-
tic characteristics compared to melanoma patients from Tübingen. This was observed for all 
variables with known prognostic impact, such as tumour thickness, histological subtypes, ul-
ceration, regression of the primary and the rate of naevus associated melanomas. Further-
more, the rate of familial and multiple melanomas was higher among the patients from Bris-
bane. 
The higher rate of prognostic favourable melanomas in the cohort from Brisbane compared 
to Germany supports the impact of UV exposure on the development of initially less aggres-
sive melanomas. 
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6. Association of PPARGC1A/B variants with Pigment Traits and Melanoma 
6.1. Introduction 
PGC-1 alpha and beta are two proteins belonging to the family of Peroxisome proliferator-
activated receptors (PPARs) which are metabolic transcriptional co-factors. The first member 
of this family was discovered in 1998 by Puigserver in brown fat tissue with an elevated ex-
pression after cold exposure.174 A role of PGC-1 in melanocytic pathways was first described 
by Shoag et al.181 They found an induction of PGC-1 alpha and beta through a-MSH signalling 
and an activation of MITF in human melanoma cell lines through PGC-1 alpha and beta. The 
expression of PGC-1 alpha was found to be regulated by MC1R and BRAF through different 
pathways and described as essential for mitochondrial biogenesis and function by Torrens-
Mas et al.236 An overexpression of PGC-1 alpha mediated by MITF in melanoma cells increased 
the mitochondrial energy metabolism and the survival capacities of these cells.188 The work 
by Luo et al. showed for the first time an influence of PGC-1 alpha on melanoma metastasis 
growth in mice.237 They postulated two roles for PGC-1 alpha, one promoting growth and sur-
vival of the tumours and one suppressing the development of metastases. 
Based on these findings, an influence of genetic germline variants within the coding regions 
for PGC-1 alpha and beta on pigmentation traits, melanoma risk and survival in humans was 
postulated and investigated here, using both the German and Australian datasets. 
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6.2. Methods 
The following analyses were based on two cohort studies, one from Tübingen, Germany and 
one from Brisbane, Australia.  
Patient inclusion, data and material collection and genotyping methods are described in Chap-
ter 2. 
The analyses on PGC-1 associations were performed in the following three steps: 
Initially a cohort with either extreme high (n=40) or extreme low (n=38) naevus count was 
selected to explore an association of PGC-1 with naevus count and melanoma risk. The geno-
typing method was Sanger Sequencing with a selection of 7 SNPs of interest as described be-
low. 
The positive results lead to an extension of the cohort with not specifically selected individuals 
from Brisbane in order to confirm the observed significant association with one of the previ-
ously assessed SNPs. The genotyping method was again Sanger Sequencing. 
The third step was initiated in parallel to the second step and included an increase of the 
sample size to 893 individuals from Brisbane and 614 individuals from Tübingen. Further-
more, the genotyping method was changed to a high throughput genotyping method, a chip 
based array, the Illumina CoreExome Chip. This technique allowed a detection of more than 
500 000 SNPs throughout the whole exome plus tagging intron SNPs at one time. 
Statistical analyses were performed using R and SPSS. Initial association analyses were done 
using fishers exact test and the Kruskal-Wallis-test. The final association analyses including the 
complete cohort were done with logistic regression analyses.  
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6.2.1. SNP Selection for Sanger Sequencing 
A search in the database dbSNP on Pubmed was performed in 2013 to search for SNPs within 
PPARGC1B and PPARGC1A, the two coding genes for PGC-1 alpha and PGC-1 beta. A set of 
inclusion criteria was applied as follows, in order to focus on a relevant selection of SNPs: 
• missense changing SNPs 
• location in an exon 
• minor allele frequency of near or >1% 
These criteria were met by 7 SNPs for PGC-1ß and 4 SNPs for PGC-1α. The rs numbers were 
retrieved and additional information such as the variant associated base change and the re-
sulting amino acid change and position within the protein product and the previously pub-
lished minor allele frequency (MAF) were recorded (Table 22). 
 
Table 22: Selected SNPs within PPARGC1B and PPARGC1A for the initial analyses 
Gene Amino acid Posi-
tion & Change 
dbSNP rs number* Base 
Change 
MAF** MAF*** 
updated 
PPARGC1B 
(encoding for 
PGC-1ß) 
Ala203Pro rs7732671 C/G 0.1028 C=0.1096 
Arg226Gln rs45520937 A/G 0.0808 A=0.0705 
Val240Ile rs17572019 A/G 0.0661 A=0.0659 
Arg253Ser rs11959820 A/C 0.0900 A=0.1048 
Arg291Trp rs45470697 C/T 0.0188 T=0.0174 
Val312Met rs77687445 A/C/G 0.0096 A=0.0088 
Ser350Tyr rs45519432 A/C 0.0197 A=0.0174 
PPARGC1A 
(encoding for 
PGC-1α) 
Leu438Ser rs35437002 A/G 0.0110 G=0.0106 
Gly482Ser rs8192678 A/G 0.2911 T=0.2658 
Arg566Cys rs58772979 C/T 0.0115 A=0.0108 
Thr612Lys (or 
Met) 
rs3736265 A/G/T 0.1094 A=0.1094 
* dbSNP rs number = Single Nucleotid Polymorphism Database reference number 
** Minor Allele Frequency (Global) data from dbSNP, ***updated 20th Sep 17 
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The localisation of the retrieved SNPs within the two genes was identified and plotted on a 
draft of the two genes (Figure 37). The retrieved SNPs for the protein PGC-1 beta were all 
located in exon 5 of PPARGC1B. A previously published intronic SNP (rs32579) by Shoag et al. 
was located between exon 4 and exon 5. The retrieved SNPs for the protein PGC-1 alpha were 
located in exon 8 and exon 9 of PPARGC1B. Primers were designed around exon 5 of 
PPARGC1B. Sanger Sequencing was performed for 175 individuals of the cohort from Brisbane 
as described in chapter 2.4.2.  
 
 
 
 
 
 
Figure 37: Drafts of the genes PPARGC1B and PPARGC1A and the localisation of the selected SNPs. 
The blue boxes represent the exons. The red flags mark the position of the designed primers. 
  
PPARGC1B 
PPARGC1A 
Dr. med. Annette Pflugfelder  Phenotypes and Genotypes of Melanoma Patients 
 
176 
 
6.3. Results of the Initial Association Analyses based on Sanger Sequencing 
A total of 78 individuals from the BNMS were genotyped with Sanger sequencing at the 
PPARGC1B locus. PCR and Sanger sequencing resulted in chromatograms of 671bp long frag-
ments which included the 7 pre-selected SNPs. Variants of the 3 SNPs rs45520937, rs17572019 
and rs11959820 were identified in 21 of 78 individuals. The other 4 SNP locations showed no 
variant in comparison to the reference sequence. The frequencies of the identified minor al-
leles are presented in Table 23. 
 
Table 23: Frequency of PGC-1b minor alleles in the initial analyses pf 78 individuals 
 High NC Low NC 
History of 
MM  
No history 
of MM  
Total 
Reported 
MAF 
Individuals/Alleles 40/80 38/76 35/70 43/86 78/156  
rs number/Amino acid 
change 
n(%) n(%) n(%) n(%) n(%) % 
rs45520937 
Arg226Gln 
2 (3) 3 (4) 4 (6) 1 (1) 5 (3) 8 
rs17572019 
Val240Ile 
4 (5) 6 (8) 2 (3) 8 (9) 10 (6) 6 
rs11959820 
Arg253Ser 
7 (9) 1 (1) 4 (6) 4 (5) 8 (5) 9 
rs7732671 
Ala203Pro 
0 0 0 0 0 10 
rs45470697 
Arg291Trp 
0 0 0 0 0 2 
rs77687445 
Val312Met 
0 0 0 0 0 1 
rs45519432 
Ser350Tyr 
0 0 0 0 0 2 
NC= naevus count, low naevus count was defined as < 100 naevi, high naevus count ≥ 100 naevi; MM= malignant 
melanoma. MAF= minor allele frequency. 
 
An association of the retrieved variants with naevus count and melanoma risk was tested. The 
allele frequencies of each of the three SNPs were plotted against the variables naevus number 
and history of malignant melanoma in the study cohort. There was a significant difference for 
rs11959820 (Arg253Ser), with 7 minor alleles found in the high naevus group, while only one 
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minor allele was found in the low naevus group (p= 0.047, one-tailed fisher´s exact test). Fur-
thermore, there was a difference between the minor allele frequencies for rs45520937 
(Arg226Gln) of individuals with a history of malignant melanoma compared to controls, how-
ever this was not statistically significant (p= 0.137, one-tailed fisher´s exact test). The results 
are presented in Figure 38. 
 
 
 
 
 
 
 
 
Figure 38: Comparison of the allele frequencies of three assessed PGC-1 SNPs between a. individual 
with high versus low naevus count and b. melanoma patients versus controls. The difference be-
tween the minor allele frequency of rs11959820 (Arg253Ser) in the high versus low naevus count 
group was significant p= 0.047. 
 
Based on these findings, the study cohort was extended with unselected cases of the Brisbane 
cohort to a sample size of 175. Allele variants at rs45520937, rs17572019 and rs11959820 
were found in a similar number as before. Additionally, 22 new and previously not detected 
minor allele variants were found for rs7732671 in the extended sample size. This SNP location 
was located at the beginning of the retrieved PCR fragment resulting in an impaired quality of 
the chromatogram at that location. This explained the false negative findings for minor vari-
ants at that location in the beginning of the analyses. 
A common presence of the two minor alleles at the SNP locations rs7732671 (Ala203Pro) and 
rs17572019 (Val240Ile) was detected in the assessed samples, defined as Linkage Disequilib-
rium between those two SNPs. 
Association analyses were performed with the four SNPs rs11959820 (Arg253Ser), rs7732671 
(Ala203Pro), rs45520937 (Arg226Gln) and rs17572019 (Val240Ile) in the extended cohort us-
ing the Kruskal-Wallis-Test. 
p=0.047 
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The genotype of the individuals for each of the 4 SNPs was plotted against the naevus number. 
In accordance to the previous analysis, the strongest association was found for the SNP 
rs11959820, with a C to A transition, leading to an amino acid change from Arginine (R) to 
Serine (S) at position 253. Individuals with a minor allele at this locus had a trend towards a 
higher naevus number. However, this association was not significant in the assessed cohort. 
Furthermore, no association with naevus number could be shown for the other investigated 
SNPs (Figure 39). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: Comparison of naevus number between the different genotypes of the study participants 
at a. rs11959820 (Arg253Ser), b. rs7732671 (Ala203Pro), c. rs45520937 (Arg226Gln) and d. 
rs17572019 (Val240Ile). No significant associations were found. 
 
The association of the different genotypes at PGC-1b with melanoma risk was assessed in the 
extended cohort as well. None of the discovered minor allele variants showed an association 
with either increased or decreased risk of melanoma development. 
a b 
c d 
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To answer the question if PGC-1ß variants would increase or decrease pigment production, 
the different genotypes were compared with the measured data of skin reflectance. A low 
value for skin reflectance was obtained from dark skin, which had higher light absorbent prop-
erties. The measurement at the sun protected inner forearm was referred to as the constitu-
tive skin colour. The outer, more UV exposed forearm, was referred to as the facultative skin 
colour. The difference between those two measurements was used as a value for tanning abil-
ity. The minor variant at rs45520937 with a G to A transition, inducing an Arginine to Gluta-
mine change at the amino acid position 226, was strongly associated with an increased pig-
mentation on the inner and on the outer forearm (Figure 40). This association reached statis-
tical significance (p=0.039 and p=0.015). In addition, there was a trend for an increased tan-
ning ability associated with the minor allele at rs45520937. This association was not significant 
(p=0.058). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40: Significant association of rs45520937 (Arg226Gln) with dark skin (low skin reflectance) at 
the a. inner (p=0.039) and b. the outer forearm (p=0.015) and association with c. an increased tanning 
ability (p=0.058). 
  
a b 
c 
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6.4. Results of the Association Analyses based on Chip Array Genotyping 
In parallel to the extension of the cohort for Sanger Sequencing the complete cohorts from 
Brisbane and from Tübingen were genotyped with the Illumina Human CoreExome chip. This 
included a total of 893 individuals from Brisbane and 614 individuals from Tübingen. Both co-
horts included patients with a personal history of melanoma and unaffected individuals. The 
utilized chip was the Infinium® CoreExome-24 v1.2 BeadChip with a total number of more than 
500,000 markers. The Illumina Chip included a total of 19 exon SNPs of the gene PPARGC1A 
and 40 exon SNPs of the gene PPARGC1B. The high genotyping quality of the chip results were 
demonstrated as described below with the retrieved yield of results and with the comparison 
of the previous Sanger sequence findings. 
6.4.1. Sequencing Quality 
6.4.1.1. Yield of valid SNP Results 
The first analysed samples with the Illumina HumanCoreExome-24 BeadChip included a total 
number of 232 samples from Germany.  
All samples were successfully assessed with a high yield of valid SNP measurements. A total of 
545 710 SNPs were analysed per sample. Of these SNPs the mean percentage of failed meas-
urements was <0.00186%, ranging from <0.00137% to 0.0064%. In absolute numbers these 
were a mean of 471 missing SNPs out of 545 710 per sample with a range of 204 to 3510 SNPs 
(Figure 41). 
 
 
 
 
 
 
 
Figure 41: Missing SNPs (%) per 545 710 assessed SNPs of each sample: mean <0.00186%, resulting in 
a mean of 99.99914% valid SNP results per sample. 
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6.4.1.2. Comparison of Illumina Sequencing with Sanger Sequencing Results 
A total of 175 individuals from Brisbane were genotyped with both methods, Sanger Sequenc-
ing and with the Illumina chip. Of the 7 SNPs assessed by Sanger Sequencing all but one SNP 
were covered by the chip. The SNP which was not covered was rs45520937 with the amino 
acid change Arg226Gln. All findings of the chip could be confirmed via Sanger Sequencing. One 
homozygous variant for rs17572019, one homozygous variant and 10 heterozygous variants 
for rs7732671 were missed by the initial analyses of the chromatograms but were retrospec-
tively identified. The findings are summarized in Table 24. 
 
Table 24: Quality control of SNP Sequencing, Sanger results compared with Illumina Chip results 
rs number AS position Sanger (n=175) Illumina (n=175) Matches/Mismatches 
rs7732671 Ala203Pro 156 wildtype 
19 heterozygous 
0 homozygous 
144 wildtype 
29 heterozygous 
2 homozygous 
163/24 
rs45520937 Arg226Gln 167 wildtype 
7 heterozygous 
1 homozygous 
- - 
rs17572019 Val240Ile 146 wildtype 
28 heterozygous 
1 homozygous 
145 wildtype 
28 heterozygous 
2 homozygous 
145/1 
rs11959820 Arg253Ser 163 wildtype 
11 heterozygous 
1 homozygous 
163 wildtype 
11 heterozygous 
1 homozygous 
163/0 
rs45470697 Arg291Trp 175 wildtype 175 wildtype 175/0 
rs77687445 Val312Met 175 wildtype 175 wildtype 175/0 
rs45519432 Ser350Tyr 175 wildtype 175 wildtype 175/0 
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6.4.2. Sequencing Results – Frequencies 
The frequencies of the minor alleles at the respective SNP localisations for the two analysed 
cohorts from Brisbane and Tübingen were calculated for the retrieved SNP locations of the 
gene PPARGC1A and of the gene PPARGC1B. The results are presented in Table 25 and Table 
26. The respective amino acid change for each SNP, the Illumina Map number, rs number, the 
bases of the variant type and wild type and the published frequencies of the respective minor 
alleles within the European population were retrieved and recorded.  
The cohort from Brisbane had less frequently variants in the gene PPARGC1A compared to the 
cohort from Tübingen. Of the 19 different SNP loci, 15 SNPs had a zero frequency in the Bris-
bane cohort. Variants were found at 4 SNP loci. Those variants were found in a similar number 
than previously published frequencies. The frequency of SNP variants for PPARGC1A was 
higher in Tübingen and 6 loci with minor alleles were found (Table 25). A total of 40 exon SNP 
locations variants from the gene PPARGC1B were assessed for minor alleles. Variants were 
found in both cohorts at 8 different locations in a similar frequency of previously published 
data (Table 26). 
Table 25: Assessed PGC-1a SNPs. Available SNPs located in the PGC-1a coding gene PPARGC1A. The 
amino acid position and change, the rs number (Single-nucleotide polymorphism database reference 
number) and the MAF (Minor allele frequency) in the European (non-finish) population is given for 
each SNP. WT = wild-type, VT = variant-type. 
G
e
n
e
 
 
No 
Amino acid position 
and change 
 
Illumina Map 
Info 
rs number VT/WT 
European 
(Non-Fin) 
MAF* 
MAF 
Brisbane 
Cohort 
(n=893) 
MAF 
Tübingen 
Cohort 
(n=614) 
P
P
A
R
G
C
1
A
 
1. A774G exm2072194 rs201337076 C/G 0 0 0 
2. E733V exm392323 rs149018936 A/T 3.01e-05 0 0 
3. R690Q exm392330 rs148144750 C/T <0.0011799 0 0 
4. Q664R exm392335 rs139102065 C/T 4.521e-05 0 0 
5. T612M exm392344 rs3736265 A/G 0.05686 0.056 0.067 
6. R611H exm392345 rs144103777 C/T 0.002293 0.001 0.008 
7. Indel indel.80441  I/D  0 0 
8. R594S exm392351 rs148669466 G/T <0.0011859 0 0 
9. R580Q exm392353 rs143326747 C/T <0.0011213 0 0 
10. S577L exm392355 rs17847360 C/T <0.0015431 0.001 0 
11. R566C exm392358 rs58772979 C/T <0.0016152 0 0.001 
12. F534L exm392363 rs199669057 A/G <0.00118 0 0 
13. K496Q exm392367 rs200661963 G/T <0.00112 0 0.001 
14. L438S exm392378 rs35437002 A/G <0.0015248 0 0.001 
15. L410I exm392379 rs34514918 G/T <0.0014199 0 0 
16. E369K exm392383 rs201353657 C/T 7.5e-05 0 0 
17. E353K exm392386 rs199902625 C/T <0.0011055 0 0 
18. A304V exm392392 rs200841362 A/G <0.0011055 0 0 
19. S74L exm392419 rs142669571 A/G 0.001414 0.002 0.002 
* data from http://exac.broadinstitute.org 
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Table 26: Assessed PGC-1b SNPs. Available SNPs located in the PGC-1b coding gene PPARGC1B. The 
amino acid position and change, the rs number (Single-nucleotide polymorphism database reference 
number) and the MAF (Minor allele frequency) in European (non-finish) population is given for each 
SNP. WT = wild-type, VT = variant-type. 
G
e
n
e
 
 
No 
Amino acid position 
and change* 
 
Illumina Map 
Info 
rs number VT/WT 
European 
(Non-Fin) 
MAF** 
MAF 
Brisbane 
Cohort 
(n=893) 
MAF 
Tübingen 
Cohort 
(n=614) 
P
P
A
R
G
C
1
B
 
1. G31R, G31R, G6R exm494061 rs45518035 A/G 9.04e-05 0 0.001 
2. S50N, S50N, S25N exm494065 rs146830741 A/G 1.502e-05 0 0 
3. R180H,Silent,Silent exm494085 rs148461382 A/G 0.087140 0 0 
4. A203P, A164P, A139P exm494090 rs7732671 G/C 0.08714 0.086 0.080 
5. T221N, T182N, T157N exm494093 rs139476696 A/C 0.001991 0.002 0.002 
6. S222L, S183L, S158L exm494094 rs75266799 C/T <0.001214 0 0 
7. S239N, S200N, S175N exm494100 rs151338666 A/G <0.0018256 0.001 0 
8. S256N, S217N, S192N exm494105 rs147103978 A/G 1.551e-05 0 0 
9. P264T, P225T, P200T exm494107 rs138677083 A/C 0 0 0 
10. V279I, V240I, V215I exm494114 rs17572019 A/G 0.0876 0.085 0.080 
11. R292S, R253S, R228S exm494117 rs11959820 A/C 0.0324 0.030 0.035 
12. R330W, R291W, R266W exm494124 rs45470697 C/T 6.072e-05 0 0 
13. V351M, V312M, V287M exm494127 rs77687445 A/G 6.059e-05 0 0 
14. T363M, T324M, T299M exm494128 rs45526537 C/T 7.604e-05 0 0 
15. R374G, R335G, R310G exm494131 rs201630695 A/G <0.0011531 0 0 
16. S389Y, S350Y, S325Y exm494136 rs45519432 A/C 6.155e-05 0 0 
17. R413Q, R374Q, R349Q exm494142 rs138692598 A/G 9.322e-05 0 0 
18. R421G, R382G, R357G exm494143 rs141717472 C/G 0 0 0 
19. E446V, E407V, E382V exm494147 rs139404347 A/T 0 0 0 
20. W451X, W412X, W387X newrs142816441 rs142816441 A/G NA 0 0 
21. R455S, R416S, R391S exm494149 rs144236856 G/T 4.814e-05 0 0 
22. V473L, V434L, V409L exm494151 rs142359633 C/G 0 0 0 
23. P475H, P436H, P411H exm494153 rs140114166 A/C 0.004207 0.001 0.003 
24. R480Q, R441Q, R416Q exm494157 rs142640674 A/G <0.0019096 0 0 
25. S500L, S461L, S436L exm494161 rs45549037 C/T 9.284e-05 0 0 
26. E528K, E489K, E464K exm494168 rs114581116 A/G 2.339e-05 0 0 
27. G702V, G663V, G638V exm494186 rs202211888 G/T <0.0011055 0 0 
28. P714L, P675L, P650L exm494188 rs45509002 C/T 3.014e-05 0 0 
29. T753M, T714M, T689M exm494194 rs149663552 C/T 0 0 0 
30. R761C, R722C, R697C exm494195 rs146710258 C/T <0.0013017 0 0 
31. S763N, S724N, S699N exm494197 rs200739030 A/G 9.053e-05 0 0 
32. L780V, L741V, L716V exm494201 rs149078416 C/G 1.51e-05 0.001 0 
33. R851H, R812H, R787H exm494213 rs200880286 A/G 1.505e-05 0 0 
34. R853C, R814C, R789C exm494214 rs201680092 C/T 7.524e-05 0 0 
35. R853H, R814H, R789H exm2091813 rs201238869 A/G 3.011e-05 0 0 
36. A890T, A851T, A826T exm494225 rs150637009 A/G 0.002134 0.001 0.001 
37. R893W, R854W, R829W exm494226 rs149399240 C/T <0.0011066 0 0 
38. R893Q, R854Q, R829Q exm2091817 rs138772212 A/G <0.0012137 0 0 
39. R894Q, R855Q, R830Q exm494228 rs201959772 A/G <0.0011838 0 0.001 
40. I906M, I867M, I842M exm494232 rs114273610 G/T 1.5e-05 0 0 
41. Intronic SNP  rs251468 A/G NA 0.214 0.215 
42. Intronic SNP  rs32579 A/G NA 0.233 0.223 
* 3 different transcripts of PGC-1b 
** data from http://exac.broadinstitute.org 
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6.4.3. Cohort Description 
The different characteristics of the two cohorts from Tübingen and Brisbane are summarized 
in Table 27. The numbers in regard to the melanoma cases were previously shown in  
chapter 5. The individuals without a personal history of melanoma were included in the pre-
sent analyses as well and are listed as controls.  
 
Table 27: Baseline Characteristics of the two cohorts from Tübingen and Brisbane 
 Brisbane Cohort Tübingen Cohort 
 MM Controls Total MM Controls Total 
 n % n % n % n % n % n % 
 454 100 439 100 893 100 556 100 58 100 614 100 
Sex 
female 
male 
 
208 
246 
 
45.8 
54.2 
 
237 
202 
 
54.0 
46.0 
 
445 
448 
 
49.8 
50.2 
 
248 
308 
 
44.6 
55.4 
 
32 
26 
 
55.2 
44.8 
 
280 
334 
 
54.4 
45.6 
Age median, range 58, 
14-88 
 30, 
11-76 
 42, 
11-88 
 59, 
17-91 
 40, 
23-81 
 58, 
17-91 
 
BMI median, range 27, 
16.9-
56.8 
 23.9, 
17.3-
48.8 
 25.3, 
16.9-
56.8 
 26.2, 
17.2-
69.9 
 23.1, 
17.6-
37.0 
 26.0, 
17.2-
69.9 
 
Sun reaction  
always burn, never tan 
burn then tan 
only tan 
na 
 
194 
220 
35 
5 
 
43.2 
49.0 
7.8 
 
139 
257 
40 
3 
 
31.9 
58.9 
9.2 
 
333 
477 
75 
8 
 
37.6 
53.9 
8.5 
 
97 
401 
52 
6 
 
17.6 
72.9 
9.5 
 
5 
47 
6 
0 
 
8.6 
81.0 
10.3 
 
102 
448 
58 
6 
 
16.8 
73.7 
9.5 
Eye colour  
blue/grey 
green 
brown 
na 
 
265 
125 
64 
0 
 
58.4 
27.5 
14.1 
 
212 
126 
101 
0 
 
48.3 
28.7 
23.0 
 
477 
251 
165 
0 
 
53.4 
28.1 
18.5 
 
328 
91 
133 
4 
 
59.4 
16.5 
24.1 
 
27 
8 
23 
0 
 
46.6 
13.8 
39.7 
 
355 
99 
156 
4 
 
58.2 
16.2 
25.6 
Hair colour  
red 
blonde 
brown 
black 
na 
 
74 
92 
269 
17 
2 
 
16.4 
20.4 
59.5 
3.8 
 
31 
83 
308 
17 
 
7.1 
18.9 
70.2 
3.9 
 
105 
175 
577 
34 
2 
 
11.8 
19.6 
64.8 
3.8 
 
33 
239 
242 
32 
10 
 
6.0 
43.8 
44.3 
5.9 
 
2 
23 
28 
5 
0 
 
3.4 
39.7 
48.3 
8.6 
 
35 
262 
270 
37 
10 
 
5.8 
43.4 
44.7 
6.1 
Naevus count* 
0-10 
11-30 
31-50 
51-100 
>100 
na 
 
110 
170 
79 
66 
28 
1 
 
24.3 
37.5 
17.4 
14.6 
6.2 
 
278 
106 
29 
21 
5 
 
63.3 
24.1 
6.6 
4.8 
1.1 
 
388 
276 
108 
87 
33 
1 
 
43.5 
30.9 
12.1 
9.8 
3.7 
 
 
134 
198 
105 
79 
38 
2 
 
24.2 
35.7 
19.0 
14.3 
6.9 
 
16 
19 
10 
8 
5 
0 
 
27.6 
32.8 
17.2 
13.8 
8.6 
 
150 
217 
115 
87 
43 
2 
 
24.5 
35.5 
18.8 
14.2 
7.0 
Family history of  
melanoma  
yes** 
no 
na 
 
 
168 
283 
3 
 
 
37.3 
62.7 
 
 
110 
328 
1 
 
 
25.1 
74.9 
 
 
278 
611 
4 
 
 
31.3 
68.7 
 
 
29 
508 
19 
 
 
5.4 
94.6 
 
 
0 
58 
0 
 
 
0 
100 
 
 
29 
566 
19 
 
 
4.9 
95.1 
**Naevi were recorded from 5mm size in Brisbane and from 3mm size in Tübingen 
**(1st degree relatives) 
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6.4.4. Association Analyses 
Association analyses were performed including the whole cohorts – melanoma patients and 
controls – from both countries independently. The analysed SNPs were selected in accordance 
to their frequency, excluding the very rare variants. This resulted in one exon SNP at the gene 
PPARGC1A and 3 exon SNPs at the gene PPARGC1B which were analysed individually in regard 
to an association with pigment traits, naevus count and melanoma risk. Additionally, the Taq-
Man genotype data for the intronic SNP rs251468 and the intronic SNP rs32579 were included 
into the analyses based on two recent publications238, Duffy et al., in submission. The variables of in-
terest were tanning capacity, naevus count and melanoma risk.  
The results for the 6 assessed SNPs and their influence on the tanning response in each of the 
two cohorts are presented in Table 28. A significant increase (estimate 0.64, 95%CI 0.10 - 1.18, 
p=0.02) of the tanning ability was calculated for individuals from Brisbane having two minor 
alleles of the intronic SNP rs251468 of PPARGC1B. Heterozygous individuals still had a positive 
estimate for tanning, but this was not significant. A trend for an increased tanning ability was 
likewise found for the homozygous individuals from Tübingen with overlapping confidence 
intervals supporting this finding. In contrast a trend towards an impaired tanning ability for 
individuals with a minor allele at rs11959820 (R253S) was found for both cohorts.  
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Table 28: Analyses with the selected SNPs of PPARGC1A and PPARGC1B and the impact on the  
tanning response in both cohorts using an ordinal regression model 
Gene 
rs number 
Amino acid position and 
change* 
Cohort Genotype Individuals (n) Estimate (95%CI) P-value 
PPARGC1A 
rs3736265 
T612M 
Brisbane 
 
G/G 
A/G 
A/A 
missing 
789 
90 
5 
9 
0 (Reference) 
0.31 (-0.12 - 0.74) 
0.25 (-1.48 - 1.97) 
 
0.15 
0.78 
 
Tübingen G/G 
A/G 
A/A 
missing 
529 
76 
3 
6 
0 (Reference) 
-0.38 (-0.91 - 0.16) 
-2.38 (-4.79 - 0.03) 
 
0.17 
0.05 
PPARGC1B 
rs7732671 
A203P, A164P, A139P 
Brisbane C/C 
C/G 
G/G 
missing 
741 
137 
7 
8 
0 (Reference) 
-0.03 (-0.38 - 0.33) 
-0.87 (-2.37 - 0.62) 
 
0.89 
0.25 
Tübingen C/C 
C/G 
G/G 
missing 
516 
86 
6 
6 
0 (Reference) 
0.31 (-0.22 - 0.83) 
-0.99 (-2.62 - 0.65) 
 
0.25 
0.24 
PPARGC1B 
rs17572019 
V279I, V240I, V215I 
Brisbane G/G 
A/G 
A/A 
missing 
743 
135 
7 
8 
0 (Reference) 
-0.04 (-0.40 - 0.31) 
-0.87 (-2.37 - 0.62) 
 
 
0.81 
0.25 
Tübingen G/G 
A/G 
A/A 
missing 
516 
86 
6 
6 
0 (Reference) 
0.31 (-0.22 - 0.83) 
-0.99 (-2.62 - 0.65) 
 
0.25 
0.24 
PPARGC1B 
rs11959820 
R292S, R253S, R228S 
Brisbane C/C 
C/A 
A/A 
missing 
833 
51 
1 
8 
0 (Reference) 
-0.53 (-1.01 - 0.02) 
0.91 (-3.02 - 4.83) 
 
 
0.06 
0.65 
Tübingen C/C 
C/A 
A/A 
missing 
566 
42 
0 
6 
0 (Reference) 
-0.11 (-0.81 - 0.59) 
 
0.75 
PPARGC1B 
rs251468 
Intronic SNP 
 
Brisbane G/G 
A/G 
A/A 
missing 
551 
250 
58 
34 
0 (Reference) 
0.19 (-0.10 - 0.48) 
0.64 (0.10 - 1.18) 
 
0.21 
0.02 
Tübingen G/G 
A/G 
A/A 
missing 
389 
180 
38 
7 
0 (Reference) 
-1.11 (-0.51 - 0.28) 
0.57 (-0.19 - 1.32) 
 
0.58 
0.14 
PPARGC1B 
rs32579 
Intronic SNP 
 
Brisbane G/G 
A/G 
A/A 
missing 
470 
339 
74 
8 
0 (Reference) 
0.31 (-0.17 - 0.80) 
0.07 (-0.21 - 0.34) 
 
 
0.20 
0.63 
Tübingen G/G 
A/G 
A/A 
missing 
336 
223 
49 
6 
0 (Reference) 
-0.05 (-0.43 - 0.33) 
0.53 (-0.15 - 1.22) 
 
0.80 
0.13 
*3 different transcripts of PGC-1b 
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The association analyses for total body naevus count are presented in Table 29. The coding 
SNP rs3736265 (T612M) of the gene PPARGC1A was significantly associated with naevus count 
in the cohort of Brisbane. Individuals with one minor allele had a calculated reduction of nae-
vus counts with an estimate of -0.61 (95%CI -1.03 - -0.18, p=0.005). Although this was not 
confirmed in the cohort of Tübingen the confidence intervals did still overlap. The association 
of this SNP with naevus count is illustrated in Figure 42A, showing the high prevalence of minor 
alleles in individuals with a low naevus count in the Brisbane cohort. Likewise, individuals from 
Tübingen had higher MAFs within the low naevus count categories, however individuals with 
more than 100 naevi had again a high MAF. The highest naevus count category (>100 naevi, 
3mm Tübingen, 5mm Brisbane) included only 43 individuals in Tübingen and 33 individuals in 
Brisbane while the other categories included a higher number of individuals with a lower 
chance of outliers. The previously detected SNP rs11959820 (R253S) of the gene PPARGC1B, 
assessed with Sanger Sequencing in a smaller cohort with initially significant results, did still 
show a trend towards an increased naevus count in the cohort of Brisbane. However, this 
finding was not reproducible in the cohort of Tübingen. Figure 42B is illustrating the increase 
of the MAF with increasing naevus count in the cohort of Brisbane. The intronic SNP rs32579 
in PPARGC1B showed a significant reduction of naevus counts for heterozygous individuals in 
the cohort of Tübingen (estimate -0.48, 95%CI -0.78 - -0.17, p=0.002) with a similar trend for 
the cohort of Brisbane. This association is illustrated in Figure 42C. 
The potential influence on melanoma risk was assessed for the 6 SNPs individually and pre-
sented in Table 30. Individuals with a minor allele at SNP rs3736265 (T612M) of the gene 
PPARGC1A had a trend towards a lower risk of melanoma. The result was significant for ho-
mozygous individuals from Tübingen, albeit this was based on only 3 cases. However, the risk 
reduction was congruent for both cohorts in heterozygous and homozygous individuals each 
with positive estimates. The other assessed SNPs revealed no influence on melanoma risk. 
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Table 29: Analyses with the selected SNPs of PPARGC1A and PPARGC1B and the impact on the  
total body naevus count in both cohorts using an ordinal regression model 
Gene 
rs number 
Amino acid position and 
change* 
Cohort Genotype Individuals (n) Estimate (95%CI) P-value 
PPARGC1A 
rs3736265 
T612M 
Brisbane 
 
G/G 
A/G 
A/A 
missing 
796 
90 
5 
2 
0 (Reference) 
-0.61 (-1.03 - -0.18) 
-0.28 (-1.92 - 1.37) 
 
0.005 
0.74 
 
Tübingen G/G 
A/G 
A/A 
missing 
533 
76 
3 
2 
0 (Reference) 
0.02 (-0.41 – 0.45) 
1.60 (-0.43 – 3.63) 
 
0.94 
0.12 
PPARGC1B 
rs7732671 
A203P, A164P, A139P 
Brisbane C/C 
C/G 
G/G 
missing 
747 
138 
7 
1 
0 (Reference) 
0.01 (-0.33 – 0.34) 
1.15 (-0.17-2.48) 
 
0.96 
0.09 
Tübingen C/C 
C/G 
G/G 
missing 
520 
86 
6 
2 
0 (Reference) 
-0.29 (-0.70 – 0.13) 
-1.46 (-3.03 – 0.11) 
 
0.18 
0.07 
PPARGC1B 
rs17572019 
V279I, V240I, V215I 
Brisbane G/G 
A/G 
A/A 
missing 
749 
136 
7 
1 
0 (Reference) 
0.01 (-0.33 – 0.35) 
1.15 (-0.17 – 2.48) 
 
 
0.96 
0.09 
Tübingen G/G 
A/G 
A/A 
missing 
520 
86 
6 
0 (Reference) 
-0.29 (-0.70 -0.13) 
-1.46 (-3.03 – 0.11) 
 
0.18 
0.07 
PPARGC1B 
rs11959820 
R292S, R253S, R228S 
Brisbane C/C 
C/A 
A/A 
missing 
839 
52 
1 
1 
0 (Reference) 
0.45 (-0.06 – 0.96) 
 
0.08 
Tübingen C/C 
C/A 
A/A 
missing 
569 
43 
0 
2 
0 (Reference) 
-0.30 (-0.86 – 0.26) 
 
0.29 
 
PPARGC1B 
rs251468 
Intronic SNP 
 
Brisbane G/G 
A/G 
A/A 
missing 
554 
250 
60 
29 
0 (Reference) 
-0.10 (-0.38 - 0.18) 
-0.20 (-0.70 - 0.29) 
 
0.48 
0.42 
Tübingen G/G 
A/G 
A/A 
missing 
391 
182 
38 
3 
0 (Reference) 
-0.26 (-0.58 – 0.06) 
-0.10 (-0.70 – 0.50) 
 
0.11 
0.74 
PPARGC1B 
rs32579 
Intronic SNP 
 
Brisbane G/G 
A/G 
A/A 
missing 
475 
339 
76 
0 (Reference) 
-0.02 (-0.28 – 0-23) 
-0.13 (-0.58 – 0.32) 
 
0.86 
0.56 
Tübingen G/G 
A/G 
A/A 
missing 
338 
225 
49 
2 
0 (Reference) 
-0.48 (-0.78 - -0.17) 
0.04 (-0.50 – 0.58) 
 
0.002 
0.88 
*3 different transcripts of PGC-1b 
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Figure 42: Analyses of the minor allele frequency of three different SNPs in individuals divided in 5 
naevus count categories of the two cohorts of Brisbane and Tübingen. A rs3736265 (T612M)  
B rs11959820 (R253S) and C rs32579 (intronic variant) 
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Table 30: Analyses with the selected SNPs of PPARGC1A and PPARGC1B and the impact on melanoma 
risk in both cohorts using an ordinal regression model 
Gene 
rs number 
Amino acid position and 
change* 
Cohort Genotype Individuals (n) Estimate (95%CI) P-value 
PPARGC1A 
rs3736265 
T612M 
Brisbane 
 
G/G 
A/G 
A/A 
missing 
797 
90 
5 
1 
0 (Reference) 
0.44 (-0.01 – 0.88) 
0.48 (-1.31 - 2.28) 
 
0.05 
0.60 
Tübingen G/G 
A/G 
A/A 
missing 
535 
76 
3 
0 
0 (Reference) 
0.01 (-0.83 – 0.84) 
2.99 (0.57 – 5.41) 
 
0.99 
0.02 
PPARGC1B 
rs7732671 
A203P, A164P, A139P 
Brisbane C/C 
C/G 
G/G 
missing 
747 
139 
7 
0 
0 (Reference) 
0.09 (-0.27 – 0.45) 
-0.24 (-1.75 – 1.26) 
 
0.63 
0.75 
Tübingen C/C 
C/G 
G/G 
missing 
522 
86 
6 
0 
0 (Reference) 
-0.39 (-1.27 – 0.49) 
 
 
0.39 
PPARGC1B 
rs17572019 
V279I, V240I, V215I 
Brisbane G/G 
A/G 
A/A 
missing 
749 
137 
7 
0 (Reference) 
0.09 (-0.28 – 0.45) 
-0.24 (-1.75 – 1.26) 
 
0.63 
0.75 
Tübingen G/G 
A/G 
A/A 
missing 
522 
86 
6 
0 
0 (Reference) 
-0.39 (-1.27 – 0.49) 
 
 
0.39 
PPARGC1B 
rs11959820 
R292S, R253S, R228S 
Brisbane C/C 
C/A 
A/A 
missing 
840 
52 
1 
0 
0 (Reference) 
0.03 (-0.53 – 0.59) 
 
 
0.91 
Tübingen C/C 
C/A 
A/A 
missing 
571 
43 
0 
0 
0 (Reference) 
-0.02 (-1.06 – 1.05) 
 
0.97 
PPARGC1B 
rs251468 
Intronic SNP 
 
Brisbane G/G 
A/G 
A/A 
missing 
555 
250 
60 
28 
0 (Reference) 
0.19 (-0.11 – 0.49) 
0.02 (-0.51 – 0.56) 
 
0.22 
0.93 
Tübingen G/G 
A/G 
A/A 
missing 
393 
182 
38 
0 (Reference) 
0.03 (-0.57 – 0.62) 
-0.66 (-2.12 – 0.81) 
 
0.93 
0.38 
PPARGC1B 
rs32579 
Intronic SNP 
 
Brisbane G/G 
A/G 
A/A 
missing 
475 
340 
76 
2 
0 (Reference) 
0.05 (-0.23 – 0.33) 
0.12 (-0.37 – 0.60) 
 
0.72 
0.64 
Tübingen G/G 
A/G 
A/A 
missing 
475 
340 
76 
2 
0 (Reference) 
0.06 (-0.50 – 0.62) 
-0.93 (-2.39 – 0.53) 
 
0.84 
0.21 
*3 different transcripts of PGC-1b 
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6.4.5. Survival Analyses 
Survival data were available for the cohort from Tübingen, but not for the Brisbane cohort. 
Survival analyses based on the single exon SNPs failed to reach validity due to the low overall 
incidence of variants with only single cases among patients who died from melanoma. Survival 
analyses considering the presence of any variant at the gene PPARGC1A as well as for the gene 
PPARGC1B were performed. However, no significant survival difference between patients 
with a variant and patients having a wild type at the genes PPARGC1A and PPARGC1B were 
detected (Figure not shown). 
Recently Li et al. reported an improved survival probability for melanoma patients who were 
carriers of the minor allele A at rs32579 of the gene PPARGC1B. This was investigated in a 
cohort of 858 melanoma patients from the United States with a total number of 95 mela-
noma specific deaths. The Hazard rate for melanoma specific death was decreased to 0.64 in 
the additive model with a p-value of 0.013. 
The respective SNP rs32579 was identified within the SNP dataset obtained as tagging SNP 
from the Illumina CoreExome Chip assay. The survival probability was analysed with the data 
from the Tübingen cohort using the additive model. A point estimate of 0.84 was calculated 
indicating a risk reduction for patients with a variant at rs32579. However, this was not sig-
nificant, the 95% confidence interval ranged from 0.57 to 1.26. 
The data of the present study and the data published by Li et al. were used for a meta-analy-
sis performed with R. The test for heterogeneity resulted in a p-value of 0.454, indicating 
consistency between the two studies. Together the two studies showed a significant result 
with a summary effect of 0.73 and a 95% confidence interval of 0.47 – 0.99 (p= 6.11e-08). 
The result is summarized in a Forest plot in Figure 43. 
 
Figure 43: Forest plot of the Hazard Ratios of two studies investigating the impact of PPARGC1B 
rs32579 on melanoma survival. 
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6.5. Discussion 
The presented analyses were based on a large set of SNPs located predominantly in the exons 
of two genes coding for two proteins, both belonging to one protein family of transcription 
factors, the peroxisome proliferator-activated receptor gamma coactivator. An interaction of 
these proteins with pigmentation pathways has been demonstrated181 as well as an influence 
in melanoma cells and the development of metastases in mice.188,237 Based on these findings 
a positive association of germline variants in the respective genes with pigmentation and mel-
anoma risk and prognosis was assumed. The present analyses focused on exon SNPs which 
are variants in coding regions. Variants in coding regions result in an altered amino-acid se-
quence of the respective protein with an optional change of the tertiary protein structure and 
a potential altered protein function. The assessed variants were previously published and 
were overall relatively rare in the general population. The effect of these variants on the pro-
tein function is unknown. It is interesting to note that all selected exon variants of PPARGC1B 
were located in close proximity at exon 5, assuming a functional relevance of this region. None 
of the exon variants had an influence on melanoma survival in the investigated cohort of Tü-
bingen (survival data is not yet available for the Brisbane cohort) with the limitation of low 
MAF of the exon SNPs resulting in only single events among the minor allele carriers. Two exon 
SNPs of PPARGC1B had an influence on pigmentation and naevus count. The SNP rs45520937 
(Arg226Gln) was associated with increased pigmentation and tanning ability in individuals 
from Brisbane. The results were based on Sanger sequencing and were not available for the 
German cohort. The SNP rs11959820 (R253S) showed in contrast a trend towards an impaired 
tanning ability for minor allele carriers in Tübingen and Brisbane and a trend towards in-
creased naevus numbers in the Brisbane cohort. However, this was not confirmed in the Ger-
man cohort. The contrary effect on tanning of this two adjacent SNPs and the lack of confir-
mation in the second cohort require further studies and these preliminary findings have to be 
considered with caution. 
A rather robust finding was the impact of the PPARGC1A SNP rs3736265 (T612M) on naevus 
count with a significant reduction of naevus counts for minor allele carriers in the Brisbane 
cohort. This was confirmed by a similar trend in the cohort from Tübingen. A decreased risk 
for melanoma was likewise observed for both cohorts. The risk reduction was significant for 
homozygous patients from Tübingen. 
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Variants within intron regions are more likely to influence protein expression levels. There-
fore, an intronic variant in a transcription factor might be even more likely associated with an 
altered phenotype compared to variants in coding regions. Two intronic SNPs of PPARGC1B 
have been investigated within the present analyses. Both SNPs, rs251468 and rs32579 were 
associated with increased tanning and decreased naevus count. The results reached signifi-
cance for rs251468 and tanning in the Brisbane cohort and for rs32579 and naevus count in 
the Tübingen cohort. The results were in accordance with the published data.182, Duffy et al. in 
submission Additionally a significant impact on melanoma survival with improved survival proba-
bilities for minor allele carriers was demonstrated for rs3257 using the data of the cohort Tü-
bingen and the recently published data in a meta-analysis. 
6.6. Conclusions 
The present analyses of this large SNP set predominantly located in exons of the two genes 
PPARGC1A and PPARGC1B added further evidence for the influence of the transcription fac-
tors PGC-1a and PGC-1b on pigmentation, naevus count and melanoma risk and progression. 
The exon SNP rs3736265 (T612M) of PPARGC1A was found to reduce naevus count and mel-
anoma risk. The effects of rs45520937 (Arg226Gln) and rs11959820 (R253S) on tanning and 
naevus count still have to be confirmed with a larger sample size or in another cohort. The 
meta-analyses of the present data with data from another group confirmed the reported sur-
vival benefit for the intronic SNP rs32579 in PPARGC1B and demonstrated how smaller effects 
can be substantiated by collaborative analyses. Therefore, genetic association analyses should 
be undertaken in a collaborative way to avoid the publication of false positive or false negative 
findings derived from small sample sizes. 
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7. Summary of Findings 
The research of the presented work started with a personal observation as a physician working 
with metastatic melanoma patients: Few metastatic patients seemed to have multiple Naevi. 
The initial question was: Do metastatic melanoma patients represent a distinct subpopulation 
in the cohort of melanoma patients? 
The field was opened towards four areas: The exploration of dermoscopic naevus pattern in 
melanoma patients, the comparison of early and late melanoma patients, the comparison of 
melanoma patients from Brisbane versus Tübingen and genetic association studies with 
PPARGC1A and PPARGC1B variants. 
Dermoscopy was used to classify the naevus pattern in the patients of the pilot study. The 
occurrence of an individual dominant pattern was reported previously.199,239 An individual 
dominant pattern was found likewise in most of the melanoma patients of the pilot study. 
However, a recurrent pattern among the melanoma patients was not detectable and further 
explorations of naevus pattern in melanoma patients were not pursued. 
Differences between early and late stage melanoma patients were explored in a well de-
scribed cohort of 556 patients from Tübingen. These patients were recruited between 2007 
and 2011 in a University hospital outpatient setting. The main variable of interest, the total 
body naevus count was not different between early and late stage patients. This finding was 
contrasted by a reported survival benefit of patients with high naevus numbers.59 Beside sta-
tistical concerns the results were restricted by a possible amount of screen-detected indolent 
melanomas.60 Those patients were not included in the present analysed cohort. Further ex-
ploration of phenotype variables, tumour specific and genetic markers revealed a survival im-
pact for the variables Skin type (p=0.031, dichotomized Skin type I/II versus III/IV), Tumour 
thickness (p=0.040, pairwise comparison), Ulceration (p=0.001), Unknown primary (p=0.008) 
and the presence of a MC1R r allele (p=0.049). A genome-wide association study enabled the 
detection of four potentially relevant SNPs associated with survival probability. Three of these 
SNPs, rs7551288, rs12146110 and rs1007271 are located on chromosome 1, the SNP 
rs1993585 on chromosome 4. The SNP rs7551288 is an intronic variant of DHCR24. The protein 
DHCR24 was previously reported to impede oxidative stress-induced apoptosis and to be up-
regulated in melanoma metastases.212 The SNP rs12146110 is an intronic variant of the gene 
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coding for USH2A, a protein associated with the Usher syndrome.209 Both SNPs had a con-
sistent influence on survival in Stage IV as well and might serve as potential predictors for 
melanoma progression. 
Two melanoma cohorts from two regions with fair skinned inhabitants, Queensland, Australia 
and Southern Germany were investigated. Individuals in Australia are exposed to a higher cu-
mulative UV exposure, and the melanoma incidence and mortality rates are higher compared 
to Western Europe.3 The two analysed cohorts were both recruited in a hospital outpatient 
setting and were well balanced according to age and gender. Phenotypes and genotypes 
showed characteristic features in relation to the ethnical differences. The melanoma patients 
from Brisbane had a higher frequency of prognostic favourable tumour characteristics, such 
as a lower tumour thickness, a high proportion of superficial spreading melanomas, less ulcer-
ated primaries, more frequently a histopathological regression of the primary and a higher 
rate of naevus associated melanomas compared to the patients from Tübingen. This remained 
statistical significant after the exclusion of in situ cases from the Brisbane cohort. Further-
more, significantly more patients from Brisbane had a positive family history of melanoma 
(p<0.001) and significantly more patients had multiple melanomas (p<0.001) compared to pa-
tients from Tübingen. 
Genetic association analyses were performed with a set of SNPs located predominantly in ex-
ons of PPARGC1A and PPARGC1B. The frequency of PPARGC1A variants was higher among the 
individuals from Tübingen compared to those from Brisbane, while the PPARGC1B variants 
were found in a similar frequency in both cohorts. The data revealed a Linkage Disequilibrium 
for rs7732671 (Ala203Pro) and rs17572019 (Val240Ile). The exon SNP rs3736265 (T612M) of 
PPARGC1A was associated with decreased total body naevus count (estimate -0.61, 95% CI-
1.03 - -0.18, p=0.005) and decreased melanoma risk (estimate 2.99, 95% CI 0.57 – 5.41, 
p=0.02). Furthermore, a significant association of the intronic SNP rs32579 with melanoma 
survival (p= 6.11e-08) was found based on a meta-analysis with previously published results in 
a similar cohort. The previously reported associations of both intronic SNPs rs251468 and 
rs32579 in PPARGC1B with increased tanning ability and decreased naevus count were con-
firmed. 
.  
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8. Final Conclusion 
Dermoscopic analyses of naevi from melanoma patients revealed no distinctive pattern and, 
the detection of a specific naevus pattern in a patient is in turn not feasible for a risk classifi-
cation. Total body naevus count did not qualify as a prognostic marker in melanoma patients. 
The genes DHCR24 and USH2A will need further investigation and might serve as new marker 
for melanoma progression. Variants of PPARGC1A and PPARGC1B have been shown to influ-
ence tanning, naevus count, melanoma risk and melanoma progression. Further exploration 
of other intronic variants within these genes might reveal additional significant associations. 
Primary melanomas with favourable prognostic characteristics seem to be more common 
among patients living in an UV intense country with a higher cumulative sun exposure. How-
ever, these higher rates of initially less aggressive primaries vanish among the extreme high 
incidence rates with the world highest melanoma mortality rates in Australia and New Zea-
land. The depletion and recent healing in the Antarctic ozone layer with altered UV protection 
levels should be considered in melanoma incidence rate discussions.  
In summary, genotypes have an influence on melanoma risk and progression. However, the 
relevance of genetic variations is low compared to the impact of UV radiation on melanoma. 
This should urge the efforts towards UV protection, both individually and globally. Early de-
tection and treatment can cure initially less aggressive UV induced melanomas. Both measures 
are important to reduce the number of melanoma deaths. 
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Sequencher® software. A previously analysed set of approx. 200 patients at the MC1R locus 
was analysed with the Sequencher® software by AP as quality control. 
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10. Abbreviations 
AEGRC    Australian Equine Genetics Research Centre 
AJCC    American Joint Committee on Cancer 
ALM    Acral lentiginous melanoma 
ASIP     Agouti signalling protein 
BAP1    encodes BRCA1 associated protein-1  
BMI    Body mass index 
CDK4    Cyclin-dependent kinase 4 
CDKN2A    cyclin-dependent kinase Inhibitor 2A 
CRP    C-reactive protein 
csv     comma separated values 
dbSNP    Single Nucleotide Polymorphism Database 
DCT    tyrosinase-related protein 2/dopachrome tautomerase 
DHCR24   24-Dehydrocholesterol Reductase 
DMSO    Dimethyl sulfoxide 
DNA    deoxyribonucleic acid 
dNTP    deoxy-nucleoside triphosphate 
EDTA    Ethylendiamintetraacetat 
ERRs     estrogen-related receptors 
GenoMEL   the Melanoma Genetics Consortium 
GNAQ    G protein alpha-subunit 
GWAS    Genome-wide association study 
HUMARA   human androgen receptor 
IMB     Institute for Molecular Bioscience 
IRF4    interferon regulatory factor 4 
KC    keratinocyte cancers 
LDH    Lactate dehydrogenase 
LMM    Lentigo maligna melanoma 
MAF    Minor allele frequency 
MC1R    melanocortin-1 receptor 
MIA    melanoma inhibitory activity protein 
MITF     microphthalmia transcription factor 
MPM    multiple primary melanomas 
na    not available 
NM    Nodular melanoma 
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NRF1    nuclear respiratory factor 1 
OCA2    oculocutaneous albinism type II 
PCR    Polymerase chain reaction 
PGC-1     Peroxisome proliferator-activated receptor gamma coactivator 
POT1    encodes Protection of telomeres protein 1 
POT1    protection of telomeres 1 gene 
PRC    PGC-1 related coactivator 
Rb    retinoblastoma 
ROS     reactive oxygen species 
rs number   reference SNP ID number 
SLC24A4   solute carrier family 24 
SLC45A2   solute carrier family 45, member 2 
SNP    single nucleotide polymorphism 
SPSS    Statistical Package for the Social Sciences 
SSM    Superficial spreading melanoma 
Stata    Statistics and data 
TE buffer   Tris-EDTA buffer 
TNM    tumour, nodes, metastasis 
TRI     Translational Research Institute 
TYR    tyrosinase 
TYRP1    tyrosinase-related protein-1 
USH2A    Usherin 
UQCCG    UQ Centre for Clinical Genomics 
UV    ultraviolet 
VPN    virtual private network 
VT    variant-type 
WT    wild-type 
α MSH     α-melanocyte-stimulating hormone 
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